<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
 <QvdTableHeader>
   <QvBuildNo>12904</QvBuildNo>
   <CreatorDoc>C:\Users\cjohnson\Desktop\Salesforce\SalesForce_Prometic2_1.qvw</CreatorDoc>
   <CreateUtcTime>2015-12-10 16:32:55</CreateUtcTime>
   <SourceCreateUtcTime></SourceCreateUtcTime>
   <SourceFileUtcTime></SourceFileUtcTime>
   <SourceFileSize>-1</SourceFileSize>
   <StaleUtcTime></StaleUtcTime>
   <TableName>OpsRaw</TableName>
   <Fields>
     <QvdFieldHeader>
       <FieldName>OpportunityId</FieldName>
       <BitOffset>0</BitOffset>
       <BitWidth>11</BitWidth>
       <Bias>0</Bias>
       <NumberFormat>
         <Type>ASCII</Type>
         <nDec>0</nDec>
         <UseThou>0</UseThou>
         <Fmt></Fmt>
         <Dec></Dec>
         <Thou></Thou>
       </NumberFormat>
       <NoOfSymbols>1625</NoOfSymbols>
       <Offset>0</Offset>
       <Length>32500</Length>
       <Comment></Comment>
       <Tags>
         <String>$ascii</String>
         <String>$text</String>
         <String>$key</String>
       </Tags>
     </QvdFieldHeader>
     <QvdFieldHeader>
       <FieldName>OpportunityIsDeleted</FieldName>
       <BitOffset>0</BitOffset>
       <BitWidth>0</BitWidth>
       <Bias>0</Bias>
       <NumberFormat>
         <Type>INTEGER</Type>
         <nDec>0</nDec>
         <UseThou>0</UseThou>
         <Fmt></Fmt>
         <Dec>.</Dec>
         <Thou>,</Thou>
       </NumberFormat>
       <NoOfSymbols>1</NoOfSymbols>
       <Offset>32500</Offset>
       <Length>5</Length>
       <Comment></Comment>
       <Tags>
         <String>$numeric</String>
         <String>$integer</String>
       </Tags>
     </QvdFieldHeader>
     <QvdFieldHeader>
       <FieldName>AccountId</FieldName>
       <BitOffset>11</BitOffset>
       <BitWidth>10</BitWidth>
       <Bias>0</Bias>
       <NumberFormat>
         <Type>ASCII</Type>
         <nDec>0</nDec>
         <UseThou>0</UseThou>
         <Fmt></Fmt>
         <Dec></Dec>
         <Thou></Thou>
       </NumberFormat>
       <NoOfSymbols>546</NoOfSymbols>
       <Offset>32505</Offset>
       <Length>10920</Length>
       <Comment></Comment>
       <Tags>
         <String>$ascii</String>
         <String>$text</String>
         <String>$key</String>
       </Tags>
     </QvdFieldHeader>
     <QvdFieldHeader>
       <FieldName>OpportunityName</FieldName>
       <BitOffset>21</BitOffset>
       <BitWidth>11</BitWidth>
       <Bias>0</Bias>
       <NumberFormat>
         <Type>ASCII</Type>
         <nDec>0</nDec>
         <UseThou>0</UseThou>
         <Fmt></Fmt>
         <Dec></Dec>
         <Thou></Thou>
       </NumberFormat>
       <NoOfSymbols>1443</NoOfSymbols>
       <Offset>43425</Offset>
       <Length>40931</Length>
       <Comment></Comment>
       <Tags>
         <String>$text</String>
       </Tags>
     </QvdFieldHeader>
     <QvdFieldHeader>
       <FieldName>OpportunityDescription</FieldName>
       <BitOffset>55</BitOffset>
       <BitWidth>9</BitWidth>
       <Bias>-2</Bias>
       <NumberFormat>
         <Type>ASCII</Type>
         <nDec>0</nDec>
         <UseThou>0</UseThou>
         <Fmt></Fmt>
         <Dec></Dec>
         <Thou></Thou>
       </NumberFormat>
       <NoOfSymbols>458</NoOfSymbols>
       <Offset>84356</Offset>
       <Length>86243</Length>
       <Comment></Comment>
       <Tags>
         <String>$text</String>
       </Tags>
     </QvdFieldHeader>
     <QvdFieldHeader>
       <FieldName>StageName</FieldName>
       <BitOffset>74</BitOffset>
       <BitWidth>6</BitWidth>
       <Bias>0</Bias>
       <NumberFormat>
         <Type>ASCII</Type>
         <nDec>0</nDec>
         <UseThou>0</UseThou>
         <Fmt></Fmt>
         <Dec></Dec>
         <Thou></Thou>
       </NumberFormat>
       <NoOfSymbols>9</NoOfSymbols>
       <Offset>170599</Offset>
       <Length>141</Length>
       <Comment></Comment>
       <Tags>
         <String>$ascii</String>
         <String>$text</String>
       </Tags>
     </QvdFieldHeader>
     <QvdFieldHeader>
       <FieldName>Amount</FieldName>
       <BitOffset>32</BitOffset>
       <BitWidth>10</BitWidth>
       <Bias>-2</Bias>
       <NumberFormat>
         <Type>MONEY</Type>
         <nDec>0</nDec>
         <UseThou>0</UseThou>
         <Fmt></Fmt>
         <Dec>.</Dec>
         <Thou>,</Thou>
       </NumberFormat>
       <NoOfSymbols>815</NoOfSymbols>
       <Offset>170740</Offset>
       <Length>8945</Length>
       <Comment></Comment>
       <Tags>
         <String>$numeric</String>
       </Tags>
     </QvdFieldHeader>
     <QvdFieldHeader>
       <FieldName>ExpectedRevenue</FieldName>
       <BitOffset>64</BitOffset>
       <BitWidth>10</BitWidth>
       <Bias>-2</Bias>
       <NumberFormat>
         <Type>MONEY</Type>
         <nDec>0</nDec>
         <UseThou>0</UseThou>
         <Fmt></Fmt>
         <Dec>.</Dec>
         <Thou>,</Thou>
       </NumberFormat>
       <NoOfSymbols>693</NoOfSymbols>
       <Offset>179685</Offset>
       <Length>7664</Length>
       <Comment></Comment>
       <Tags>
         <String>$numeric</String>
       </Tags>
     </QvdFieldHeader>
     <QvdFieldHeader>
       <FieldName>TotalOpportunityQuantity</FieldName>
       <BitOffset>48</BitOffset>
       <BitWidth>7</BitWidth>
       <Bias>-2</Bias>
       <NumberFormat>
         <Type>REAL</Type>
         <nDec>0</nDec>
         <UseThou>0</UseThou>
         <Fmt></Fmt>
         <Dec>.</Dec>
         <Thou>,</Thou>
       </NumberFormat>
       <NoOfSymbols>89</NoOfSymbols>
       <Offset>187349</Offset>
       <Length>545</Length>
       <Comment></Comment>
       <Tags>
         <String>$numeric</String>
       </Tags>
     </QvdFieldHeader>
     <QvdFieldHeader>
       <FieldName>CloseDateRaw</FieldName>
       <BitOffset>98</BitOffset>
       <BitWidth>10</BitWidth>
       <Bias>0</Bias>
       <NumberFormat>
         <Type>DATE</Type>
         <nDec>0</nDec>
         <UseThou>0</UseThou>
         <Fmt>YYYY-MM-DD</Fmt>
         <Dec></Dec>
         <Thou></Thou>
       </NumberFormat>
       <NoOfSymbols>915</NoOfSymbols>
       <Offset>187894</Offset>
       <Length>6659</Length>
       <Comment></Comment>
       <Tags>
         <String>$numeric</String>
         <String>$timestamp</String>
       </Tags>
     </QvdFieldHeader>
     <QvdFieldHeader>
       <FieldName>Type</FieldName>
       <BitOffset>118</BitOffset>
       <BitWidth>2</BitWidth>
       <Bias>-2</Bias>
       <NumberFormat>
         <Type>ASCII</Type>
         <nDec>0</nDec>
         <UseThou>0</UseThou>
         <Fmt></Fmt>
         <Dec></Dec>
         <Thou></Thou>
       </NumberFormat>
       <NoOfSymbols>2</NoOfSymbols>
       <Offset>194553</Offset>
       <Length>33</Length>
       <Comment></Comment>
       <Tags>
         <String>$ascii</String>
         <String>$text</String>
       </Tags>
     </QvdFieldHeader>
     <QvdFieldHeader>
       <FieldName>NextStep</FieldName>
       <BitOffset>89</BitOffset>
       <BitWidth>9</BitWidth>
       <Bias>-2</Bias>
       <NumberFormat>
         <Type>ASCII</Type>
         <nDec>0</nDec>
         <UseThou>0</UseThou>
         <Fmt></Fmt>
         <Dec></Dec>
         <Thou></Thou>
       </NumberFormat>
       <NoOfSymbols>318</NoOfSymbols>
       <Offset>194586</Offset>
       <Length>8963</Length>
       <Comment></Comment>
       <Tags>
         <String>$text</String>
       </Tags>
     </QvdFieldHeader>
     <QvdFieldHeader>
       <FieldName>LeadSource</FieldName>
       <BitOffset>84</BitOffset>
       <BitWidth>5</BitWidth>
       <Bias>-2</Bias>
       <NumberFormat>
         <Type>ASCII</Type>
         <nDec>0</nDec>
         <UseThou>0</UseThou>
         <Fmt></Fmt>
         <Dec></Dec>
         <Thou></Thou>
       </NumberFormat>
       <NoOfSymbols>18</NoOfSymbols>
       <Offset>203549</Offset>
       <Length>248</Length>
       <Comment></Comment>
       <Tags>
         <String>$ascii</String>
         <String>$text</String>
       </Tags>
     </QvdFieldHeader>
     <QvdFieldHeader>
       <FieldName>IsClosed</FieldName>
       <BitOffset>124</BitOffset>
       <BitWidth>1</BitWidth>
       <Bias>0</Bias>
       <NumberFormat>
         <Type>UNKNOWN</Type>
         <nDec>0</nDec>
         <UseThou>0</UseThou>
         <Fmt></Fmt>
         <Dec></Dec>
         <Thou></Thou>
       </NumberFormat>
       <NoOfSymbols>2</NoOfSymbols>
       <Offset>203797</Offset>
       <Length>10</Length>
       <Comment></Comment>
       <Tags>
         <String>$numeric</String>
         <String>$integer</String>
       </Tags>
     </QvdFieldHeader>
     <QvdFieldHeader>
       <FieldName>IsWon</FieldName>
       <BitOffset>125</BitOffset>
       <BitWidth>1</BitWidth>
       <Bias>0</Bias>
       <NumberFormat>
         <Type>UNKNOWN</Type>
         <nDec>0</nDec>
         <UseThou>0</UseThou>
         <Fmt></Fmt>
         <Dec></Dec>
         <Thou></Thou>
       </NumberFormat>
       <NoOfSymbols>2</NoOfSymbols>
       <Offset>203807</Offset>
       <Length>10</Length>
       <Comment></Comment>
       <Tags>
         <String>$numeric</String>
         <String>$integer</String>
       </Tags>
     </QvdFieldHeader>
     <QvdFieldHeader>
       <FieldName>ForecastCategory</FieldName>
       <BitOffset>108</BitOffset>
       <BitWidth>4</BitWidth>
       <Bias>0</Bias>
       <NumberFormat>
         <Type>ASCII</Type>
         <nDec>0</nDec>
         <UseThou>0</UseThou>
         <Fmt></Fmt>
         <Dec></Dec>
         <Thou></Thou>
       </NumberFormat>
       <NoOfSymbols>5</NoOfSymbols>
       <Offset>203817</Offset>
       <Length>47</Length>
       <Comment></Comment>
       <Tags>
         <String>$ascii</String>
         <String>$text</String>
       </Tags>
     </QvdFieldHeader>
     <QvdFieldHeader>
       <FieldName>ForecastCategoryName</FieldName>
       <BitOffset>112</BitOffset>
       <BitWidth>3</BitWidth>
       <Bias>0</Bias>
       <NumberFormat>
         <Type>ASCII</Type>
         <nDec>0</nDec>
         <UseThou>0</UseThou>
         <Fmt></Fmt>
         <Dec></Dec>
         <Thou></Thou>
       </NumberFormat>
       <NoOfSymbols>5</NoOfSymbols>
       <Offset>203864</Offset>
       <Length>46</Length>
       <Comment></Comment>
       <Tags>
         <String>$ascii</String>
         <String>$text</String>
       </Tags>
     </QvdFieldHeader>
     <QvdFieldHeader>
       <FieldName>CampaignId</FieldName>
       <BitOffset>42</BitOffset>
       <BitWidth>6</BitWidth>
       <Bias>-2</Bias>
       <NumberFormat>
         <Type>ASCII</Type>
         <nDec>0</nDec>
         <UseThou>0</UseThou>
         <Fmt></Fmt>
         <Dec></Dec>
         <Thou></Thou>
       </NumberFormat>
       <NoOfSymbols>45</NoOfSymbols>
       <Offset>203910</Offset>
       <Length>900</Length>
       <Comment></Comment>
       <Tags>
         <String>$ascii</String>
         <String>$text</String>
       </Tags>
     </QvdFieldHeader>
     <QvdFieldHeader>
       <FieldName>HasOpportunityLineItem</FieldName>
       <BitOffset>126</BitOffset>
       <BitWidth>2</BitWidth>
       <Bias>0</Bias>
       <NumberFormat>
         <Type>INTEGER</Type>
         <nDec>0</nDec>
         <UseThou>0</UseThou>
         <Fmt></Fmt>
         <Dec>.</Dec>
         <Thou>,</Thou>
       </NumberFormat>
       <NoOfSymbols>2</NoOfSymbols>
       <Offset>204810</Offset>
       <Length>10</Length>
       <Comment></Comment>
       <Tags>
         <String>$numeric</String>
         <String>$integer</String>
       </Tags>
     </QvdFieldHeader>
     <QvdFieldHeader>
       <FieldName>FiscalQuarter</FieldName>
       <BitOffset>120</BitOffset>
       <BitWidth>2</BitWidth>
       <Bias>0</Bias>
       <NumberFormat>
         <Type>INTEGER</Type>
         <nDec>0</nDec>
         <UseThou>0</UseThou>
         <Fmt></Fmt>
         <Dec>.</Dec>
         <Thou>,</Thou>
       </NumberFormat>
       <NoOfSymbols>4</NoOfSymbols>
       <Offset>204820</Offset>
       <Length>20</Length>
       <Comment></Comment>
       <Tags>
         <String>$numeric</String>
         <String>$integer</String>
       </Tags>
     </QvdFieldHeader>
     <QvdFieldHeader>
       <FieldName>FiscalYear</FieldName>
       <BitOffset>80</BitOffset>
       <BitWidth>4</BitWidth>
       <Bias>0</Bias>
       <NumberFormat>
         <Type>INTEGER</Type>
         <nDec>0</nDec>
         <UseThou>0</UseThou>
         <Fmt></Fmt>
         <Dec>.</Dec>
         <Thou>,</Thou>
       </NumberFormat>
       <NoOfSymbols>15</NoOfSymbols>
       <Offset>204840</Offset>
       <Length>75</Length>
       <Comment></Comment>
       <Tags>
         <String>$numeric</String>
         <String>$integer</String>
       </Tags>
     </QvdFieldHeader>
     <QvdFieldHeader>
       <FieldName>Op_Currency</FieldName>
       <BitOffset>122</BitOffset>
       <BitWidth>2</BitWidth>
       <Bias>0</Bias>
       <NumberFormat>
         <Type>ASCII</Type>
         <nDec>0</nDec>
         <UseThou>0</UseThou>
         <Fmt></Fmt>
         <Dec></Dec>
         <Thou></Thou>
       </NumberFormat>
       <NoOfSymbols>3</NoOfSymbols>
       <Offset>204915</Offset>
       <Length>15</Length>
       <Comment></Comment>
       <Tags>
         <String>$ascii</String>
         <String>$text</String>
       </Tags>
     </QvdFieldHeader>
     <QvdFieldHeader>
       <FieldName>Probability</FieldName>
       <BitOffset>115</BitOffset>
       <BitWidth>3</BitWidth>
       <Bias>0</Bias>
       <NumberFormat>
         <Type>REAL</Type>
         <nDec>0</nDec>
         <UseThou>0</UseThou>
         <Fmt>##############</Fmt>
         <Dec>.</Dec>
         <Thou>,</Thou>
       </NumberFormat>
       <NoOfSymbols>7</NoOfSymbols>
       <Offset>204930</Offset>
       <Length>55</Length>
       <Comment></Comment>
       <Tags>
         <String>$numeric</String>
       </Tags>
     </QvdFieldHeader>
   </Fields>
   <Compression></Compression>
   <RecordByteSize>16</RecordByteSize>
   <NoOfRecords>1625</NoOfRecords>
   <Offset>204985</Offset>
   <Length>26000</Length>
   <Lineage>
     <LineageInfo>
       <Discriminator>INLINE</Discriminator>
       <Statement></Statement>
     </LineageInfo>
     <LineageInfo>
       <Discriminator>Provider=QvSalesforceConnector.exe;mode=BULK;timeout=100;batchSize=500;ProxyAuthentication=0;</Discriminator>
       <Statement>OpportunityLineItemRaw:
LOAD
    OpportunityId,
    PricebookEntryId,
    Quantity as [Opportunity Qty],
    TotalPrice as [Opportunity Total Price],
    UnitPrice as [Opportunity Unit Price],
    ListPrice as [Opportunity List Price];SELECT *
FROM OpportunityLineItem</Statement>
     </LineageInfo>
     <LineageInfo>
       <Discriminator>Provider=QvSalesforceConnector.exe;mode=BULK;timeout=100;batchSize=500;ProxyAuthentication=0;</Discriminator>
       <Statement>OpsRaw:
LOAD Id as  OpportunityId, 
	IsDeleted as  OpportunityIsDeleted, 
	AccountId, 
	Name as  OpportunityName, 
	Description as  OpportunityDescription, 
	StageName, 
	Amount, 
	ExpectedRevenue, 
	TotalOpportunityQuantity, 
	CloseDate as CloseDateRaw, 
	Type, 
	NextStep, 
	LeadSource, 
	if(IsClosed	='true',1,if(IsClosed	='false',0,IsClosed)) as IsClosed, 
	if(IsWon		='true',1,if(IsWon		='false',0,IsWon)) as IsWon, 
	ForecastCategory, 
	ForecastCategoryName, 
	CampaignId, 
	HasOpportunityLineItem
	, FiscalQuarter			
	, FiscalYear
	, CurrencyIsoCode as Op_Currency
	, Probability/100 as Probability	;SELECT *
FROM Opportunity</Statement>
     </LineageInfo>
     <LineageInfo>
       <Discriminator>Provider=QvSalesforceConnector.exe;mode=BULK;timeout=100;batchSize=500;ProxyAuthentication=0;</Discriminator>
       <Statement>PricebookEntryRaw:
LOAD Id as PricebookEntryId,
    Product2Id;Select *
FROM PricebookEntry</Statement>
     </LineageInfo>
     <LineageInfo>
       <Discriminator>Provider=QvSalesforceConnector.exe;mode=BULK;timeout=100;batchSize=500;ProxyAuthentication=0;</Discriminator>
       <Statement>ProductRaw:
LOAD 
	Id as Product2Id,
    Name as [Product Name],
    ProductCode as [Product Code],
    Description as [Product Description],
    IsActive as Product2IsActive,
    Family as Product2Family;SELECT *
FROM Product2</Statement>
     </LineageInfo>
     <LineageInfo>
       <Discriminator>Provider=QvSalesforceConnector.exe;mode=BULK;timeout=100;batchSize=500;ProxyAuthentication=0;</Discriminator>
       <Statement>QuotesRaw:
LOAD
Id as QuoteId, 
	IsDeleted as QuoteIsDeleted, 
	Name as QuoteName, 
	CurrencyIsoCode, 
	Date(CreatedDate) as QuoteCreatedDate, 
	LastModifiedDate, 
	OpportunityId, 
	Pricebook2Id, 
	ContactId, 
	QuoteNumber, 
	ShippingHandling, 
	Tax, 
	Status, 
	ExpirationDate, 
	Description  as QuoteDescription, 
	Subtotal as QuoteSubtotal, 
	TotalPrice as QuoteTotalPrice, 
	LineItemCount, 
	Discount as QuoteDiscount, 
	GrandTotal as QuoteGrandTotal
	,date(MonthStart(Date(CreatedDate)),'MMM YY') as QuoteMonth;SELECT *
FROM Quote</Statement>
     </LineageInfo>
     <LineageInfo>
       <Discriminator>Provider=QvSalesforceConnector.exe;mode=BULK;timeout=100;batchSize=500;ProxyAuthentication=0;</Discriminator>
       <Statement>SELECT *
FROM Account</Statement>
     </LineageInfo>
     <LineageInfo>
       <Discriminator>Provider=QvSalesforceConnector.exe;mode=BULK;timeout=100;batchSize=500;ProxyAuthentication=0;</Discriminator>
       <Statement>SELECT *
FROM Opportunity</Statement>
     </LineageInfo>
     <LineageInfo>
       <Discriminator>Provider=QvSalesforceConnector.exe;mode=BULK;timeout=100;batchSize=500;ProxyAuthentication=0;</Discriminator>
       <Statement>SELECT *
FROM OpportunityLineItem</Statement>
     </LineageInfo>
     <LineageInfo>
       <Discriminator>Provider=QvSalesforceConnector.exe;mode=BULK;timeout=100;batchSize=500;ProxyAuthentication=0;</Discriminator>
       <Statement>SELECT *
FROM Product2</Statement>
     </LineageInfo>
     <LineageInfo>
       <Discriminator>Provider=QvSalesforceConnector.exe;mode=BULK;timeout=100;batchSize=500;ProxyAuthentication=0;</Discriminator>
       <Statement>SELECT *
FROM Quote</Statement>
     </LineageInfo>
     <LineageInfo>
       <Discriminator>Provider=QvSalesforceConnector.exe;mode=BULK;timeout=100;batchSize=500;ProxyAuthentication=0;</Discriminator>
       <Statement>SFRaw:
LOAD  
	Id 					As AccountId, 
	IsDeleted 			As AccountIsDeleted, 
	Name				As AccountName, 
	Type 				As AccountType, 
	BillingStreet, 
	BillingCity, 
	BillingPostalCode, 
	BillingCountry, 
	
	
	ShippingStreet, 
	ShippingCity, 
	ShippingState, 
	ShippingPostalCode, 
	
	
	Phone 				As AccountPhone, 
	Fax 					As AccountFax, 
	if(AccountNumber='' or(AccountNumber=' '),Null(),AccountNumber)		As Customer, 
	Website, 
	Industry, 
	Description 			As AccountDescription, 
	Rating, 
	Site, 
	OwnerId 			As AccountOwnerId, 
	CreatedDate 			As AccountCreatedDate, 
	LastModifiedDate 	As AccountLastModifiedDate, 
	LastActivityDate		As AccountLastActivityDate	, 
	Total_Sales__c
	;SELECT *
FROM Account</Statement>
     </LineageInfo>
     <LineageInfo>
       <Discriminator>Provider=QvSalesforceConnector.exe;mode=BULK;timeout=100;batchSize=500;ProxyAuthentication=0;</Discriminator>
       <Statement>Select *
FROM PricebookEntry</Statement>
     </LineageInfo>
     <LineageInfo>
       <Discriminator>STORE - Opportunity.qvd (qvd)</Discriminator>
       <Statement></Statement>
     </LineageInfo>
     <LineageInfo>
       <Discriminator>STORE - SalesForceAccounts.qvd (qvd)</Discriminator>
       <Statement></Statement>
     </LineageInfo>
   </Lineage>
   <Comment></Comment>
 </QvdTableHeader>
 00620000001P8u2AAC 00620000001PLUJAA4 00620000001PphUAAS 00620000001PuyYAAS 00620000001Q77rAAC 00620000001RASJAA4 00620000001RAofAAG 00620000001Tt2aAAC 00620000001xmkhAAA 00620000002QPeTAAW 00620000003JS20AAG 006200000073jjcAAA 00620000007ivSLAAY 0062000000ALiNTAA1 0062000000CEQUPAA5 0062000000DDi3TAAT 0062000000DRMB0AAP 0062000000DRcV2AAL 0062000000DRcVOAA1 0062000000DqUxAAAV 0062000000EM1JfAAL 0062000000EOAAUAA5 0062000000ElbwdAAB 00620000001TEGBAA4 00620000001YYKnAAO 00620000001wa0xAAA 00620000001wsl6AAA 006200000021LLgAAM 006200000021QCkAAM 006200000024pA5AAI 00620000002DDEHAA4 00620000002GFvHAAW 00620000002GsMBAA0 00620000002diTUAAY 00620000004MotRAAS 00620000006aYHtAAM 006200000072cozAAA 006200000072wegAAA 006200000073yTdAAI 006200000074J9EAAU 006200000074JCVAA2 00620000007kFfuAAE 0062000000840XLAAY 00620000008579FAAQ 00620000008RGBrAAO 00620000008RGCxAAO 00620000009H4KeAAK 00620000009JAXvAAO 0062000000ANoSKAA1 0062000000Bd88dAAB 0062000000C0UnmAAF 0062000000C0XKJAA3 0062000000C0cvOAAR 0062000000DVlEMAA1 0062000000DqNhAAAV 0062000000DqmNiAAJ 0062000000E3jDnAAJ 0062000000ElQeEAAV 0062000000F1EWtAAN 0062000000F8rXnAAJ 0062000000Gj6XmAAJ 0062000000DRV0MAAX 0062000000DRKqiAAH 00620000001zDF9AAM 00620000001YsMFAA0 00620000003uWomAAE 0062000000Ac5BuAAJ 006200000024h1iAAA 006200000029tSsAAI 00620000002EAkwAAG 006200000073jlpAAA 006D000000MZsGQIA1 0062000000DRKbAAAX 0062000000CtocTAAR 0062000000DRLUOAA5 0062000000E4B5IAAV 0062000000CqdtHAAR 00620000001OPnyAAG 00620000001QNQcAAO 006200000071pO9AAI 0062000000DE30PAAT 006D000000MZs45IAD 00620000001TEFDAA4 00620000001b3xMAAQ 00620000006bsFKAAY 006200000072hQPAAY 00620000002FPdMAAW 00620000009FxioAAC 0062000000C0UwjAAF 00620000001MjwNAAS 00620000001XofrAAC 0062000000847i2AAA 006200000020qi5AAA 00620000002Eit5AAC 00620000002GFx8AAG 006200000073jfuAAA 006200000022vQpAAI 00620000001Ood9AAC 00620000001OoilAAC 00620000001Oor2AAC 00620000001OoskAAC 00620000001Op3xAAC 00620000001Q7B2AAK 00620000001QeiUAAS 00620000001Qf4HAAS 00620000001Qf5bAAC 00620000001UCgdAAG 00620000001akILAAY 00620000001bfsvAAA 00620000001c8P8AAI 00620000001kpvMAAQ 00620000001lPOQAA2 00620000001wsLFAAY 006200000021M3KAAU 00620000002379pAAA 0062000000237BeAAI 00620000002EUSXAA4 00620000002EqxuAAC 00620000002QLvUAAW 00620000002TQkvAAG 00620000002gWFuAAM 006200000033OcmAAE 006200000033OgPAAU 006200000033aNnAAI 0062000000344ClAAI 0062000000344ERAAY 0062000000345D1AAI 006200000034uRNAAY 00620000003uBQ6AAM 006200000060PUzAAM 006200000062j1fAAA 006200000063rpZAAQ 00620000006a3dhAAA 006200000084Gz7AAE 006200000085WoKAAU 00620000008qfGNAAY 00620000008rYwEAAU 00620000009JDzXAAW 00620000009mNo7AAE 0062000000AMUaWAAX 0062000000AchLMAAZ 0062000000AxfMqAAJ 0062000000AzdeXAAR 0062000000BIaC4AAL 0062000000CGMdqAAH 0062000000CtydjAAB 0062000000DDTz4AAH 0062000000DRdcUAAT 0062000000DqP5KAAV 0062000000FC29iAAD 0062000000FCb6XAAT 0062000000GOwSjAAL 0062000000GksA2AAJ 006D000000H3vogIAB 006D000000La4G6IAJ 006D000000MZs1QIAT 006D000000MZsCYIA1 006D000000MZsJGIA1 006D000000MZsR0IAL 006D000000MZsgsIAD 006D000000NflG8IAJ 006D000000NgoXZIAZ 006D000000QY4wlIAD 006D000000QYAIQIA5 006D000000TiD54IAF 006D000000Tiw7JIAR 006D000000Tj8ONIAZ 006D000000Y9humIAB 00620000001PwPpAAK 00620000001Q13vAAC 00620000001QgAkAAK 00620000001S2dDAAS 00620000001TECxAAO 00620000001UV6AAAW 00620000001YYu4AAG 00620000001ZL4EAAW 00620000001apN7AAI 00620000001dKKxAAM 00620000001eA0kAAE 00620000001eA5ZAAU 00620000001eIR6AAM 00620000001eITgAAM 00620000001mQCQAA2 00620000001mdtMAAQ 00620000001mdu9AAA 00620000001zA54AAE 00620000001zosAAAQ 00620000001zsegAAA 00620000001ztx7AAA 006200000021QdWAAU 006200000023AEDAA2 006200000023AF5AAM 006200000023fdfAAA 006200000023qLGAAY 006200000024brAAAQ 006200000024kckAAA 006200000029K6eAAE 006200000029gV7AAI 00620000002Q8bRAAS 00620000002diV5AAI 00620000002diVEAAY 00620000003JipiAAC 00620000003KBIfAAO 00620000003KBKJAA4 00620000003LYQYAA4 00620000004vpIuAAI 006200000064CaHAAU 00620000006Y0UPAA0 00620000006Y1MKAA0 00620000006Y1TpAAK 006200000074JAsAAM 006200000074RaNAAU 006200000074RbpAAE 00620000007hbeUAAQ 00620000007hbu3AAA 00620000007hbu4AAA 00620000007hqwmAAA 00620000007iOODAA2 00620000007kFm4AAE 00620000007lE1nAAE 00620000007lE2CAAU 00620000007lE4aAAE 00620000007lE4bAAE 00620000007lE4lAAE 00620000007lE5YAAU 00620000009FxpeAAC 00620000009bwE3AAI 00620000009dqhXAAQ 00620000009lLVUAA2 0062000000ANcsgAAD 0062000000ANie1AAD 0062000000Ach2fAAB 0062000000Ach5oAAB 0062000000Ach5pAAB 0062000000Ach5uAAB 0062000000AchAOAAZ 0062000000AchAPAAZ 0062000000AchCPAAZ 0062000000AchEgAAJ 0062000000AchFKAAZ 0062000000AfQ0XAAV 0062000000B0HiOAAV 0062000000B0I6tAAF 0062000000CsBg6AAF 0062000000DP9rhAAD 0062000000DR3wYAAT 0062000000F8jbAAAR 0062000000F8rY7AAJ 0062000000F8rYHAAZ 0062000000GMqKmAAL 0062000000GO3DMAA1 0062000000GOHAdAAP 0062000000GPDFwAAP 0062000000GPsZvAAL 0062000000Gi5eFAAR 006D000000H3qobIAB 006D000000H3vs4IAB 006D000000H4oaqIAB 006D000000H5jSKIAZ 006D000000HiOopIAF 006D000000NfkkpIAB 006D000000NgPTlIAN 006D000000NgPUUIA3 006D000000NgPuIIAV 006D000000NgPvIIAV 006D000000NgPvRIAV 006D000000NgPvkIAF 006D000000NgQ1EIAV 006D000000NgQ1xIAF 006D000000NgQ6EIAV 006D000000NgQ7DIAV 006D000000NgQ7OIAV 006D000000NgQA2IAN 006D000000NgRBuIAN 006D000000NgREKIA3 006D000000NgRFrIAN 006D000000NgRGfIAN 006D000000NgTdnIAF 006D000000NgUzTIAV 006D000000NgV23IAF 006D000000NgV3kIAF 006D000000NgVWFIA3 006D000000NgVe9IAF 006D000000Pb4pEIAR 006D000000QYqHHIA1 006D000000RKw1tIAD 006D000000RKySDIA1 006D000000RLhHiIAL 006D000000RLhL1IAL 006D000000S57heIAB 006D000000TiCfRIAV 006D000000TiCfbIAF 006D000000TiCflIAF 006D000000TiCgMIAV 006D000000TiCgRIAV 006D000000TiCgqIAF 006D000000TiCh5IAF 006D000000TiChFIAV 006D000000TiChKIAV 006D000000TiChZIAV 006D000000TiChjIAF 006D000000TiCiDIAV 006D000000TiCiNIAV 006D000000TiDPPIA3 006D000000TiDPZIA3 006D000000TiDYpIAN 006D000000TjV6mIAF 006D000000V7TvJIAV 006D000000V8wz3IAB 006D000000VvTLlIAN 006D000000NgTTcIAN 006200000029xfUAAQ 00620000002Q6jbAAC 00620000001RoClAAK 00620000001SIm9AAG 00620000002EWhoAAG 0062000000CEZT1AAP 0062000000E70JmAAJ 00620000006bwjEAAQ 00620000001WElEAAW 00620000001QNqkAAG 00620000002E9ouAAC 0062000000720awAAA 006200000072cp1AAA 006200000074PMrAAM 00620000001mQ1VAAU 0062000000CtKUJAA3 00620000001RFNpAAO 00620000001mafLAAQ 00620000007S69KAAS 0062000000Ach5nAAB 00620000002BRZKAA4 0062000000FiiKKAAZ 006D000000NgQ7mIAF 006D000000NgPyjIAF 006D000000NgVZYIA3 006D000000PZUKvIAP 00620000001TEEdAAO 006D000000SYb73IAD 00620000001gCo9AAE 006D000000S6Qd4IAF 006D000000NgUxIIAV 00620000001wZV1AAM 0062000000ElY5EAAV 00620000001Re2sAAC 006D000000NgUueIAF 00620000001RJHyAAO 00620000001OQwwAAG 00620000001PvHQAA0 006200000021N4LAAU 006D000000NgQAqIAN 00620000001LttOAAS 00620000001LuV8AAK 00620000001xmmqAAA 00620000001xmoOAAQ 006200000029JTmAAM 00620000002H0fjAAC 00620000002H0hMAAS 00620000002H0hbAAC 006D000000VwJzuIAF 006D000000VzCrPIAV 0062000000GMHhlAAH 006D000000X8gvOIAR 006D000000VxB7dIAF 006D000000S57moIAB 006D000000TjVkTIAV 006D000000S57l7IAB 006D000000YBcpdIAD 006D000000X70n2IAB 006D000000cZLm8IAG 006D000000aZF9HIAW 00620000001QrW7AAK 006D000000eETXRIA4 006D000000cbMAxIAM 006D000000Vx2ySIAR 006D000000TiCeeIAF 0062000000DRLNsAAP 006D000000g9gtKIAQ 006D000000V8pkNIAR 006D000000MZsflIAD 006D000000RKvqaIAD 006D000000RLhBpIAL 006D000000RO0BMIA1 006D000000TiDPtIAN 006D000000TiDQ8IAN 006D000000TiDQIIA3 006D000000V8Y95IAF 006D000000V8YAIIA3 006D000000V8YB6IAN 006D000000V9XgMIAV 006D000000VzCq1IAF 006D000000X7P6QIAV 006D000000X7l8ZIAR 006D000000X7lGlIAJ 006D000000X7lH0IAJ 006D000000X7lHUIAZ 006D000000X7lHeIAJ 006D000000X7lHoIAJ 006D000000X7lI8IAJ 006D000000cbEntIAE 006D000000eETgsIAG 006D000000eETh2IAG 006D000000eETh7IAG 006D000000eEThCIAW 006D000000bPfaQIAS 00620000003LqLmAAK 006D000000H3y1rIAB 006D000000NfkzlIAB 006200000072hYOAAY 00620000009e3TaAAI 006D000000YCkFfIAL 006D000000fJgi9IAC 006D000000fK8kkIAC 006D000000hHl5DIAS 006D000000fK21MIAS 006D000000gA9KNIA0 006D000000bPYoiIAG 006D000000ThlROIAZ 0062000000GPuCkAAL 00620000001dKRuAAM 00620000007SLwPAAW 00620000001PPNGAA4 0062000000840XFAAY 0062000000DP9G4AAL 00620000001PqmDAAS 006D000000NgV15IAF 006200000021Q6aAAE 006200000072cp2AAA 0062000000ANi4IAAT 006D000000NgTnTIAV 006D000000Sa0E5IAJ 006D000000SZpYOIA1 00620000006aXjPAAU 00620000008tyWgAAI 0062000000FhDbuAAF 006D000000NgTV5IAN 00620000001SgLQAA0 00620000001dK45AAE 006D000000MZs8gIAD 00620000002cm8LAAQ 006D000000h2vWeIAI 006D000000V9HRcIAN 00620000001buX0AAI 006D000000isR2mIAE 006D000000SaynFIAR 00620000001b1GYAAY 006200000029HJ9AAM 006D000000fGiTRIA0 006D000000iuUXyIAM 006D000000fI8WXIA0 006D000000fIAE8IAO 006D000000hHNq2IAG 006D000000cbF3MIAU 006D000000fHihlIAC 006D000000fIA43IAG 006D000000fIA4SIAW 006D000000fIA8UIAW 006D000000fIAA6IAO 006D000000fIABYIA4 006D000000fIADUIA4 006D000000fIGKPIA4 006D000000hGtNdIAK 006D000000i2KC6IAM 006D000000i2KF5IAM 006D000000itTY0IAM 006D000000k0UESIA2 006D000000k1GofIAE 006D000000k24QhIAI 006D000000k24dRIAQ 006D000000ksDHUIA2 006D000000lIAPAIA4 006D000000lIOr9IAG 006D000000TiDHdIAN 006D000000TiDMTIA3 006D000000X70j2IAB 006D000000aXGxOIAW 006D000000cc1YJIAY 006D000000fIAAzIAO 006D000000YA9q1IAD 006D000000kpKxGIAU 006D000000kr4zLIAQ 006D000000kr4zQIAQ 006D000000lIOWfIAO 006D000000lIOWkIAO 006D000000lIOWpIAO 006D000000lIOWuIAO 006D000000kp9rbIAA 006D000000iuVH3IAM 006D000000iuVHDIA2 006D000000iuVIQIA2 006D000000iuVJJIA2 006D000000iuVJTIA2 006D000000iuVJmIAM 006D000000iuVKBIA2 006D000000iuVKaIAM 006D000000iuVLEIA2 006D000000iuVLrIAM 006D000000iuVMVIA2 006D000000kr5FmIAI 006D000000kr5FnIAI 00620000001M33rAAC 00620000001MIwOAAW 00620000001MJ8RAAW 00620000001Mj63AAC 00620000001OPw3AAG 00620000001OiMRAA0 00620000001OoiwAAC 00620000001OopkAAC 00620000001P96RAAS 00620000001PE3wAAG 00620000001PEc3AAG 00620000001PEgHAAW 00620000001PPXiAAO 00620000001PbipAAC 00620000001QSRmAAO 00620000001QW7yAAG 00620000001R6JWAA0 00620000001R6NLAA0 00620000001RASwAAO 00620000001RAfcAAG 00620000001RJrRAAW 00620000001Re33AAC 00620000001RsYMAA0 00620000001S3coAAC 00620000001SHjPAAW 00620000001SI73AAG 00620000001SL8eAAG 00620000001SSFMAA4 00620000001Say4AAC 00620000001SbRRAA0 00620000001TArgAAG 00620000001TDN6AAO 00620000001TDNkAAO 00620000001UGihAAG 00620000001UGkQAAW 00620000001UGrXAAW 00620000001UIrmAAG 00620000001UTN8AAO 00620000001UV64AAG 00620000001Vn4mAAC 00620000001WaSBAA0 00620000001WaUVAA0 00620000001WbSYAA0 00620000001WmJwAAK 00620000001X8flAAC 00620000001Xc6eAAC 00620000001Y63EAAS 00620000001YJ9rAAG 00620000001YR44AAG 00620000001Yg6pAAC 00620000001ZUwTAAW 00620000001agPEAAY 00620000001b2DLAAY 00620000001bfojAAA 00620000001cLX9AAM 00620000001ceu1AAA 00620000001d3NBAAY 00620000001e15iAAA 00620000001eLmDAAU 00620000001jv74AAA 00620000001kccxAAA 00620000001kpTyAAI 00620000001kpWTAAY 00620000001kqBgAAI 00620000001ltPPAAY 00620000001mSFsAAM 00620000001mUUzAAM 00620000001mctDAAQ 00620000001oel3AAA 00620000001wsv0AAA 00620000001x0WxAAI 00620000001xcbfAAA 00620000001xmgpAAA 00620000001yaWAAAY 00620000001zAfjAAE 00620000001zCluAAE 00620000001zpueAAA 00620000001zpxWAAQ 006200000020qyLAAQ 006200000021Ey6AAE 006200000021H5tAAE 006200000021LhqAAE 006200000021QXXAA2 006200000021UJdAAM 006200000022bUaAAI 006200000022bmLAAQ 006200000022bsMAAQ 006200000022dcTAAQ 006200000022i74AAA 006200000022i9QAAQ 006200000022jdeAAA 006200000022jdoAAA 006200000022vS9AAI 0062000000237HIAAY 006200000023IBwAAM 006200000023IUfAAM 006200000023IZ6AAM 006200000023iMcAAI 006200000023qH9AAI 006200000023qQbAAI 006200000023sAfAAI 006200000024H0CAAU 006200000024hH0AAI 006200000024mWRAAY 006200000024no6AAA 006200000024p0iAAA 006200000024p7nAAA 006200000029GCiAAM 006200000029XrJAAU 006200000029XriAAE 006200000029d0QAAQ 006200000029dSzAAI 006200000029eq9AAA 006200000029quvAAA 00620000002AgLYAA0 00620000002AgosAAC 00620000002AnEFAA0 00620000002AnJcAAK 00620000002AtNrAAK 00620000002BB09AAG 00620000002BC5iAAG 00620000002BC6WAAW 00620000002DJNuAAO 00620000002DJO4AAO 00620000002E1AKAA0 00620000002EULFAA4 00620000002EZc5AAG 00620000002EfWYAA0 00620000002EfcDAAS 00620000002FPcvAAG 00620000002FPeVAAW 00620000002H4aoAAC 00620000002HL2cAAG 00620000002HMvGAAW 00620000002PnZIAA0 00620000002PnntAAC 00620000002PqaPAAS 00620000002Pqh6AAC 00620000002QeftAAC 00620000002Qu24AAC 00620000002St3FAAS 00620000002TOTTAA4 00620000002cWXLAA2 00620000002cjxjAAA 00620000002diTDAAY 00620000002diUIAAY 00620000002feVQAAY 00620000002g5MJAAY 00620000002g6veAAA 00620000002gLlMAAU 00620000002gLplAAE 006200000032ctdAAA 006200000032elHAAQ 006200000032eq5AAA 006200000032eqpAAA 0062000000345HmAAI 006200000034uP4AAI 00620000003Ir5nAAC 00620000003JikWAAS 00620000003JiojAAC 00620000003JnKbAAK 00620000003JuvGAAS 00620000003JyqjAAC 00620000003LSXHAA4 00620000004KMVLAA4 00620000004M24xAAC 00620000004vXSJAA2 00620000004vxnkAAA 00620000004vxxzAAA 00620000004whzyAAA 00620000004xCYLAA2 00620000004xCYMAA2 00620000004xqLyAAI 0062000000615ABAAY 006200000062jw0AAA 006200000062xTmAAI 0062000000633ezAAA 006200000063u4FAAQ 006200000064CPsAAM 00620000006YHh8AAG 00620000006ZGG9AAO 00620000006Zq5UAAS 00620000006a3wRAAQ 00620000006a67qAAA 00620000006a8maAAA 00620000006aXcMAAU 00620000006aYIYAA2 00620000006bY1FAAU 00620000006bZknAAE 006200000071VMHAA2 006200000071pNuAAI 006200000072h8IAAQ 006200000073joEAAQ 006200000073jodAAA 006200000073jqeAAA 006200000073jrWAAQ 006200000074IFHAA2 006200000074PMsAAM 006200000074PQEAA2 006200000074PVIAA2 006200000074PYVAA2 006200000074QBLAA2 006200000074RZ5AAM 006200000074RZ6AAM 0062000000756X4AAI 006200000075IkJAAU 00620000007RDuqAAG 00620000007RDy8AAG 00620000007RrbFAAS 00620000007Sa26AAC 00620000007hbSGAAY 00620000007hky9AAA 00620000007hmPtAAI 00620000007hqPkAAI 00620000007hr27AAA 00620000007iCjAAAU 00620000007iCtpAAE 00620000007iF1XAAU 00620000007iIznAAE 00620000007iXPEAA2 00620000007iYjgAAE 00620000007ijP2AAI 00620000007ixEHAAY 00620000007kJCXAA2 00620000007lE2WAAU 006200000083aUyAAI 006200000083dkIAAQ 0062000000840XKAAY 006200000084RtSAAU 006200000084S6pAAE 006200000084sCyAAI 006200000085D9KAAU 006200000085RcrAAE 006200000085SguAAE 006200000085fsrAAA 0062000000860nxAAA 0062000000860tQAAQ 0062000000860zRAAQ 006200000086AVlAAM 006200000086ElxAAE 00620000008RJe4AAG 00620000008SJj7AAG 00620000008SVIFAA4 00620000008SVW8AAO 00620000008Txe6AAC 00620000008qblhAAA 00620000008qbulAAA 00620000008qovNAAQ 00620000008qpIHAAY 00620000008ttsWAAQ 006200000094X70AAE 00620000009H3DGAA0 00620000009HMRXAA4 00620000009HddpAAC 00620000009Hv2GAAS 00620000009IGvUAAW 00620000009IGvVAAW 00620000009IHmNAAW 00620000009adqUAAQ 00620000009bhLdAAI 00620000009dH85AAE 00620000009dHE9AAM 00620000009df2SAAQ 00620000009e5lCAAQ 00620000009lKohAAE 00620000009mLQEAA2 00620000009mLQFAA2 00620000009mMz9AAE 0062000000ALhLuAAL 0062000000AMRRcAAP 0062000000ANnvXAAT 0062000000AO3YZAA1 0062000000AcvlCAAR 0062000000AdCLIAA3 0062000000Af3qEAAR 0062000000Af70PAAR 0062000000AfQ3cAAF 0062000000AfQ9jAAF 0062000000AwdVAAAZ 0062000000AxK7CAAV 0062000000AxppKAAR 0062000000AxpqhAAB 0062000000AzTgNAAV 0062000000B06ELAAZ 0062000000BIBBLAA5 0062000000BIBFXAA5 0062000000Be6woAAB 0062000000Be747AAB 0062000000BgLJaAAN 0062000000C0UpZAAV 0062000000CEX4mAAH 0062000000CF4IPAA1 0062000000CF4RgAAL 0062000000CFPuPAAX 0062000000CFfatAAD 0062000000CGM34AAH 0062000000CGMNcAAP 0062000000CGWqkAAH 0062000000CHG04AAH 0062000000CHh8SAAT 0062000000CHp4pAAD 0062000000CqlJUAAZ 0062000000CqnFiAAJ 0062000000Cr6EgAAJ 0062000000CrrKwAAJ 0062000000Cscy3AAB 0062000000CtuYaAAJ 0062000000DDMcjAAH 0062000000DDckbAAD 0062000000DDitPAAT 0062000000DQ6hlAAD 0062000000DRKtwAAH 0062000000DRdgUAAT 0062000000DqNYAAA3 0062000000DqNg4AAF 0062000000DqNhyAAF 0062000000DqNp8AAF 0062000000DqO1UAAV 0062000000DqXa4AAF 0062000000Dqh2tAAB 0062000000DqsOvAAJ 0062000000E3p7bAAB 0062000000EM0g5AAD 0062000000EM0wVAAT 0062000000EMJcCAAX 0062000000EdGHBAA3 0062000000EdpFvAAJ 0062000000ElAswAAF 0062000000ElWKOAA3 0062000000F8w1wAAB 0062000000FA4ZIAA1 0062000000FC1YXAA1 0062000000FgoIOAAZ 0062000000Fgp2pAAB 0062000000FhDEcAAN 0062000000FhDFgAAN 0062000000FiMkGAAV 0062000000FjN58AAF 0062000000FjcMgAAJ 0062000000FkEnuAAF 0062000000GMUaZAAX 0062000000Ghi2BAAR 0062000000GkmGuAAJ 006D000000H4udMIAR 006D000000H5e4VIAR 006D000000HlakPIAR 006D000000NgVJYIA3 006D000000PaYLAIA3 006D000000PashFIAR 006D000000PbdiEIAR 006D000000RLhJ0IAL 006D000000Sad0xIAB 006D000000SadBCIAZ 006D000000SadBlIAJ 006D000000SadGWIAZ 006D000000SalQiIAJ 006D000000SauXiIAJ 006D000000Ti5npIAB 006D000000Ti64PIAR 006D000000Ti69iIAB 006D000000Ti69nIAB 006D000000Ti6A2IAJ 006D000000Ti6AHIAZ 006D000000Ti6AlIAJ 006D000000TiCFnIAN 006D000000TiCGmIAN 006D000000TiCH5IAN 006D000000TiDKcIAN 006D000000TiLv6IAF 006D000000TiM1OIAV 006D000000TiM5JIAV 006D000000TiMBdIAN 006D000000TiP5nIAF 006D000000TiP7EIAV 006D000000TiP82IAF 006D000000TiPADIA3 006D000000TiPCjIAN 006D000000TiPGfIAN 006D000000TiPaLIAV 006D000000TiPbsIAF 006D000000TiPdPIAV 006D000000TiQQFIA3 006D000000TiQQZIA3 006D000000TiQR8IAN 006D000000TiQijIAF 006D000000TiQkGIAV 006D000000TiQlnIAF 006D000000TiQnoIAF 006D000000TiQoNIAV 006D000000TiQpQIAV 006D000000TiR1VIAV 006D000000TiR4dIAF 006D000000TiRA6IAN 006D000000TiRGPIA3 006D000000TiRqLIAV 006D000000TiRrhIAF 006D000000TiS0UIAV 006D000000TiS2BIAV 006D000000TiS3sIAF 006D000000TiS4qIAF 006D000000TiScMIAV 006D000000TiSemIAF 006D000000TiSoEIAV 006D000000TibjiIAB 006D000000TioHhIAJ 006D000000TioJTIAZ 006D000000TioPiIAJ 006D000000Tir4FIAR 006D000000TiuzcIAB 006D000000TiwC9IAJ 006D000000TiwCJIAZ 006D000000Tiws6IAB 006D000000TiwskIAB 006D000000TiwwDIAR 006D000000TiwxaIAB 006D000000TiwyEIAR 006D000000TixOpIAJ 006D000000TixeiIAB 006D000000TixkvIAB 006D000000TjMmNIAV 006D000000TjMugIAF 006D000000TjN1DIAV 006D000000TjN4QIAV 006D000000TjN6MIAV 006D000000TjN96IAF 006D000000TjNA4IAN 006D000000TjNKTIA3 006D000000TjOLpIAN 006D000000TjOP8IAN 006D000000TjOsBIAV 006D000000TjOwSIAV 006D000000TjOyEIAV 006D000000TjP13IAF 006D000000TjP2BIAV 006D000000TjP6XIAV 006D000000TjP7uIAF 006D000000TjPAoIAN 006D000000TjPDdIAN 006D000000TjPGYIA3 006D000000TjPMHIA3 006D000000TjUhnIAF 006D000000TjV3dIAF 006D000000TjV4WIAV 006D000000TjV5PIAV 006D000000TjV8EIAV 006D000000TjVDOIA3 006D000000TjVFUIA3 006D000000TjVG8IAN 006D000000TjVHpIAN 006D000000TjVI0IAN 006D000000TjVJvIAN 006D000000TjVZWIA3 006D000000TjVeuIAF 006D000000TjVf0IAF 006D000000TjVgWIAV 006D000000TjVi8IAF 006D000000TjVopIAF 006D000000TjYPHIA3 006D000000TjYS2IAN 006D000000TjYSzIAN 006D000000TjYVLIA3 006D000000TjYXCIA3 006D000000TjYZXIA3 006D000000TjYaLIAV 006D000000TjYafIAF 006D000000TjYakIAF 006D000000TjYb9IAF 006D000000TjYbUIAV 006D000000TjYgLIAV 006D000000TjYi7IAF 006D000000TjYnbIAF 006D000000TjYoAIAV 006D000000TjYoLIAV 006D000000TjYpSIAV 006D000000TjYtzIAF 006D000000TjZzAIAV 006D000000Tja0mIAB 006D000000TjjYsIAJ 006D000000TjuyzIAB 006D000000TjwozIAB 006D000000Tjwp4IAB 006D000000Tjwp9IAB 006D000000TjwpYIAR 006D000000TkRTCIA3 006D000000TkRTWIA3 006D000000TkUGAIA3 006D000000TkUGuIAN 006D000000TkUICIA3 006D000000TkUIMIA3 006D000000TkUIbIAN 006D000000Tkk43IAB 006D000000Tkk6iIAB 006D000000V6wJdIAJ 006D000000V72sEIAR 006D000000V7YnHIAV 006D000000V8LhjIAF 006D000000V8Q7rIAF 006D000000V8Q9iIAF 006D000000V8aPAIAZ 006D000000V8hdqIAB 006D000000V8plfIAB 006D000000V8pm3IAB 006D000000V8pm8IAB 006D000000V8pmIIAR 006D000000V8pmSIAR 006D000000V8pn1IAB 006D000000V8pnBIAR 006D000000V8pnfIAB 006D000000V8xd3IAB 006D000000V9Lb4IAF 006D000000V9cHIIAZ 006D000000VvowbIAB 006D000000Vwf2AIAR 006D000000VwqlrIAB 006D000000Vx2viIAB 006D000000Vy2kjIAB 006D000000VyCdJIAV 006D000000VyCdsIAF 006D000000VyHoaIAF 006D000000X51HOIAZ 006D000000X51HhIAJ 006D000000X51HmIAJ 006D000000X51HwIAJ 006D000000X51KHIAZ 006D000000X51KbIAJ 006D000000X51KlIAJ 006D000000X51LFIAZ 006D000000X57DiIAJ 006D000000X5JrqIAF 006D000000X5JzjIAF 006D000000X606MIAR 006D000000X6ByZIAV 006D000000X6BytIAF 006D000000X73KxIAJ 006D000000X79maIAB 006D000000X79mpIAB 006D000000X79muIAB 006D000000X7yZrIAJ 006D000000X8LL5IAN 006D000000X8LLyIAN 006D000000X8LN7IAN 006D000000Y9hkVIAR 006D000000YAYfVIAX 006D000000YCEwlIAH 006D000000ZcDZ8IAN 006D000000aWxiUIAS 006D000000aWxjSIAS 006D000000aX1pIIAS 006D000000aXGcBIAW 006D000000aXGeRIAW 006D000000aZfTJIA0 006D000000aZlNVIA0 006D000000aaTVbIAM 006D000000bRSKpIAO 006D000000bSYtPIAW 006D000000bSktDIAS 006D000000bSkxZIAS 006D000000bSwq7IAC 006D000000cZBSNIA4 006D000000dEXVRIA4 006D000000dGFcTIAW 006D000000dIYjkIAG 006D000000eCaQDIA0 006D000000eD6KuIAK 006D000000eD6LJIA0 006D000000eDyUrIAK 006D000000fGSbwIAG 006D000000fGo6rIAC 006D000000fHDYGIA4 006D000000fHU7lIAG 006D000000fHbAgIAK 006D000000fHbBFIA0 006D000000fHbBUIA0 006D000000fHcejIAC 006D000000fHeQaIAK 006D000000fHqKQIA0 006D000000fJ9wBIAS 006D000000fJCOtIAO 006D000000fJejcIAC 006D000000fKDNIIA4 006D000000fKQH2IAO 006D000000g97uCIAQ 006D000000gAw1JIAS 006D000000gCUNCIA4 006D000000h1ge5IAA 006D000000h2pb7IAA 006D000000h2urcIAA 006D000000hFcuZIAS 006D000000hGWvuIAG 006D000000hGep1IAC 006D000000hGexnIAC 006D000000hGmFgIAK 006D000000hGmcnIAC 006D000000hGnrdIAC 006D000000hGns7IAC 006D000000hGwSfIAK 006D000000i2QvyIAE 006D000000i5JNMIA2 006D000000i5aj2IAA 006D000000iqjnzIAA 006D000000itSuGIAU 006D000000iuCpQIAU 006D000000k159UIAQ 006D000000k15BuIAI 006D000000k38TLIAY 006D000000koWY5IAM 006D000000koyRJIAY 006D000000koyZKIAY 006D000000kqwCHIAY 006D000000hGtMuIAK 006D000000fI05qIAC 006D000000aXGcpIAG 006200000023fuWAAQ 006200000083dibAAA 00620000008rYy3AAE 00620000008rYyDAAU 00620000008sa4gAAA 0062000000EOAG8AAP 006D000000i51d1IAA 006D000000hGY0QIAW 006D000000fJiARIA0 006D000000Vwe0PIAR 006D000000k24fNIAQ 006D000000k25EBIAY 006D000000krA5uIAE 006D000000i2ZRIIA2 006D000000fIBivIAG 006D000000cbEOZIA2 006D000000RLhCtIAL 006D000000cbERdIAM 006D000000RKyRyIAL 006D000000cbEYoIAM 006D000000lZf3YIAS 006D000000lZf3dIAC 006D000000lZf47IAC 006D000000lZf4CIAS 006D000000lZf4RIAS 006D000000lZf4qIAC 006D000000lZf5AIAS 006D000000lZf5FIAS 006D000000lZf5PIAS 006D000000lZf3sIAC 006D000000lZf3iIAC 006D000000lZneEIAS 006D000000lZo93IAC 006D000000i5anBIAQ 006D000000i2wAEIAY 006D000000hGtLXIA0 006D000000lZ0mJIAS 006D000000i5anuIAA 006D000000bSkw2IAC 006D000000i5az2IAA 006D000000fIACWIA4 006D000000fIAEhIAO 00620000001OrMxAAK 00620000001PuzbAAC 006200000022qcGAAQ 006200000023qnNAAQ 006200000024h4HAAQ 006200000029e2EAAQ 00620000002AfFtAAK 006200000033Mb7AAE 0062000000345FIAAY 00620000003IxPbAAK 00620000003LYZsAAO 00620000003M6aEAAS 00620000006a8jYAAQ 0062000000860s3AAA 00620000008sNQqAAM 006200000093iDSAAY 006200000094RlEAAU 006200000095MOcAAM 0062000000AMQHsAAP 0062000000BIBHtAAP 0062000000DQ6QyAAL 0062000000FjIwcAAF 0062000000GOwIoAAL 0062000000GkXyeAAF 0062000000Gkk9oAAB 006D000000MZrmGIAT 006D000000NgPPAIA3 006D000000NgPSTIA3 006D000000NgPW1IAN 006D000000NgPtUIAV 006D000000NgPxqIAF 006D000000NgPzDIAV 006D000000NgQ2DIAV 006D000000NgQ2EIAV 006D000000NgQ35IAF 006D000000NgQ3fIAF 006D000000NgQ5LIAV 006D000000NgQ5uIAF 006D000000NgQ6nIAF 006D000000NgQ8LIAV 006D000000NgQ8aIAF 006D000000NgQ9KIAV 006D000000NgQ9nIAF 006D000000NgQA7IAN 006D000000NgQBUIA3 006D000000NgQBtIAN 006D000000NgR9eIAF 006D000000NgReIIAV 006D000000NgTOdIAN 006D000000NgTXBIA3 006D000000NgTZvIAN 006D000000NgV8GIAV 006D000000NgVSjIAN 006D000000NgVY1IAN 006D000000Og4qhIAB 006D000000PbdTIIAZ 006D000000PbdqDIAR 006D000000QXHQKIA5 006D000000RLzFDIA1 006D000000Ti099IAB 006D000000TiJ8pIAF 006D000000TiP6GIAV 006D000000TiRoEIAV 006D000000TiSdKIAV 006D000000TiSlFIAV 006D000000TiSmDIAV 006D000000TiUUJIA3 006D000000TibTlIAJ 006D000000TibUoIAJ 006D000000TiblFIAR 006D000000TibmIIAR 006D000000TibpHIAR 006D000000TibqUIAR 006D000000Ticv1IAB 006D000000TicvPIAR 006D000000Tid7GIAR 006D000000Tid9lIAB 006D000000TioTfIAJ 006D000000TiwWjIAJ 006D000000TiwzMIAR 006D000000TjMdBIAV 006D000000TjMonIAF 006D000000TjMqyIAF 006D000000TjMsBIAV 006D000000TjMsVIAV 006D000000TjNB2IAN 006D000000TjNBvIAN 006D000000TjNFZIA3 006D000000TjNImIAN 006D000000TjNLMIA3 006D000000TjNRQIA3 006D000000TjNSSIA3 006D000000TjNTkIAN 006D000000TjOJZIA3 006D000000TjOKcIAN 006D000000TjOz2IAF 006D000000TjPHgIAN 006D000000TjPJmIAN 006D000000TjPKVIA3 006D000000TjV2aIAF 006D000000TjVHCIA3 006D000000TjVIxIAN 006D000000TjVhPIAV 006D000000TjVjpIAF 006D000000TjYNLIA3 006D000000TjYQZIA3 006D000000TjYTTIA3 006D000000TjYYeIAN 006D000000TjYcvIAF 006D000000TjYfLIAV 006D000000TjYrEIAV 006D000000TjYtFIAV 006D000000TjYuOIAV 006D000000TjYxNIAV 006D000000Tja0SIAR 006D000000Tja1GIAR 006D000000Tja1aIAB 006D000000Tk2nUIAR 006D000000TkU4cIAF 006D000000TkU5LIAV 006D000000V6wiUIAR 006D000000V72oqIAB 006D000000V72u1IAB 006D000000V7d2UIAR 006D000000V8OkWIAV 006D000000V8khvIAB 006D000000V8kjXIAR 006D000000V9Dq3IAF 006D000000V9DrpIAF 006D000000V9LcvIAF 006D000000V9RyRIAV 006D000000VAi16IAD 006D000000VArRRIA1 006D000000VArS5IAL 006D000000VvO5iIAF 006D000000VvWJeIAN 006D000000VwntjIAB 006D000000Vx1L1IAJ 006D000000VxDXHIA3 006D000000VxQIFIA3 006D000000VxX97IAF 006D000000VxmmAIAR 006D000000VxsmsIAB 006D000000VxspgIAB 006D000000VxsuWIAR 006D000000VxxCPIAZ 006D000000VybrAIAR 006D000000Vz6wMIAR 006D000000Vz79IIAR 006D000000X4mjXIAR 006D000000X5eKPIAZ 006D000000X5r1ZIAR 006D000000X6YObIAN 006D000000X74FEIAZ 006D000000X7mBzIAJ 006D000000Y9ha0IAB 006D000000YACzzIAH 006D000000YAu3pIAD 006D000000YAu49IAD 006D000000YBIKLIA5 006D000000YBKWBIA5 006D000000YBKdbIAH 006D000000YBZYBIA5 006D000000YBZYzIAP 006D000000YCrUqIAL 006D000000YCw3cIAD 006D000000YDRNGIA5 006D000000YDeiyIAD 006D000000ZMP1MIAX 006D000000ZMs3SIAT 006D000000ZMs9SIAT 006D000000ZNAGsIAP 006D000000ZaKWQIA3 006D000000ZaKhnIAF 006D000000ZanaOIAR 006D000000Zb59RIAR 006D000000Zb61tIAB 006D000000Zb7tgIAB 006D000000ZbAf8IAF 006D000000ZbAr4IAF 006D000000ZbRkkIAF 006D000000ZbSCFIA3 006D000000ZcGlZIAV 006D000000ZdrmdIAB 006D000000aWaLbIAK 006D000000aXLNWIA4 006D000000aXkmDIAS 006D000000aXx7hIAC 006D000000aXx8uIAC 006D000000aY3tmIAC 006D000000aYur9IAC 006D000000aZ3Q8IAK 006D000000aZF9gIAG 006D000000aZp7qIAC 006D000000aZx4lIAC 006D000000aacA6IAI 006D000000aaiKAIAY 006D000000bPT4gIAG 006D000000bQNSiIAO 006D000000bQYHLIA4 006D000000bQg38IAC 006D000000bRL9dIAG 006D000000bRThFIAW 006D000000bS5xVIAS 006D000000bS7vJIAS 006D000000bS91TIAS 006D000000bS91dIAC 006D000000bS91xIAC 006D000000bSCYjIAO 006D000000bSClJIAW 006D000000bScjMIAS 006D000000bShVpIAK 006D000000bTCmAIAW 006D000000cYVwAIAW 006D000000cYsKbIAK 006D000000cZSZvIAO 006D000000cZSbwIAG 006D000000caKtgIAE 006D000000caLVWIA2 006D000000caaAGIAY 006D000000cabv5IAA 006D000000caflgIAA 006D000000cafyaIAA 006D000000cbGDbIAM 006D000000cbie5IAA 006D000000cbjMDIAY 006D000000cbqVhIAI 006D000000dEWoBIAW 006D000000dEelVIAS 006D000000dFD3NIAW 006D000000dFFSVIA4 006D000000dFPLgIAO 006D000000dG0irIAC 006D000000dGLcDIAW 006D000000dHoaQIAS 006D000000eC8SfIAK 006D000000eCB7lIAG 006D000000eCO1HIAW 006D000000eCQoOIAW 006D000000eCgETIA0 006D000000eCh9zIAC 006D000000eDK5gIAG 006D000000eE2mIIAS 006D000000eE431IAC 006D000000eE452IAC 006D000000eENQxIAO 006D000000fGLwiIAG 006D000000fGlcFIAS 006D000000fGo1rIAC 006D000000fGrHiIAK 006D000000fHT73IAG 006D000000fHn6uIAC 006D000000fIBACIA4 006D000000fIJ7xIAG 006D000000fIOCyIAO 006D000000fIpHbIAK 006D000000fJG7SIAW 006D000000fJONPIA4 006D000000fJeqOIAS 006D000000fJxuNIAS 006D000000fKEZoIAO 006D000000g9emBIAQ 006D000000g9n23IAA 006D000000gAFvcIAG 006D000000gCODfIAO 006D000000gClhSIAS 006D000000gCvWCIA0 006D000000h1RhfIAE 006D000000h2NbFIAU 006D000000h2YOeIAM 006D000000h2loDIAQ 006D000000hFcxYIAS 006D000000hGA6aIAG 006D000000hGHk0IAG 006D000000hGIrkIAG 006D000000hGIsTIAW 006D000000hGosoIAC 006D000000hH3zYIAS 006D000000hHjpYIAS 006D000000hI4KtIAK 006D000000i2V9eIAE 006D000000i2ogIIAQ 006D000000i2vJhIAI 006D000000i36I7IAI 006D000000i3QICIA2 006D000000i3rO8IAI 006D000000i4dQMIAY 006D000000i4eZRIAY 006D000000i4gd6IAA 006D000000i4ggBIAQ 006D000000i4ggtIAA 006D000000i5zkXIAQ 006D000000i5zluIAA 006D000000i67I0IAI 006D000000i6LR3IAM 006D000000i6RzJIAU 006D000000iqfBnIAI 006D000000ir709IAA 006D000000ir71HIAQ 006D000000ir8bUIAQ 006D000000is4UPIAY 006D000000isJR1IAM 006D000000itIruIAE 006D000000itUNjIAM 006D000000itUanIAE 006D000000iuFCoIAM 006D000000iuFD3IAM 006D000000iup2cIAA 006D000000k00g0IAA 006D000000k00iBIAQ 006D000000k0Gz2IAE 006D000000k0HDJIA2 006D000000k0sneIAA 006D000000k0srgIAA 006D000000k11XpIAI 006D000000k144qIAA 006D000000k1g2NIAQ 006D000000k2lJWIAY 006D000000k2rPMIAY 006D000000k2rUPIAY 006D000000k2rZ6IAI 006D000000k3UgiIAE 006D000000kpKnVIAU 006D000000kpLrBIAU 006D000000kpQlAIAU 006D000000kpwieIAA 006D000000kq9kHIAQ 006D000000kq9yfIAA 006D000000kqBNNIA2 006D000000kqt6BIAQ 006D000000kqzOJIAY 006D000000kr5NWIAY 006D000000krhxAIAQ 006D000000ksFRaIAM 006D000000lI9C3IAK 006D000000lI9DuIAK 006D000000lZ0PjIAK 006D000000lZDdwIAG 006D000000lZS9iIAG 006200000072cp0AAA 006D000000eEmBaIAK 006D000000lZahfIAC 006D000000bSl17IAC 006D000000lII1yIAG 006D000000laProIAE 006D000000lah9gIAA 006D000000lZGfwIAG 006D000000i4PlaIAE 006D000000kr4iGIAQ 006D000000fIupJIAS 006D000000fIupNIAS 006D000000fIuphIAC 006D000000fIuq1IAC 006D000000fIuqaIAC 006D000000fIuqpIAC 006D000000i5apvIAA 006D000000i5aqKIAQ 006D000000i5aqtIAA 006D000000i6InGIAU 006D000000iupICIAY 006D000000krZkJIAU 006D000000lZ8QyIAK 006D000000lZo7HIAS 006D000000lZo8UIAS 006D000000lZsuAIAS 006D000000itTeGIAU 006D000000krEJHIA2 006D000000i5aoTIAQ 006D000000lb20MIAQ 006D000000lb22XIAQ 006D000000lb236IAA 006D000000lb23QIAQ 006D000000lb249IAA 006D000000lZf4HIAS 006D000000lb26UIAQ 006D000000fKDRZIA4 006D000000X6BkdIAF 006D000000X6BzwIAF 006D000000X6Bz8IAF 006D000000X6BunIAF 006D000000X6BzcIAF 006D000000lbGURIA2 006D000000TiCHUIA3 006D000000Y9jzcIAB 006D000000k3GioIAE 006D000000iuV94IAE 006D000000lZf4bIAC 006D000000lb228IAA 006D000000bSkv9IAC 006D000000laX8OIAU 006D000000lZDgRIAW 006D000000isohNIAQ 006D000000lIJlxIAG 006D000000X6C0GIAV 006D000000lZo6nIAC 006D000000cbEVaIAM 006D000000cbEZSIA2 006D000000k24MBIAY 006D000000k24PjIAI 006D000000k24SYIAY 006D000000k24Y2IAI 006D000000k24bkIAA 0062000000DDTgfAAH 006D000000k24NTIAY 006D000000k24YgIAI 006D000000lbVFBIA2 006D000000kpA0sIAE 006D000000lbOk4IAE 006D000000S87LSIAZ 006D000000loWO3IAM 006D000000TiCEzIAN 006D000000VyBQ5IAN 006D000000TiCDIIA3 006D000000TiCCPIA3 006D000000TiCCeIAN 006D000000TiCD3IAN 006D000000TiCDrIAN 006D000000TiCELIA3 006D000000TiCEaIAN 006D000000TiCEpIAN 006D000000TiCEuIAN 006D000000VyBOUIA3 006D000000VyBPqIAN 006D000000VyBQPIA3 006D000000aYEx1IAG 006D000000aYExGIAW 006D000000aYExfIAG 006D000000aYExpIAG 006D000000aYEy9IAG 006D000000aYEydIAG 006D000000aYEz7IAG 006D000000aYEzbIAG 006D000000aYEzgIAG 006D000000aYEzvIAG 006D000000krZhNIAU 006D000000krZhXIAU 006D000000krZhcIAE 006D000000krZhmIAE 006D000000krZi1IAE 006D000000krZiDIAU 006D000000krZiNIAU 006D000000krZiSIAU 006D000000krZiXIAU 006D000000krZiwIAE 006D000000krZj6IAE 006D000000krZjLIAU 006D000000krZjaIAE 006D000000krZjfIAE 006D000000krZjkIAE 006D000000krZjuIAE 006D000000krZjzIAE 006D000000krZk4IAE 006D000000krZk9IAE 006D000000krZkOIAU 006D000000krZkYIAU 006D000000krZksIAE 006D000000krZkxIAE 006D000000lZDKGIA4 006D000000i5b8JIAQ 006D000000lZDK1IAO 006D000000koyO5IAI 006D000000logzRIAQ 006D000000lbUrAIAU 006D000000k2gdcIAA 006D000000lI9EdIAK 006D000000itThgIAE 006D000000lomkZIAQ 006D000000X6C06IAF 006D000000lZc2aIAC 006D000000lonCFIAY 006D000000lomIzIAI     00120000001g77nAAA 00120000001b3SsAAI 00120000001g76gAAA 00120000001b3SdAAI 00120000001g749AAA 00120000001b3SfAAI 00120000001g751AAA 00120000001ujrBAAQ 00120000001b3SgAAI 00120000001b3SXAAY 0012000000I7mRJAAZ 00120000001vFBJAA2 0012000000PeT12AAF 0012000000UWdeGAAT 0012000000XC3ztAAD 00120000001mc8VAAQ 0012000000Y7azAAAR 0012000000Y7bdEAAR 00120000002D2XzAAK 0012000000Yp2BaAAJ 0012000000Vfe9XAAR 00120000001g75NAAQ 00120000001hHRMAA2 00120000001gWMAAA2 00120000002zJVCAA2 00120000003SnjSAAS 00120000001kdjTAAQ 001200000022XONAA2 00120000001gDG2AAM 0012000000GVd35AAD 0012000000H98s8AAB 00120000001g75GAAQ 00120000003TURyAAO 00120000001g75cAAA 00120000004eLHtAAM 00120000001g78HAAQ 0012000000HfIwFAAV 00120000002Axo9AAC 0012000000SpAwkAAF 0012000000TkY71AAF 0012000000I4GHvAAN 0012000000YTLf0AAH 0012000000UYEoAAAX 0012000000Y8gbCAAR 0012000000LAWrhAAH 0012000000Zk77tAAB 0012000000aUmUMAA0 0012000000Y7YmEAAV 00120000001g773AAA 00120000002gvIpAAI 0012000000259qkAAA 001200000028teVAAQ 00120000001b3U5AAI 00120000001b3SbAAI 0012000000Y7YmAAAV 00120000001b3TGAAY 0012000000VhQZbAAN 00120000001b3T9AAI 00120000001g76RAAQ 00120000003oGjSAAU 0012000000HfIwPAAV 00120000002zP1PAAU 00120000001g768AAA 00120000001g74SAAQ 00120000001g770AAA 0012000000H0q35AAB 00120000003hY3zAAE 0012000000KWdxmAAD 00120000001b3TFAAY 00120000001g780AAA 0012000000KXDNHAA5 00120000001g74dAAA 00120000001hVHbAAM 00120000001b3THAAY 00120000001g76jAAA 00120000001b3TdAAI 00120000001b3TWAAY 00120000001b3SpAAI 00120000001lz44AAA 00120000001srHyAAI 0012000000298w2AAA 00120000002CmjKAAS 00120000001g76LAAQ 00120000002CmgaAAC 00120000001mHmOAAU 00120000002o5njAAA 00120000002GnU7AAK 001200000025IzYAAU 00120000001b3U6AAI 00120000001b3ThAAI 00120000005pKxfAAE 00120000005Vki1AAC 00120000005UOUpAAO 00120000001b3U4AAI 00120000005rOHSAA2 00120000006HUeIAAW 0012000000EgGu2AAF 0012000000FT0SnAAL 0012000000FzNmsAAF 0012000000H8kIrAAJ 00120000005W2NsAAK 00120000001fDq3AAE 00120000001b3SlAAI 0012000000MktXxAAJ 0012000000I40gNAAR 0012000000PHMjQAAX 00120000001goydAAA 0012000000I7lxyAAB 0012000000Rr3B1AAJ 00120000001b3TtAAI 0012000000WMqqDAAT 0012000000XBoguAAD 00120000001b3TYAAY 00120000002Cyy7AAC 00120000001g77gAAA 001D000000egXnCIAU 001D000000pkIx4IAE 001D000000vH5vpIAC 001D000000vH68xIAC 0012000000dRwRAAA0 00120000002U2jXAAS 00120000002CyxeAAC 0012000000256S4AAI 00120000001b3T4AAI 0012000000dRwRUAA0 00120000001j18RAAQ 00120000001g760AAA 00120000001g763AAA 00120000001qAEaAAM 00120000001nHXCAA2 00120000001j13KAAQ 001200000025y8rAAA 001200000029O4FAAU 00120000001gwj3AAA 00120000001g76vAAA 00120000001g77kAAA 00120000001z5PvAAI 00120000001gWaaAAE 00120000002gOkeAAE 00120000001g74LAAQ 00120000002mpTcAAI 00120000002n1MSAAY 00120000002o9jwAAA 00120000002E2y9AAC 00120000001g75pAAA 00120000001g78KAAQ 00120000002ymvFAAQ 00120000002z88DAAQ 00120000002Jdv7AAC 00120000002zwpGAAQ 00120000001kdKQAAY 00120000001g74WAAQ 00120000002zz9CAAQ 00120000001g78OAAQ 001200000082wVbAAI 0012000000GW0AGAA1 00120000002Gjc0AAC 0012000000GVzvdAAD 00120000001g77xAAA 00120000001g77DAAQ 00120000002Dc6NAAS 00120000001g77PAAQ 00120000001g77lAAA 00120000008MVZNAA4 0012000000N72UjAAJ 00120000002dVZIAA2 0012000000OdHciAAF 0012000000PvIieAAF 00120000001g77dAAA 00120000001g746AAA 00120000001g78IAAQ 00120000002E1wlAAC 0012000000MhLD0AAN 0012000000WLgc3AAD 0012000000beq7HAAQ 0012000000dViCkAAK 0012000000Pw5EAAAZ 0012000000dy7CcAAI 0012000000e3pNTAAY 0012000000PvUnEAAV 00120000001g74OAAQ 001D000000vIxEqIAK 001D000000wtBGCIA2 001D000000wtBJuIAM 001D000000wtAjKIAU 001D000000wtAj5IAE 001D000000wtBFsIAM 0012000000PhWdNAAV 00120000001g78FAAQ 001200000096eo7AAA 00120000001g77GAAQ 001D000000wt7vlIAA 001D000000wt7woIAA 00120000001g764AAA 00120000001g76uAAA 001D000001C4IZUIA3 001D0000015YvByIAK 00120000005TlYnAAK 0012000000WMmdOAAT 00120000001g74iAAA 001D000001CXlQ9IAL 001D000001Eh0GAIAZ 0012000000QQs0nAAD 00120000008L6icAAC 0012000000UWkmtAAD 00120000002zz8eAAA 001D0000015b7ReIAI 00120000002o1MfAAI 0012000000Gz1DhAAJ 00120000002TTm4AAG 00120000003Tlr9AAC 00120000002UD9MAAW 0012000000GWLmDAAX 00120000001g75HAAQ 001D000000wtBHjIAM 001D000000wtBJ1IAM 00120000001g752AAA 00120000002P1EUAA0 00120000001g76FAAQ 0012000000NOInZAAX 001D0000017C6fLIAS 00120000001i72xAAA 00120000002dVPtAAM 00120000001pFJcAAM 00120000002Dc7tAAC 00120000001kcPJAAY 00120000001imD1AAI 001D000001CW1cHIAT 001D000001NQPDNIA5 001D000001C675uIAB 001D000001SiFHjIAN 00120000001b3TCAAY 001D000000vH6o4IAC 0012000000300eBAAQ 001D0000019AisQIAS 0012000000ZjFrpAAF 001D000001CXT39IAH 001D0000012CvUkIAK 001D000001VcVrnIAF 00120000001hAHWAA2 00120000006uLXtAAM 001D000000vIxKPIA0 001D000001C5NH9IAN 001D000001hDdRMIA0 00120000002GjbDAAS 001D000001fT5ukIAC 001D000001TYqAMIA1 0012000000305OoAAI 0012000000JDmBgAAL 0012000000XZPJMAA5 00120000001imA8AAI 00120000001g76nAAA 00120000002gqW8AAI 00120000001h7ScAAI 00120000001b3TpAAI 001D000001gcuCTIAY 001D000001CXJTKIA5 00120000002AW16AAG 001D000001OwHEOIA3 001D000001dAutXIAS 001D000001XjfnoIAB 001D000001hD27hIAC 001D000001VcltNIAR 001D000001Ko3e8IAB 001D000001C5tsaIAB 001D000001NQPMrIAP 001D000001NQPOAIA5 00120000004RspNAAS 00120000001g75SAAQ 00120000002E3A3AAK 00120000001g761AAA 00120000001g74wAAA 00120000001g74sAAA 0012000000dRwGVAA0 001D000001NQPSrIAP 001D000001CYPTYIA5 00120000001b3TDAAY 00120000001b3TbAAI 00120000001b3SjAAI 00120000001gvycAAA 00120000001g77bAAA 00120000001g76ZAAQ 00120000001nGqoAAE 00120000001b3SuAAI 00120000001j1A2AAI 00120000001qKGtAAM 00120000001g75yAAA 00120000001rFIrAAM 00120000001g76WAAQ 00120000001rbv4AAA 00120000001b3TJAAY 00120000001g75KAAQ 00120000001yomRAAQ 0012000000229sFAAQ 001200000023bgwAAA 001200000028rV2AAI 00120000001g76OAAQ 00120000002DzjjAAC 00120000002If7RAAS 00120000002T9WUAA0 00120000001kZKvAAM 00120000002eXs4AAE 00120000002JdvJAAS 00120000002nyaCAAQ 00120000002o9XEAAY 00120000001g75MAAQ 00120000002hUZNAA2 00120000001mVbTAAU 00120000002oMA3AAM 00120000002D2WzAAK 00120000001ujukAAA 00120000002pHRGAA2 00120000001g74tAAA 00120000002dugCAAQ 00120000001srs1AAA 00120000002yzlTAAQ 00120000001g75iAAA 00120000002ziS7AAI 00120000001g74IAAQ 001200000030EVtAAM 001200000030dsLAAQ 00120000001g75wAAA 00120000003VNcHAAW 001200000030GZyAAM 00120000003Sux9AAC 00120000001g74hAAA 00120000001b3TEAAY 00120000003ebMSAAY 00120000003hY3PAAU 00120000001b3SxAAI 00120000001g78EAAQ 0012000000D5tajAAB 00120000001onR9AAI 0012000000H8yDgAAJ 0012000000HUNIhAAP 0012000000I7lvkAAB 0012000000I7mXvAAJ 0012000000I7mYQAAZ 00120000002D2ZFAA0 0012000000I49iqAAB 0012000000I4DRPAA3 00120000001gwMMAAY 0012000000JHEKkAAP 0012000000JdgRfAAJ 0012000000Kr6CVAAZ 0012000000KsHzFAAV 0012000000Ksq9kAAB 0012000000Jd1GGAAZ 0012000000L9cfLAAR 0012000000LoKqsAAF 0012000000N0BJXAA3 00120000001vQtjAAE 0012000000OPTVPAA5 0012000000NmeBnAAJ 00120000001b3TlAAI 00120000005TZRXAA4 0012000000QRCEOAA5 0012000000QjcU0AAJ 0012000000QkYnGAAV 0012000000RqkCoAAJ 0012000000SqyS9AAJ 0012000000StG8FAAV 00120000001m9kGAAQ 0012000000UY1WnAAL 0012000000Vg32aAAB 00120000005VYXwAAO 00120000001b3TKAAY 0012000000XBwkVAAT 0012000000XC4cOAAT 0012000000XcKhxAAF 0012000000Y7VkAAAV 0012000000Y8Y4yAAF 0012000000aWxBkAAK 0012000000bepxTAAQ 00120000004DQe7AAG 0012000000c45JoAAI 0012000000c5v33AAA 001D000000hjEVnIAM 001D000000hJaszIAC 001D000001CXVJkIAP 001D000001CXlReIAL 001D0000012AXxaIAG 001D0000012AaFMIA0 0012000000eoMocAAE 001D0000012AaZ2IAK 001D0000012AauJIAS 001D000001Eik0QIAR 001D0000017ALLuIAO 001D0000012CyQ7IAK 00120000002JdwTAAS 001D0000018ABiMIAW 00120000002D2VNAA0 001D000001Dkyt3IAB 001D000001DlU6hIAF 00120000001g75hAAA 001D000001FodVbIAJ 001D000001HCCGkIAP 00120000001b3T6AAI 00120000005rVRTAA2 001D000001C5OwyIAF 00120000002TSTWAA4 001D000001NQPN9IAP 001D000001Sj6ExIAJ 001D000001Sjqz3IAB 00120000001g76VAAQ 001D000001BcwADIAZ 001D000001dC9MZIA0 001D000001eK7QKIA0 001D000001hBF7AIAW 001D000001iB2neIAC 001D000001j2KspIAE 001200000022XP0AAM 001D000001NQPJrIAP 001D0000018ABsuIAG 0012000000305VEAAY 001D000001Phi1WIAR 001D0000012AbugIAC 001D000001VcgCNIAZ 001D000001VclsPIAR 00120000008tdzPAAQ 001D000001nsiolIAA 001D000001BdhxXIAR 001D000001NQPJaIAP 00120000001fj4aAAA 001D000001nsirVIAQ 001D000001iCVChIAO 001D000001NQPBZIA5 00120000001g77TAAQ 00120000001b3ScAAI 00120000002U0rtAAC 00120000002yZ9BAAU 00120000001eShNAAU 0012000000XcKTTAA3 001D000000wt3gWIAQ 001D000000wtBKiIAM 001D000000wtBKOIA2 001D000000wtB5VIAU 001D000000wtBJGIA2 001D000000wtBDmIAM 001D000000wtBEvIAM 001D000000wtBFnIAM 001D000000wtBFTIA2 001D000000wtBGWIA2 001D000000wtBIIIA2 001D000000wtBGqIAM 00120000009pLy5AAE 00120000002U0rpAAC 001D000000wtBJpIAM 001D000000wtAilIAE 001D000000wtAeyIAE 001D000000wtBD9IAM 001D000000wtBHFIA2 001D000000wt8oiIAA 001D000000wtAQkIAM 00120000002zts3AAA 001D000000wtAJQIA2 001D000000wtFTnIAM 0012000000dRwHaAAK 001D0000015b7RVIAY 001D0000012AcOeIAK 001D0000012AcfxIAC 001D0000012AcksIAC 001D0000012AgjFIAS 00120000001g779AAA 001D000001EilTCIAZ 001D0000015Xmh4IAC 001D0000015b7RjIAI 001D000001EjTahIAF 00120000005Vog5AAC 001D000001FlmC7IAJ 001D000001CXmfiIAD 00120000001b3TQAAY 00120000001g76sAAA 001D000001IPWnNIAX 001D000001IQGQ1IAP 001D000001ISOjRIAX 001D000001J2saRIAR 001D000001JrsfjIAB 001D000001EfwxIIAR 001D000001Koiz8IAB 001D000001MpoZnIAJ 0012000000AE9LCAA1 001D000001O3IGGIA3 00120000001g76UAAQ 001D000001ObTXCIA3 001D000001QKdALIA1 001D000001Phy2mIAB 001D000001PiMjmIAF 001D000001KodoPIAR 001D000001NQPSPIA5 001D000001CWdU7IAL 00120000001b3SmAAI 001D000001SjQ0hIAF 00120000005r94LAAQ 001D000001Oup4zIAB 001D000001PiN97IAF 001D000001NQPSgIAP 001D000001RPGbEIAX 00120000001g77vAAA 001D000001WHyoWIAT 001D000001ZKM5xIAH 001D000001ZKlCLIA1 001D000001ZN5HyIAL 001D000001Oup6bIAB 001D000001bAVt8IAG 0012000000GWDWNAA5 001D000001dEOjjIAG 001D000001C5Lj8IAF 00120000004eIrlAAE 001D00000118KPqIAM 001D000001gL8hgIAC 001D000001hBA4ZIAW 001D000001hD7FmIAK 001D000001iCSvkIAG 0012000000Y7bYoAAJ 001D000001j2wu7IAA 001D000001XiRpbIAF 001D000001NQPJZIA5 001D000001leMo4IAE 001D000001PhctDIAR 001D000001kr8M9IAI 001D000001XjfurIAB 001D000001NQPMPIA5 001D000001mI7G5IAK 001D000001HDi67IAD 001D000001gKw0cIAC 0012000000YqQyvAAF 001D000001mHtQXIA0 001D000001nriBBIAY 001D000001XjfnPIAR 001D000001komttIAA 001D000001SieP2IAJ 001D000001fT7M6IAK 001D000001nt42FIAQ 001D000001VcgBFIAZ 001D000001lgj9DIAQ 001D000001lgjA6IAI 001D000001lgjBaIAI 001D000001j1RiNIAU 0012000000XBoNIAA1 00120000001kbJCAAY 001D000001CXrkkIAD 001D000001AdxUKIAZ 001D000001jjx2EIAQ 001D000001PhopQIAR 001D000001nu4UGIAY Red 2 @ Adelphi MAbsorbent @ GSK Custom @ Biogen Idec MAbsorbent Ligand @ CAT Custom @ Medimmune Mimetic Ligand 1L @ Cobra Blue @ GTC MAbsorbent @ Alpha Biologics Blue SA HL (Manufacturing) @ GSK 20% EtOH @ Novozymes Delta BlueSAHL@Avecia Fabsorbent @ Lonza Mimetic Screening @ Bibitec Purabead @ Dextra Laboratories Fibrinogen @ ProFibrix pABA @ BBI Enzymes MAbsorbents @ Nacalai Tesque, Inc. Fabsorbent @ Avipep Pty Ltd MAbsorbent @ Kokusai Kinzoku Yakuhin Co.,Ltd APB Screening @ Ludger Ltd Endotoxin Reduction @ Recipharm MImetic Screening @ The University of Stirling APB HL@i-SENS MAbsorbent@Baxter MAbsorbent@Genentech Mabsorbent@zymogenetics mabsorbent@BaxterHealthcare,Hayward Genentech, Inc.- MAbsorbent@Equitech-BIO Xencor- Custom@BaxterBioscience Blue@Gilead Amgen- Mimetic Ligand Screening Kit @ Allergan A2P/F1P @ Astelles F1P @ Genentech F1P @ Xoma A1P @ PacificGMP F1P @ CMC ICOS A2P 25ml @ IIC APB @ Baxter Perfluorosorb S @ Ambrx APB 25ml @ IIC Mimetic Red 25ml @ IIC Fabsorbent F1P 25ml @ Abgent Contract Manuf. @ SMWW APB @ Genentech Mimetic Blue @ Marin Bio A2P HF 100ml @ Iwai North America Inc. A2P 100ml @ Chino Labs Fibrinogen Adsorbent @ IIC ELISA @ Panacea Biotec Ltd APB 40L @ Richter-Helm BioLogics Ligand Collaberation @ LI-COR Mimetic Blue SAHL 20L @ Vasgene Mimetic Green @ University of British Columbia HIC 5x1ml Kit @ Vasgene Custom Development @ Pfenex MAbsorbent A2P HF 20L @ VasGene AxP @ Kyowa Kirin MAbsorbent Screening @ Insight Biopharmaceuticals MAbsorbent 2 @ PBT MAbsorbent (MAbs) @ CSL Mimetic Blue @ Avecia MAb/Fabsorbents@Avecia Elution Optimisation @ Octapharma Matrix 119 @ Octapharma Negative Binder Study @ Octapharma Fabsorbent @ UCB Custom development Fabsorbent @ Ludger Boehringer Ingelheim RCV GmbH & Co KG Mimetic & HIC @ University of Belgrade In2it Rapid @ Bio-Rad F1P 5x1ml column kit @ Fiveprime MAbsorbent 1L @ Morphosys Custom @ Dendreon A2P/F1P @ Alder Fabsorbent @ Anaptys Bio MAbsorbent @ Abgenix PIKSI @ Biosynexus Custom Ligand Development @ Bayer F1P @ Sea Lane Bio Blue 1 @ Colorado State U pABA @ Catalent PrioClear @ Bayer MAbsorbent HF @ Protherics Various @ BRI Business Development @ Alba Bioscience MAbsorbents@ICOS MAbsorbents@Avid MAbsorbent @ TolerRx Perfluorsorb @ RD Biotech Custom @ Biogen-Idec APB @ Provalis 06 Protein L Mimetic Ligand @ Domantis Endotoxin Removal @ Domantis Avidin Agarose Slurry on Purabead 3X1L @ Mitra Avidin Agarose Powder on Biogel 10 Litre Batch @ Mitra Endotoxin Removal @ Celltech Perflurosorb S @ Vecura Perfluorosorb S @ FIT MAbsorbent A3P @ Micromet Blue SA/MAbsorbent @ CSL Blue @ Bioprocessing Technology Institute Perfluorosorb @ GreenPak Biotech Boronate @ GreenPak Biotech Phenyl 2 @ Shasun Phenyl Scaleup @ IMTECH Blue SA @ Advy MAbsorbent @ IIBR MAbsorbent Mini Columns @ Symphogen Adsorbents @ Biovitrum Mimetic Ligand Screen @ The Binding Site PABA Scouting @ Berna DBA Ligand & Storage APB @ Provalis November Mimetic Blue SA @ Bibitec Custom@Siegfried Custom@Stallergenes Custom@Pieris Beta@Micromet A3P@Wyeth Custom@Omnicyte Blue SA HL@BIBITEC A3P@Teva Custom Affinity Chromatography Material Innsbruck Medical University- Finnzymes Oy- Mabsorbents @ Biotest AG PRDT @ Proxcys Mimetic Blue AP @ AM Pharma APB 500ml @ EKF Mimetic Orange @ BSV Bioscience ELISA @ Fisher Scientific Fabsorbent @ National University of Singapore- Fabsorbent Screening @Micromet AG Custom @GSK BD @ Micromet AG Perfluorsorb @ Symmetrix rFVIIA @ Cantab Biopharmaceuticals Ltd. Endotoxin Reduction @ Sanofi Pasteur Endotoxin Reduction @ Celonic AG Mimetic Blue AP @ Alloksys Life Sciences bv Mimetic Blue 1 @ Eden Biodesign Ltd Fabsorbent Screening @ Wacker Biotech GmbH Fibrinogen @ Biotest AG Fabsorbent 25ml @ Bioprocessing Technology Institute Mabsorbent @ Zhejiang University PuraBead 6HF@Dextra Purabeed @ AbSorber Mab dsp General Custom development@UCB Custom development@BIP A2P@ BioTest AG Novo Nordisk- Mimetic_Blue@Novartis Resin supply 2013 APB G5@biorad RSF Binder@Merck Feasibility Study@MedImmune HSA ~11 litre batch@BAC PerfS@Microbe Inotech Labs, Inc. MAbsorbent @ Merck Perf@Abbott MAbsorbent@Sigma Endotoxin@Abbott pABA@Celliance MAbsorbent@Leinco Technologies Inc. Custom @ Vaxinnate Corp. Green @ UMDNJ pABA@Uof Nebraska Mabsorbent@Pfizer Phenyl@Q.S.V. Biologics QuickScreen@Sigma Mimetic@Sigma Boronate @ BI MAbsorbent Phase III @ Centocor MAbsorbent Scale-Up @ Centocor Mimetic Blue AP @ Bio-World QuickScreen@Eli Lilly MAbsorbent @ Cold Spring Harbor Lab MAbsorbent@Apolife Perfluorosorb@Minnesota State University MAbsorbent@Nektar APBoronate@Nektar The Dow Chemical Company- Blue 1 @ Duke MAbsorbent@Cayman Chemical MAbsorbent@MUNIN Corporation MAbsorbent@Harlan Bioproducts Custom @ EpiVax APBoronate@UNL MAbsorbent 10L @International Immuno Corp BlueSA 10L @International Immuno Corp Boronate 10L@Gala QuickScreen@Vaxinnate QuickScreen@BioMarin Krikor Torossian Plasminogen @ Diosynth P E Purabead 50L@ProMedior FAbsorbent @Vyvion PRDT@Invitrogen APBoronate @ Proteon Therapeutics Perfluorosorb S 25ml @ PacificGMP Fab@MedImmune Custom@Pfizer Fab100ml@Merrimack F1P 25ml @ Planet Biotech A2P 25ml @ Planet Biotech Blue SA HL 40L@merck.com Blue SA HL 20L@Merrimack Mimetic Blue SA HL 1L @ IIC Fab 5L@Novartis Mimetics 8X25ml@GSK pABA 5L@GTC FIX 10L@GTC Fab 5L@Biolex Fab 10L@Xcellerx Screening Kit @ Multimeric Bio PRDT @ Abraxis Fab 25 ml @ OSU Contract Ligand Immobilization @ Zymogenetics Co-Marketing Agreement @ Tecan Mimetic Blue 1 100ml @ Nexbio Fab 2L@ HGS Blue SA HL 50 L@Teva Blue SA HF 1L@Biogen IDEC Blue SA HL 5L@HGS Blue SA HL 20L@HGS Blue SA HF 10L@Biogen IDEC Blue SA HF@Biogen IDEC Quickscreen @Vaxinnate Mimetic Red 80 L@Teva PrioClear B R&D Project @ Abraxis - Dec 2009 PEPuraBead 60L@ProMedior Green 200ml@Athena ES Quickscreen@Shire Determination of Bioburden @ Abraxis Empty Proxcys Column @ Abraxis Pfizer, Inc.- Custom Development @ BioMarin Pharmaceuticals PuraPlate @ Biomarin Pharmaceutical, Inc.- Mimetic Blue SAHL 100L @ ORF Genetics PuraBead @ Repligen Endotoxin Adsorbent 100ml @ Sutro Biopharma Blue AP @ Animal Cell Technology PrioClear @ OMRIX Biopharmaceuticals Teva Biopharmaceuticals- Mabsorbent 10L @ JSR Micro Mimetic Ligands @ Biogen Idec Quick Screen Albumin-binding Ligands - Amgen R&D ATO - Mimetic Blue 100L @ VasGEne Prion Project @ Bayer Jianwei Yu (EtoxiClear) Valerie Williamson Weed (EtoxiClear) Arnold Tsiomenko (EtoxiClear) Anne Pereira (EtoxiClear) John Mahlberg (EtoxiClear) Thomas Svab (EtoxiClear) Julia Poncher (EtoxiClear) Ali Moubarak (EtoxiClear) Ramesh Kashi (EtoxiClear) Andrew Lees (EtoxiClear) Elias Kvarnstrom (EtoxiClear) Marc-Andre D'Aoust (EtoxiClear) Steve Tingley (EtoxiClear) Iryna Ryzhankova (EtoxiClear) John Chickosky (EtoxiClear) Fletcher Malcom (EtoxiClear) Duncan Low (EtoxiClear) Daryl Gisch (EtoxiClear) Melissa Perkins (EtoxiClear) Hazel Aranha (EtoxiClear) Chris Grainger (EtoxiClear) Christopher Bartnicki (EtoxiClear) Sales Follow Up Email Ligand Project@Novavax Etoxiclear PII Purabead@ProMedior Albumin Fusion Protein - Mimetic Blue HL Note Quick Screen BMS Custom screens Entegrion Custom Screen Samples@ GSK Insulin @ Sigma St. Louis, MO - Nov 2013 pABA @ Merck Boulder - Dec 2013 pABA @ Lee Bio - Jan 2014 Alex Kanarek (EtoxiClear) MAbsorbent @ ImmunoGen MAbsorbentA3P@Amgen Boronate @ Intas pABA@Sigma PuraBead @ Fresenius F1P 25ml @ Ambrx Endotoxin @ Ambrx 25ml A2P @ Genentech Custom@Genentech MAbsorbent @AmgenHQ MAbsorbent@AmgenHdQtr APB @ CMC ICOS A2P @ CMC ICOS F1P 25ml @ Lpath MAbsorbent @ AmProtein Mimetic PuraPlate @ Genentech Custom @ BioMarin APBoronate@Cone Bioproducts Blue SA HL 150L@Lonza Blue SA HL 15L@Teva Custom @ Genzyme Fabsorbent 25ml@MedImmune Michael Klein (EtoxiClear) Richard Saul (EtoxiClear) Camellia Zamiri (EtoxiClear) Trevor Aldridge MAbsorbent@Aldevron Cliniqa - APB repeat order Custom @ Sanofi Pasteur Ruby Leah Casareno (EtoxiClear) MAbsorbent @ Advanced Biotechnologies Sclerostin, or Chemokines - Quick Screen - ATO PIKSI @ Protein Sciences Mark Ciboroski (EtoxiClear) Delta Blue Agarose (DBA) Custom@Delta Mimetic Blue 1 @ BRI John Endres (EtoxiClear) Endotoxin Removal @ Avecia Glutathione Ligand @ Avecia DEAE @ PBT MAbsorbent @ PBT Feasibility FVIII @ PBT RSV RSF@Novavax MAb platform@Eden Blood factors @ Reliance Life Sciences APB (repeat order) @ Cliniqa April 2014 Mimetic Blue SA HL @ Vasgene Jan 2014 IEX Samples@ Lonza Walkersville FabSorbent @ Amgen - Aug 2010 Mimetic Blue @ Univ of FL Gainesville Fabsorbent column kit AlbuPure 25ml @ Creative BioLabs Boronate @ Advy 50l CH-1@BAC AlbuPure @ CSL RSV Project@Novavax Prion@Shanghai Ligand project Lentivirus MAb & Fab unique pseuso-affinity /fluidized bed resin for polyclonal purification 2013 Development Program @ CSL A & B Ligands@CSL Ligand Project@OXB Octyl_300L@Wuhan Flu_project@Novavax HSA@Orion 210L APB @ COOK - Q1 2015 Clearant Inc- Purabeed@Dextra A1P @ Chino Labs Mimetic Blue SAHL 25ml @ Chino Labs APB 25L (repeat order) @ Avid for Hylenex May 2015 Process Dev#1@Kedrion Process Dev#2@Kedrion AutekBio, Inc.- IgG Resins@Haemonetics 30L APB@Biotechpharma Fabsorbent Column Kit @ Abbomax Grifols rA1AT - AATsorbent Custom MAb Screen @ Serono Mimetic Blue @ Osprey Pharma A2P @ Baxter Mimetic Blue 25ml @ Allegro Biotech MAbsorbent@R&D Systems Inc. Christof Schulz (EtoxiClear) Mimetics@Halozyme F1P @ Ambrx Fabsorbent F1P 25ml @ Ambrx Kenneth Nichols (EtoxiClear) R&D - IEX Screening - Sept 2013 R&D - CEX Screening - Aug 2013 Custom Ligand Dev@Allergan Mabsorbent A2P HF 2L @ Bio-Rad PuraPlate OEM @ Bio-Rad Thomas Ransohoff MAbsorbent @ Centocor 2 Custom@Eli Lilly Mimetic Blue SAHL 150L @ CoGenesys Insulin Adsorbent Etoxiclear or Q @ Merck Boulder, CO - Dec 2013 MAbsorbent@Abbott Pooled Resin@CSL Aseptically packed columns Perf@Vical Inc. MAbsorbent (packing) @ PBT Mimetic Yello LeeBio 1L PPPS Q4@Generium Etoxiclear 5ml evalution Evolve 100@JSR Mimetic Blue HSA@Farmatek Fabsorbent Evolve 100@Sorrento Evolve 100@Allergan Evolve 100@Genentech Evolve 100@Gilead Evolve 100@NEB Evolve 100@Pfanstiehl Evolve 100@Baylor Evolve 100@Centocor Mimetic Blue AP Dev stageII@Pfizer Mimetic Blue Elisa , Puraplate Evolve @ DrReddys Etoxiclear@Guelph APB A6XL 10,20L APB 2016 Mimetic Blue AP@Pfizer PE PuraBead Mimetics Misc@Wuhan Supply agreement Albiglutide DBA Resin@ Novozymes 2litres Matrix B @ Kedrion Evolve 250@HGS Merrimack Mimetic Blue 100L APB A6XL @Repligen 250L APB Cook#1 250L APB Cook#2 40L APB A6XL#1 @ Avid Bio 40L APB A6XL#2 @ Avid Bio 40L APB A6XL#3 @ Avid Bio 40L APB A6XL#4 @ Avid Bio PPPS Q4_16@Generium 100 litres A Resin Campaign 2016_July @CSL 100 litres A Resin Campaign 2016_June @CSL 50 litres A Resin Campaign 2016_Oct @CSL 50 litres B Resin Campaign 2016_June @CSL 50 liters A Resin Campaign 2016_Sept @CSL 50 liters A Resin Campaign 2016_Dec @CSL 50 litres A Resin Campaign 2016_August @CSL 100 litres A Resin Campaign 2016_Nov @CSL 50 litres B Resin Campaign 2016_July @CSL 50 litres B Resin Campaign 2016_Nov @CSL 50 litres B Resin Campaign 2016_Sept @CSL 200L Prioclear B@Octapharma Perfluorosorb S 50ml @ FIT Amediplase Binding Adsorbent Hydroxy 21-21 samples for Toxicity Testing @ Menarini Mimetic Blue ligand @ Diosynth Aminobenzamidine Agarose @ Cobra Mimetic Blue @ Diosynth Delta PhenylBoronate Agarose (PBA) Perfluorosorb S @ Cobra 05 Blue @ GSK MAbsorbent @ Centocor Mimetics @ GlycoFi Phenyl @ Shasun Phenyl @ USV Perflurosorb S 25ml @ Vecura MAbsorbent@PfizerGlobalR&D Boronate @ Trophogen MAbsorbents @ Domantis Perfluorosorb S @ Bristol Institute for Transfusion Sciences Mimetic Ligands @ Cobra IgG Agarose @ GSK APBoronate @ Avid/Halozyme Boronate @ Sachem Boronate @ Bio-Rad Mimetics @ Aptamer Blue @ Monash Uni Boronate @ BRI Perf @ Ventana MAbsorbent @ Alexion pABA @ Abbott MAbsorbent @ Antibody Research Corp Mimetics@Promega Blue SA @ CSL MAbsorbent @ CSL Aminophenylboronate @ BIBITEC Aminophenylboronate @ Roche PIKSI kit @ Cobra 23_23 Agarose @ Novo MAbsorbent@Amgen WA MAbsorbent@Cangene Mimetic Ligands @ Diosynth Mimetic Kit @ AlphaVax Boronate @ AlphaVax Orange 1 @ Gala Mimetic Blue @ Boehringer Ingelheim Albiglutide - Blue SA HL (Scale-Up) @ GSK Blue 2 @ Amura Blue 2 @ University of California, San Francisco PIKSI @ BRI Blue SA HL (Phase III) @ GSK PIKSI @ Vaxinnate Corp. MAbsorbent A2P @ Inbio Boronate @ Biorexis Phenyl @ IMTECH Blue 2 @ InSight MAbsorbent A2P @ Biosceptre Perfluorosorb @ Aldevron Custom @ Pfizer Boronate @ Ipsen Mimetic Green Screening 1 @ Diosynth Yellow@PE DBA 20L Rewash @ Delta DBA 160L Re-wash @ Delta MAbsorbents @ Sandoz PIKSI @ IMTECH Perfluorosorb S @ Cobra Custom @ Octapharma MAbsorbent @ Amgen Ligand Rescreen @ Octapharma Boronate @ U. Penn. MAbsorbent @ BI Phenyl 1 @ Shasun Blue SA HL @ CoGenesys Mimetics @ Ambrx Mimetic Blue AP @ Ventana PIKSI @ Stanford Endotoxin Removal Kit @ Invitrogen Perfluorosorb @ Invitrogen MAbsorbent @ diaDexus Mimetic Blue 1 @ AMRESCO MAbsorbent @ Avestha Mimetic Blue SA @ Ventria Mimetic Red 3 @ UOC APB Sepharose @ Provalis Mimetic Ligands @ Sanofi-Aventis Boronate 2006 @ Avid Boronate 2007 @ Avid Blue SA HL @ GSK Hexyl @ VitaCyte PIKSI @ Duke Orange 3 @ Genencor PIKSI @ Genencor Blue 1 @ Texas A&M MAbsorbent @ Pro-Lab MAbsorbent @ Biogen-Idec Mimetic Green 1 @ Diosynth MAbsorbent @ ViralAntigens MAbsorbent @ Epitomics Aminobenzamidine Agarose @ Domantis Mimetic Blue A @ Domantis Blue SA @ Med Uni Ohio MAbsorbent (tips) @ Merck MAbsorbent A2P @ Avecia Blue SAHL @ Peakadilly MAbsorbent A2P @ Peakadilly Hexyl @ Vitacyte Red 3 @ Stanford MAbsorbent @ Medarex MAbsorbent @ EMD PIKSI @ Norfolk State University Blue AP @ Norfolk State University Blue SA @ Merrimack Mimetic Blue @ Princeton Custom @ Novartis APB @ Provalis June Batroxobin Cartridges @ Vivolution DEAE @ Viral Antigens Mimetic Red 3 @ UWyoming Boronate @ Novartis Mimetic Blue SA @ Pharmexa MAbsorbent @ Viral Antigens PIKSI @ PBL Biomedical Mimetic Blue AP @ UCSF Blue SA @ Baxter Blue 2 @ U Iowa Mimetic Green 1ii @ Diosynth Mimetic Green 1iii @ Diosynth The Binding Site- Blue SA HL@GSK Blue 1 @ AMRESCO A1P Kit @ Merck A2P Kit @ Merck Mimetic Blue Elisa kit @ Pharmexa pABA 06 @ Abbott ELISA Blue Kit APB @ Provalis April Mimetic@UofWisconsin APBoronate@Avid/Halozyme APBoronate 24L @Avid/Halozyme APBoronate@Baylor College of Medicine APBoronate 14L @Avid Halozyme PhaseII@Pfizer Transferrin@Pfizer BlueSA 20L@Merck BlueSA 2L@Merck BlueSA 80L@Merck QuickScreen@Sanofi Pasteur Beta Site@GSK Beta Site@MedImmune Perf@Cobra Batroxobin@Vivolution BlueSA 40L@Merck Blue SAHL 12L@CoGenesys Blue SAHL 7L@CoGenesys DBA@Delta APBoronate 5L@Avid Halozyme20,725 Mimetic Orange@Vaxinnate APBoronate 26L@Avid Halozyme BlueSA HL 40 L@Merck APBoronate 25L@Avid Halozyme pABA 20L@Abbott APBoronate 30L@Avid Halozyme APBoronate 20L@Cook Pharmica pABA 400L@Abbott Red3 20L@Teva Red3 15L@Teva APBoronate 380L@Cook Pharmica Blue SA HL 40L@Merck APBoronate 30L@Avid Quickscreen@Sanofi Pasteur Orange 1 3L @ Celgene Blue SA HL 1L@Merck Mimetic Blue SAHL 3930L @ GSK Blue SA HL 470L@Lonza Blue SA HL 10L@Merck Blue SA HL 10L@Lonza Special Octyl 20L @ CSL 25ml A2P @ Sea Lane Biotech Fabsorbent @ Glenmark 25mL A2P @ Lpath Blue SA HL 80L@Merck F1P @ Abgent A2P/F1P @ Genentech Mimetic Blue 1 @ Pioneer Hybrid Intl. APB @ Synthon BV Fabsorbent @ Medimmune MAbsorbent screening kits @ Cypress International Ltd. AXP @ Ablynx APB 10L @ Avid Bioservices Mimetic Screening @ PLIVA DVR resin @ Octapharma APB @ Aston Uni Fabsorbent @ Pall PuraPlate Screening Kit @ Pioneer Hybrid MAbFab@Lilly Fab@Novartis Institutes Special Octyl sample @ CSL Octyl Agarose @ CSL PIKSI kit @ Halozyme F1P @ Genentech Oceanside A1P Screening @ Ablynx Phenyl Agarose @ Symmetrix Fab100@Centocor Mimetic Blue 2L @ Avecia APB Fab @ Immunocore MAbsorbents @ Avecia Blue SA HL 2L@Merck Mimetic Green 100ml @ Halozyme Mimetic Green Column Kit @ Halozyme A2P Puraplate @ Genentech Oceanside APB @ Bio-Rad Bio-Rad, APB x 10L, 2010 PIKSI Kit @ Vector Labs APB 20L @ Avid Bioservices Octyl Agarose 20L @ CSL Fab 25ml@Xcellerex F1P 5x1ml @ Amgen TO Batroxobin cartridges Q2 @ Vivolution F1P @ Baxter Fabsorbent 25ml @ Medimmune Mimetic Blue 50L @ Avecia Mimetic Blue SA 100ml @ Biosite Hexyl Agarose 25ml @ U of Arizona Mimetic Blue SA @ USC APB 10L @ Thermo Fisher A2P 200ml @ Biosite MAbsorbent A2P HF @ BTG Fabsorbent @ BTG PIKSI Kit @ Biosite Mimetic Blue 7L @ Avecia Mimetic Screening Kit @ Fisher Scientific AG Mimetic Blue SA HL 500mL @ Vasgene pABA 1x1ml @ Prozyme A2P 5x1ml @ Amgen TO PIKSI Kit @ Nexbio Decyl Agarose 6XL 25ml @ Nexbio A2P HF 25ml @ Bio-Rad Batroxobin cartridges Q4 @ Vivolution APB G5 @ Bio-Rad Mimetic Blue SA HL 1L @ Biosite F1P 25ml @ DNA 2.0 Fabsorbent F1P 25ml @ Bio-Rad APB 100ml @ Cliniqa Corporation Phenyl Agarose @ Shasun Mimetic Blue SA HL 25ml @ Bio-Rad F1P 100ml @ Amgen Fabsorbent 100ml @ Amgen pABA 25ml @ Proteon Perfluorosorb S 25 ml @ Sachem Decyl Agarose @ University of Newcastle- APB 25ml @Duke Hexyl Agarose 5x1ml @University of Idaho Mimetic Orange 1 4L @ Celgene Custom Development Phase II @ Hemcon Fabsorbent F1P 100ml @ Amgen Mimetic Blue SAHL 1L @ Amgen Mimetic Blue column kit @ Amgen Mimetic Blue 2 @ Schering-Plough Fabsorbent screening @ Domp spa- Fabsorbent @ BioInvent Fabsorbent Column Kit @ Sutro pABA 25ml @ Merck Boulder HIC @ ETH Zurich Mimetic Blue AP 25ml @ Biocare Mimetic Blue 1 100ml @ Pioneer Hybred Mimetic Green 1 25ml @ Halozyme Mimetic Red 3 25ml @ Halozyme F1P free sample (1 x 1ml column) @ Cal State Long Beach Fabsorbent 25ml @ IIC APBoronate 15L@Avid APB 60L @ Avid Bioservices Mimetic Blue SAHL 100ml @ IIC Fabsorbent Column Kit @ Sealane Bio Fabsorbent @ The Norwegian Radium Hospital Mimetic Screening @ Synatxin APB LL 25ml @ Counsultant APB 25ml @ Counsultant APB LL 25ml @ Alios BioPharma A1P 100ml @ Amgen CO A2P Column Kit @ Amgen A2P HF 100ml @ Amgen Mimetic Orange 2 5x10ml Atoll columns @ Pioneer Hybrid A1P Column Kit @ Amgen MAbsorbent @ I.D. Bio OctaplasLG and Buffer Sample Analysis @ Octapharma APB @ Richter-Helm BioLogics Octyl Agarose @ CSL Behring APB @ i-SENS Inc. Mimetic Orange 3 @ BBI Enzymes Mimetic Blue 1M @ Merck KGaA Mimetic Blue .5L @ Vasgene ELISA @ GE Healthcare PrioClear Columns 0.5Lx6 @ Abraxis Mimetic Blue @ MedImmune Limited Fabsorbent 100ml @ Amgen SF Mimetic Blue @ Sanbio b.v. Fabsorbent @ Genovis AB APB @ Bore Da Biotech Co Ltd MAbsorbent Screening @ Th. Geyer GmbH & Co. KG- Mimetic Screening @ Cancer Research UK Clinical Centre FAbsorbent @ MorphoSys AG Buffer Sample Analysis @ Octapharma Minichrom columns @ Octapharma Mimetic Blue @ Medimmune Mimetic Orange 3 @ Alna-Bioscience GmbH & Co. KG Fabsorbent @ Ablynx nv Fabsorbent @ MSD Fabsorbent @ NACALAI TESQUE, INC.- PIKSI M @ BBI Enzymes Octyl Agarose 40L @ CSL Behring Mimetic Ligands Screening Kit @ Prozyme Anti A antigen @ CSL Behring AG Fabsorbent @ MRC Centre APB @ Bore Da Biotech Co., Ltd. Fabsorbent Screening @ Roche Diagnostics GmbH Empty PIKSI kits @ Oxford Immunotec Ltd Fabsorbent Sceening @ Sanbio Fabsorbent 25ml @ University of Munich Mimetic Blue 10L @ ORF Genetics Mimetic Orange 1 1L @ Yashraj Biotechnology Mabsorbent A1P 25ml @ Sanofi Aventis Adsorbents @ Green Biotech Corporation Fabsorbent @ Nacalai Mabsorbent A2P HF 25ml @ Sanofi Aventis ELISA @ Medimmune Fabsorbent F1P @ Allozyne Identification of an anti A isoagglutinin mimetic @ CSL Behring Full Development Program @ CSL APB 1L @ Halozyme Mimetic Orange 1 2L @ Celgene M. Green @ ChemDiv Sui-Man Kelvin Lau (EtoxiClear) p-ABA Study@AbbVie 1L Fabsorbent purchase@ Allergan Matrix 115 APB 25L (repeat order) @ Avid May 2014 EtoxiClear 5mL@ GSK Aalto - ABP P6XL - 25mL Aalti - Mimetic screening & Mimetic Blue 1 & SA x Mabsorbent A2P HF Crucell - Etoxiclear Bio-Rad, APB x 20L for 2013 delivery Albupure 100ml & 4 x 5ml protoype columns -Melbourne A & B Resins Validation batch @CSL Prioclear 2014@Octapharma 200ml Matrux B & 50ml Matrux A Resin @ Kedrion 25 mL Albupure@ BioTest AG AlbuPure Column Kit AlbuPure 25mL EtoxiClear 5mL Mimetic Yellow 1 A6XL 25mL APB 500mL Mimetic Green 1 A6XL 25mL AlbuPure 1L AlbuPure 25mL Mimetic Green 1 A6XL FOC 25mL Sample Delta APB A6XL 10L Delta Aminophenylboronate Agarose 6XL ligand manufacture & testing EtoxiClear Column 5mL Mimetic Screening Kit MAbsorbent A1P Column Kit MAbsorbent A2P Column Kit p-Aminobenzamidine Agarose 6XL 500mL Mimetic Red 3 A6XL 25mL Aminophenylboronate Agarose 6XL 500mL AlbuPure Column Kit 5mL EtoxiClear Column@ Sanofi Aventis Prioclear B @ Octapharma Mimetic Red 3 A6XL 500mL 5 mL EtoxiClear Column@ Lonza Walkersville Aminophenylboronate P6XL 25mL RABBIT ANTI-MIMETIC BLUE (ANTIBODY 1) 250uL MIMETIC BLUE 1-HEMOGLOBIN CONJUGATE KIT, 2 MG 100uM MIMETIC BLUE STANDARD@ GSK Fabsorbent F1P HF MAbsorbent A1P 25mL MAbsorbent A2P 25mL Aminophenylboronate P6XL 1L Fabsorbent F1P HF 3L Mimetic Blue Standard 10x4mL p-Aminobenzamadine A6XL Miltenyi Biotech-Fabsorbent Column Kit Analysis (1)@merck Analysis (2)@merck 5mL EtoxiClear@ Catalent Pharma Phenyl Agarose 6XL 20L Phenyl P6HF 100mL 10mL EtoxiClear@ Shasun Mimetic Blue SA P6XL 200mL PrioClear B  @ Octapharma 100mL Mimetic Blue SA HL P6XL@ Amgen Free AlbuPure 1mL Evaluation Column 35L Aminophenylboronate Agarose 6XL@ Peregrine MAbsorbent A2P Column Kit EtoxiClear 5 x5mL Fabsorbent F1P HF 25ml x 3 P-aminobenzamadine Agarose 6XL 70L @ Fujifilm Mimetic Orange A6XL@ Cypress International Mimetic Blue SA HL P6XL@ Novozymes 50L of G5 Aminophenylboronate@ Bio Rad Deeside Mimetic Blue SA HL P6XL Sample@ Reliance Life Sciences Mimetic Blue Standard 10mL vial@ GSK Fabsorbent F1P HF Column Kit@ Medimmune p-Aminobenzamidine Agarose 6XL 500mL@ Zymogenetics Fabsorbent F1P HF 25mL@ Novartis Delta Blue Agarose 6XL@ Novozymes Insulin Adsorbent Column Kit@ Richter-Helm Aminophenylboronate P6XL 25mL@ Indiana University p-Aminobenzamidine Agarose 6XL 35L@FujiFilm Mimetic Blue SA HL P6HF 50mL PrioClear B @ Octapharma Aminophenylboronate P6XL Fabsorbent 25mL Method development and Analysis of 3 protein samples Analysis of 28 Plasma Sample @ Octapharma Measurement of Prion Binding @ Octapharma Elisa Kit Components @ Novozymes ELISA kit @ Eli Lilly Mimetic Blue Sample@GSK Aminophenylboronate Agarose 6XL 100mL @ Halozyme Aminophenylboronate P6XL 25mL @ Aalto Etoxiclear 100ml Slurry @ Richter Helm MAbsorbent A2P HF 25mL@ Avaxia Mimetic Blue Ligand Elisa Kit@ Eli Lily PrioClear B @Octapharma AlbuPure 25mL @ CSL Marburg Elisa Test Kit @ GSK EtoxiClear 5mL@Baylor College of Medicine APB G5 HB A6XL 52L @ BioRad Deeside AB Feasibility Study Development of ligand leachate method for A-Resin and B-Resin @ Octapharma AlbuPure Column Kit @ Scil Proteins AlbuPure 100mL@ CSL AUS AlbuPure Column Kit @ CSL AUS MAbsorbent A1P Column Kit @ CSL AUS MAbsorbent A2P Column Kit @ CSL AUS Fabsorbent F1P HF Column Kit @ CSL AUS Mimetic Blue SA HL P6XL 25mL@ Proteos Aminophenylboronate P6XL Sample 25mL @ FujiFilm 5mL EtoxiClear Column @ Abbvie Fabsorbent F1P HF 100mL@ Lonza SP Purabead 6HF 1L@ Wuhan CM PuraBead HF 2L @ PBT AlbuPure 25mL @Novo Nordisk 4L Jacketed reactor @ Octapharma Aminophenylboronate A6XL 20L @ Bio-Rad In house molecule - repeat ABP A6XL order 25mL APB - UBC - Nov 2013 A Resin Campaign 1 @CSL A Resin Campaign 2 @CSL A Resin Campaign 3 @CSL A Resin Campaign 4 @CSL Prioclear 2013@Octapharma B Resin Campaign 1 @CSL B Resin Campaign 3 @CSL Chromatography Gel PO# 800218 Mimetic Blue SA P6XL 25mL @ CSL AUS AlbuPure @ Biotechnology Research Institute EtoxiClear @ CSL 1 x 5mL PPC Etoxiclear@Lonza APB P6XL @ B-Bridge  - Dec 2013 1L EtoxiClear @ Generon Mimetic Blue SA HL P6XL 25mL @ Proteos Custom PuraPlate @ Sanofi Toronto EtoxiClear 5mL @ Lonza Slough APB P6XL @ Baylor - Dec 2013 APB Column Kit @ Baylor Mimetic Blue AP @ Lee Bio - Dec 2013 A Resin Campaign 1a @CSL Matrix A & B @ PBP Raw Materials@CSL Project II pre-work@CSL 10L Prioclear A @ PBP FcXL Validation Batch 3, 5.5l @BAC IgG-CH1 Validation batch 1 5 litres@BAC IgG-CH1 Validation batch 2 5 litres@BAC IgG-CH1 Validation batch 3 5 litres@BAC FSH Validation Batch 3, 5.5l @BAC KappaXL Validation Batch 2, 5.5l @BAC KappaXL Validation Batch 3, 5.5l @BAC FcXL Validation Batch 2, 5.5l @BAC 43L Mimetic Blue AP @KBI EtoxiClear @ Pfenex APB x 10L @ Peregrine Prioclear 2014#2@Octapharma Prioclear 2014#3@Octapharma Matrix A 200ml @Octapharma HSA Validation batch 1 HSA Validation batch 2 HSA Validation batch 3 EtoxiClear @ Allergan - April 2014 5l AAT Sorbent@PBT 6l Mimetic Blue SA@PBT 2.5l CM Purabead@PBT Cross Linking Project (stage 1)@Novozymes APB x 3L @ Peregrine 20L FcXL@BAC 154L Octyl HF@PBT Octyl P6HF@PBT-US CE Extraction#1@Aspen 50 litres A Resin Campaign 2015_August @CSL 50 litres B Resin Campaign 2015_Sept @CSL 3l Albupure@CSL Blue AP, Perf & APB x 25ml @ Moderna AlbuPure 25ml @ University of Kentucky CE Extraction#2@Aspen APB 35L @ Avid 100 litres A Resin Campaign 2015_July @CSL 50 liters A Resin Campaign 2015_Sept @CSL Blue SAHL Resin Shelflife Testing Cross Linking Project (stage 2)@Novozymes 1L AlbuPure @ University of Kentucky Etoxiclear@Allergan Insulin Adsorbent column kit Fabsorbent column kit @ Regeneron APB 7L@AVID APB 3L@AVID Aminophenylboronate x 100ml @ BioResource Technology SAFC Mimetic Blue 700ml 40L APB A6XL @ Avid Bio 75L PABA 6XL @ Abbvi 1 x APB Column Kit @ KBI 110 litres A Resin Campaign 2015_June @CSL 50 litres B Resin Campaign 2015_June @CSL 50 litres B Resin Campaign 2015_July @CSL MAbsorbent A2P 100ml @ Abbvie IL 26 litres Kappa XL@BAC Evolve 70mm Process Design Kit @ NGM Fabsorbent F1P HF Column Kit @ Ambrx 500ml Etoxiclear@catalent 11 litres HSA@BAC Albupure 25ml MAbsorbent A1P 25ml @ Haemonetics 25mL Aminophenylboronate A6XL @ International Immunology PPPS Q3@Generium Mimetic Blue BMS NJ Mimetic Blue SA HL x 500ml @ Medarex 26L Octyl @ CSL Evolve 70, P70 Renewal & column Bed Support Kit @ILW 1L Fabsorbent @ Reneron MAbsorbent A2P x 2 (25ml) @ Haemonetics Mimetic Blue SA HL, 25ml @ Allergan 70 Evolve@BMS 100 Evolve@BMS 28 litres FcXL@BAC Mimetic Blue SA P6XL & AlbuPure Column Kit Etoxiclear@hemarinas 11.2L CH1@BAC Etoxiclear 5ml x 16 ~1L Matrix A & 1L Matrix B @ PBT Epoxy Purabead@BAC Evolve 70mm @ ILWW Evolve bed support kit @ IL 5ml AlbuPure Column AlbuPure 50ml Column @ J&J APB P6 column kit@Engenic APB A6XL 4L Evolve 100@Pfizer Evolve Column@Novozymes 50 litres A Resin Campaign 2015_Oct @CSL MediaScout @ Atoll Polyclonal IgG capture @ GSK APB @ Atoll Mimetic Blue @ CSL Octyl Agarose @ Atoll Mimetic range @ Atoll Custom_Resin@BTG 200 Evolve @ Puralite Insulin columns@NN Bio-Rad, APB x 20L Evolve @ Fuji_US Evolve 250@Genentech Evolve 140 @BBI HSA for Egypt@biolead Custom Adsorbent @ Allergan - Jun 2013 Fractionation@BT OEM 96 well plates@Perkin Elmer Cell Culture@biolead Evolve and Superdex Process design kit Etoxiclear and M Blue Evolve Bracket@BMS 64L GILT@BAC VAL1 GILT1@BAC Evolve70@Cintrade Evolve 250@GSK Evolve 70mm @ JSR VAL2 GILT1@BAC 50 litres B Resin Campaign 2015_Nov @CSL 20L APB A6XL @ Avid Bio Evolve 100@IMCS Evolve 100@Probiomed MAbsorbents @ BI MAbsorbent A3P @ CAT Mimetic Blue SA @ Unipath Avidex- MAbsorbent A3P @ Lonza Mimetic Green Ligand @ Diosynth Ligand Discovery @ BI Custom@BI Beta@Celltech Green 1@Diosynth Perf S@BI Blue@Unipath Fabsorsbent @ Affimed PRDT @ BTG Fabsorbent @ Fisher Scientific AG Mimetic Blue 80L @ Avecia Fabsorbent @ DSM Biologics- Quickscreen@DSM MAbsorbent screening @ Avecia Endotoxin Removal @ Syntaxin Clemson University- HIC @ Synthon BV Phenyl Agarose 10L @ Shashun Custom Development @ Syntaxin Mimetic Red @ Celsis FSH development@ MSD Maria Bernadi (EtoxiClear) EtoxiClear@ HKPU EtoxiClear@ National Cancer Institute EtoxiClear@ Sabadobo EtoxiClear@ LYKA LABS EtoxiClear@ Ourofino Agronegocio EtoxiClear@ UNAM EtoxiClear @ Remel EtoxiClear @ Gedeon EtoxiClear @ Aimcan EtoxiClear @ Shantha EtoxiClear@ Jilin University EtoxiClear@ Berna EtoxiClear@ 3M HealthCare EtoxiClear@ Gambro EtoxiClear @ Cephalon EtoxiClear@ Australian Red Cross EtoxiClear@ Laboratorios PiSA EtoxiClear@ ConsEau Tech EtoxiClear@ National Institute for Occupational Health EtoxiClear@ BAC BV EtoxiClear @ BioTech Logic EtoxiClear @ Pioneer Scientific EtoxiClear@ Kaneka Co. EtoxiClear@ BenTen BioServices EtoxiClear@ Merck Serono EtoxiClear@ Green Cross Corp. EtoxiClear@ Roche Quick Screen Projects@ 3M Quote Request@ CSL Quote Request@ Novartis EtoxiClear@ Novimmune 5L Quote@ BAC 3M Health Care-test 100ml Fab@ Lonza Aldehyde Activated Small Bead P6HF@ BAC EtoxiClear 5mL FOC Sample@ Allergan Aminophenylboronate P6XL Column Kit@ BioCon AlbuPure 25mL@ Resolve Therapeutics Fabsorbent F1P HF Column Kit@ Yorkshire Process Technology PuraBead Evaluation@ Purolite 25mL Aminophenylboronate P6XL@ Quantimetrix 10L Aminophenylboronate Agarose 6XL@ Thermo Fisher EtoxiClear@ Walter Reed EtoxiClear 5mL@ ~Medarex PRIOCLEAR B 121.6L@ Octapharma 5mL EtoxiClear Column@ Medarex Mimetic Blue ELISA Kit MIMETIC BLUE 1-HEMOGLOBIN CONJUGATE KIT, 2 MG@ GSK RABBIT ANTI-MIMETIC BLUE (ANTIBODY 1) 250uL@ GSK EtoxiClear Column 3L@ Cobra Testing to determine detectability of prions in Heparin@ Hepalink Aldehyde Activated Small Bead P6HF 1L@ BAC p-Aminobenzamidine Agarose 6XL@ University of Turku Fabsorbent F1P HF@ Yorkshire Process Technology EtoxiClear 1L & Storage Buffer @ Generon Fabsorbent 10mL Sample@ UCB Mabsorbent A2P 10mL Sample@ UCB Fabsorbent F1P HF Column Kit @ Novartis AG 5mL EtoxiClear@ Sanofi Pasteur 2L Aldehyde Activated PuraBead P6HF @ BAC B.V Elisa Kit @ MSD Mimetic Blue SA HL P6XL 25mL @ Indiana University Phenyl PuraBead 6HF 125mL @ Symmetrix Phenyl Agarose 6XL 125mL @ Symmetrix DEAE PuraBead HF@ Symmetrix Mimetic Blue SA HL P6XL 10mL Sample@ Bharat Serum Butyl Agarose 6XL 10mL Sample @Bharat Serum ELISA test kit - Mimetic Blue 1@ Nv Organon Aminophenylboronate P6XL Sample@ GSK AlbuPure PuraPlate @ Adnexus Aldehyde activated small bead P6HF 1L@ BAC Samples@ Tech Excel Aminophenylboronate P6XL 25ml@ Protalix Purabead P6 HF aldehyde small bead 2L@ BAC Tech Transfer and Set-up Validation batch 1@ BAC Study set-up and 2013 time point testing @ BAC FSH Adsorbent study@ BAC Octyl & CM Purabead Sample @ PBT Accelerated stability study on FSH Adsorbent @ BAC AAT Adsorbent sample 2L @ PBT MAbsorbent A2P HF 25mL @ Yorkshire Process Technology Fabsorbent F1P HF 25mL @ Yorkshire Process Technology FSH Adsorbent 4.6L @ BAC B.V Mimetic Blue SA HL P6XL 500mL @ Merck Sharp & Dohme Corp Aldehyde Activated PuraBead P6HF Small Bead 1L@ BAC B.V Mimetic Screening Column Kit @ Bio-Technology General Israel KappaXL Adsorbent @ BAC 15L Mimetic Blue 2 A6XL Measurement of Prion Binding of 5 PrioClear Samples @ Octapharma Mimetic Blue Column Kit@ UCL Generon Quarterly Invoice (Q2)@ Generon Generon Quarterly Invoice (Q3)@ Generon Accelerates KappaXl Study@ BAC Fabsorbent Column Kit@ Lonza Leachables Analysis @ Merck Paba 500ml @ Wockhardt Production of fcXL Adsorbent PIKSI (R) M Test Kit @ Aptamer ELISA Kit @ Wooil Science Accelerated Stability Study FcXL Adsorbent @ BAC B.V. 5L Paba @ Zymetech 25ml PABA @ University of Aarhus Testing of PBA Matrix @ Novozymes 25ml Perflurosorb @ Oxford University 1L Aldehyde Activated P6HF@ BAC 25mL Aminophenylboronate P6XL @ Maine Standards Puraplate @ Grifols CA 5L Mimetic Blue 1M @ Merck KGaA ELISA Kit @ BioTrader Inc 5mL EtoxiClear Column@ FEG 4L Jacketed reactor @ BAC FSH Validation batch 2 5.5L  @ BAC APB P6XL 1L @ EKF Mimetic Blue 1L@ Intas MAbsorbent A1P 25ml @ YPT Fabsorbent F1P HF 25ml @ YPT AlbuPure 500mL @ NovoNordisk PIKSI Kit x 6 @ Sigma St Louis Blue SA P6XL & Mimetic Orange x 100ml@ BTGIL MAbsorbent column kit 5ml @ Serco EtoxiClear 100ml x 2 @ Richter Helm Albupure Sample 25ml @ CSL Aus Aminophenylboronate P6XL 100ml x 2 @ Advy PuraBead P6HF Small Bead x 10L @ BAC DEAE HF 25ml@ INTRAVACC APB 25ml @ Maine Standards AlbuPure 25ml x 2 @ NovoNordisk A/S FOC Sample @ Cadila DEAE Purabead HF 25 mL @ Bio Connect 100ml AlbuPure Slurrry @ NovoNordisk 5 x 1ml AlbuPure Column Kit @ NovoNordisk 200ml Mimetic Blue SA @ Sigma MO 100ml APB A6XL @ NIH 25ml x 2 AlbuPure @ NovoNordisk AlbuPure 25ml x 3 @ NovoNordisk A/S PuraPlate offer @ Teva Aus Analysis @ Octapharma Q Purabead HF x 2L @ PBT Fabsorbent 25ml @ Atoll Germany Phenyl P6HF x 20L @ Shasun IVIG Leachate Analysis @ CSL Swiss 100mL APB A6XL @ Protein Sciences CT Mimetic Yellow 2 25mL x 2 @ Sigma Analysis of 6 Samples CH1 Adsorbent Stability Study @ BAC Aldehyde Activated PuraBead 6HF x 6 @ BAC 500ml AlbuPure @ CSL Aus Aldehyde Activated Small Bead P6HF @ BAC Matrix B 200ml @ Octapharma 25ml AlbuPure @ Silver Creek 500ml EtoxiClear Slurry @ IMTECH 25ml Blue SA P6XL @ BioRad Oxford ELISA Kit x 2 @ BioTrader Mimetic Blue SA HL, 25ml @ Proteos PIKSI & Hydrophobic Screening Kit @ Bioanalytic Mimetic Blue SA 100ml x 2 Elisa Kit Components @ GSK PA 3 5L Mimetic Blue SA @ Reliance Elisa Kit @ Merrimack Fabsorbent100ml @ YPT 25ml APB P6XL @ Universidade Federal do Rio de Janeiro Mimetic Red 3 @ Celsis 25mL PABA @ TUM Munich Albupure 25ml @ University Zurich 25mL APB @ Euromedex Blue SA P6XL x 25ml @ Feldan 20L HSA @ BAC 100ml APB @ BioRad CA 25ml Mimetic Blue SA HL P6XL Column Kits (Blue 1/SA/HL & AlbuPure) 5mL Prepacked EtoxiClear x 2 & Blue @ Minapharm 200mL EtoxiClear @ FEG APB P6XL25ml @ Xellia 5mL Prepacked EtoxiClear x8 @ Medarex 2 x 40ml Red 3 @ LG Life Sciences 270L CM Purabead @ PBP 300L Mimetic Blue SA HL @ PBP 100L AATsorbent @ PBP 1mL & 5mL AlbuPure Columns @ University of Zurich 25ml Fabsorbent @ CSL Ltd  Australia 25mL Aminophenylboronate A6XL @ University of Dartmouth 1L & 25ml x 2 of APB A6XL @ Maine Standards 20L CH1 Adsorbent @ BAC 25ml EtoxiClear Slurry @ ProteinOne Q2 & Q3 Profit Share @ Generon Fabsorbent Column Kit @ Abbott 25ml 100ml x 2 Mimetic Green 1 A6XL @ Sigma AlbuPure PuraPlate x 3 @ Adnexus APB A6XL 25ml@ Richter Helm 15L Mimetic Blue 2 @ MSD 100ml APB @ BioRad 6L Aldehyde Activated Small Bead @ BAC 100ml Albupure@ Eli Lilly 500ml Fab F1P HF @ YPT 5L Blue & 2L Phenyl A6XL @ PBT 100ml EtoxiClear @FEG 25ml Mimetic Green 1 A6XL @ Teva Aldehyde Activated Small Bead P6HF x 6L @ BAC Blue (1 P6XL, SA P6XL, SA HL) & AlbuPure @ Amgen AlbuPure Column Kit for Daichii Sankyo @ Scrum Octyl P6HF x 16L @ PBT 100ml Aminophenylboronate Agarose 6XL @ BioRad 1L Matrix A/ 250ml Matrix B @ PBT 1L EtoxiClear @ ProteinArk Protein G Study @ Generon PDK @ EMP 1L Aminophenylboronate @ Maine Standards 750ml Matrix B  @PBT Analysis of 3 PrioClear B samples for prion binding @ Octapharma 1.04ml Matrix A & 963ml  Matrix B @ PBT Evolve 140@ A2S Technology 10ml EtoxiClear Slurry x 2 @ UCB 25mL Fabsorbent @ UCB 30L Plasminogen  @PBT Evolve 100@Cobra 2.5L Phenyl A6XL @ Imtech 100ml EtoxiClear Slurry x 2 @ FEG 100ml EtoxiClear Slurry @ Amgen Oxford 25mL Fabsorbent @ Wako Phenyl P6XL x 400ml & Samples @ Cadila IVIG Leachate Analysis @ CSL AG FAbsorbent_dev@amgen EtoxiClear @ Medimmune Cambs 15L DBA Rewash @ Novozymes 100ml AlbuPure Slurrry @ NRCC AlbuPure Column Kit @ University of Ferrara 25ml AlbuPure @ Hyderabad University 500ml Aminophenylboronate P6XL & EtoxiClear @ Richter HelP 500ml AlbuPure @ NovoNordisk 10L Phenyl A6XL @ Imtech 250ml Matrix 115 @ Merck 100ml AlbuPure Slurrry x 2 @ CSL Behring 1 x AlbuPure Column Kit @ CSL Behring MAbsorbent & PIKSI Kit @  Novartis Vaccines Institute for Global Health (NVGH) S.r.l. 4L Plasminogen, 20L Fibrinogen & 5L Q HF @ PBT 10L P60HF @ BAC 2015 Storage fee @ Novozymes 25ml Mimetic Orange @ University of Manchester 10ml EtoxiClear Slurry @ BioCats Fabsorbent F1P HF Column Kit @ Bio Rad France 20L Q PuraBead HF @ PBT 1L Matrix A @ Grifols 1L Mimetic Blue SA HL P6XL @ Novozymes 5 x PIKSI Kits @ Sigma Mimetic Blue SA HL P6XL Column Kit @ J&J CA AlbuPure Column Kit for Daichii Sanyo @ Scrum 1L Mimetic Blue AP @ Ryan Scientific Fab 25mL @ Jounce 500ml Purabead 6HF @ EMP IVIG ligand leachate analysis @ CSL AlbuPure Column Kit @ Amgen Munich Elisa Kit @ Sun Pharma 100ml AlbuPure @ Atoll 6.5L Phenyl A6XL 7.5L Phenyl A6XL 100ml Mimetic Blue x 5 @ Sigma 1L AbuPure @ CSL Aus Fabsorbent F1P HF 25ml @ Aggamin 70L AATsorbent @ PBT Fabsorbent Column Kit & 5ml EtoxiClear @ UCB Insulin Adsorbent 25ml @ Eli Lilly IN 25L Mimetic Blue 2 @ MSD Oss Generon Quarterly Invoice Q4 2014 & Q1 2015 MAb A1P & A2P Column Kit @ Fujifilm UK 100ml EtoxiClear @Cintrade 4L SP PuraBead HF 1L & 25ml of APB A6XL @ Maine Standards Mimetic Blue AP A6XL PuraPlate x 2 Blue SAHL Resin Shelflife Testing @ GSK EtoxiClear 10ml Slurry @ ADC Bio 500ml EtoxiClear Slurry @ Hemarina AlbuPure Column Kit x 2 & AlbuPure 5ml Column x 5 25ml AlbuPure @ J&J Fabsorbent Column Kit @ Cypress International Phenyl A6XL 3.6L (ordered through PBP) @ Emergent Elisa Kit @ Medarex Fabsorbent Column Kit @ BioRad AbD Serotec 25 mL PABA @ BioTest AG 5ml Etoxiclear x 4 @ Amgen Germany 20L Phenyl A6XL @ Symmetrix 5L Q PuraBead HF @ PBT 1L Mimetic Blue SA HAL P6XL @ Medarex 10ml EtoxiClear @ Cintrade Evolve 70mm @ Cancer Research UK MAb Column Kit & 5ml Custom Column Mimetic Blue SA HL P6XL 25ml @ MinaPharm 2 x EtoxiClear Columns @ Lonza 100ml Insulin Adsorbent @ Julphar 100ml Fabsorbent @ Wako 100ml Mimetic Blue x 5@ Sigma 6L Aldehyde Activated P60HF 10ml EtoxiClear @ Momenta 25ml Fabsorbent @ Ambrx 25ml PABA @ Enzymatica Fabsorbent Column Kit @ Absolute Antibody 100ml APB P6XL @ Syngene EtoxiClear 10ml x 2 @ GSK 100ml Epoxy Activated Purabead 60HF @ BAC 500ml EtoxiClear @ Protein Ark 7cm Evolve @ Medimmune Cambridge A2P @ PacificGMP 7L APB P6XL@ Richter Helm Matrix A @ Octapharma 50 litres A Resin Campaign 2015_Nov @CSL Mimetic Blue SA HL P6XL 100ml @ Advy 25mL EtoxiClear @ J&J (VWR) AlbuPure Column Kit @ NovoNordisk Generium rProteins Resin requote 3.5L Mimetic Blue 1 P6XL @ San Tenki 100 litres A Resin Campaign 2016_Feb @CSL 100 litres A Resin Campaign 2016_Jan @CSL 100 litres A Resin Campaign 2016_Mar @CSL 100 litres A Resin Campaign 2016_Apr @CSL 50 litres B Resin Campaign 2016_Feb @CSL 50 litres B Resin Campaign 2016_Mar @CSL VAL1 & Tech Transfer GTA@BAC VAL2 GTA@BAC VAL3 GTA@BAC 21L FSH@BAC Project II@CSL PBA Matrix @ Novozymes 36L FcXL@BAC 22L HSA@BAC Matrix B @ Octapharma PABA ligand density testing@Abbvie 5L Hexyl VAL3 GILT1@BAC Evolve 70mm @ Porton UK PDK @ Eli Lilly UK 5ml EtoxiClear @ Orla Protein Tech PDK @ Fuji Evolve 70mm @ Fuji Custom ligand dev prog @ Zepteon Evolve 70mm @ Actavis 60L Mimetic Blue SA @ Reliance Prioclear 2014#7@Octapharma Prioclear 2014#8@Octapharma Prioclear 2014#4@Octapharma Prioclear 2014#5@Octapharma Prioclear 2014#6@Octapharma Prioclear 2014#1@Octapharma Validation Batch DBPv2@Novozymes PPPS Q2_16@Generium 5ml EtoxiClear @ F-Star Camb 50 liters A Resin Campaign 2015_Dec @CSL PPPS Q4 @ PBT MAbsorbent A2P HF Column Kit x 2 Blank P6HF@CSL Insulin@Sanofi Prioclear 2014#9@Octapharma PPPS@Samarth Fibronectin@biolead Evolve @ Alvotech Evolve @ Nexvet Evolve @ mAbxience Evolve @ Glenmark Evolve @ Baxalta Endotoxin Reduction @ Phico Therapeutics Ltd Evolve @ Rentschler Evolve @ Samsung PPPS Resins#1@Winnipeg PPPS Resins#2@Winnipeg Insulin@HEC APB @ Thermo Fisher Sweden Mimetic Blue AP Dev#3Pfizer Mimetic Blue AP Dev#1Pfizer Mimetic Blue AP Dev#2Pfizer 35L APB A6XL @ Avid Bio Albupure 10ml slurry Endotoxin Removal @ Crescenso biologics TT & VAL GILT@BAC 210L APB A6XL @Repligen 4 x 5ml Delta EtoxiClear Columns Sent FOC Prioclear 2014#10@Octapharma Proxcys Columns @ PBT Albupure x 12L @ Novozymes Acivated Purabead Resins tried Mimetic Green, mixed results, Red 2 worked well from screening kit. Testing of MAbsorbent with GSK MAb supernatant/s - closed lost due to this never having been a defined opportunity - re-evaluate after discussion with Greg Mazzola and Tom Smith Project stopped at free of charge screening stage due to reorganization of priorities at Biogen-Idec. Thiswas a novel application for the supply of free A2P ligand for some rapid screening application. Due to the high sensitivity from both sides and the inherent amount of confidentiality surrounding dscussions and associated documentation, this new application was lost due to time and priority at CAT. medimmune is partnering with (as yet unknown) a german pharma 
company to purify several antibodies in a class of molecules that 
have shown some affinity to Protein L.
Prometic has an opportunity to gain a custom ligand design contract 
for Protein L Mimetics or one that might work for a whole class of the 
molecules of interest. Lost to a gel permeation step/lack of time in small development window. Key contact people have all changed.  Renew contact through Harry Meade.
Discussed with Nick Masielo on 6/20/06.  Very much on back-burner.  Close opportunity until firm reason to open new one in connection to albumin. assume 2 x 450 L
complete review of project resulted in delay of Phase III work, this volume of resin likely to be used for Phase III.  Further work at manufacturing scale unknown at this stage. Lost due to legal implications.. From: Dev Baines 
Sent: 03 June 2010 17:04
To: Mark Jackson; Steve Burton
Cc: Stuart Jordan; Richard Dodd
Subject: Dextra - PuraBead 6HF
Stuart and I met Selwyn Yorke a kiwi BD guy from NZ Pharmaceuticals who is temporarily filling in this role. 
Obviously, wanted an update on the B-antigen and was fielded off while continuing to maintain an interest. 
The PuraBead quote did not go further because the client asked them to progress with Sepharose 6FF even though Dextra folks found PuraBead 6HF to be a better material.  They are actively promoting tour base matrix their other clients and will continue to do so. 
NZP is interesting in that they manufacture cholates and deoxyholates which are used in formulation of vaccines (possible PBT interest).  
Dev Impass on MTA - refer to Steve Burton No recent activity... Change of business strategy CMO reference from Sylvia Hinds.  MD has met with Toso in the past. Tim Breece is part of a new group looking at technology evaluation.  He would like to look at MAbsorbent A2P in the presence of pleuronic F68 with an amberlyte guard column or depth filter. Mike Duell arranged this meeting for he & I to intro me to this Acct and to present info on MAbsorbents as alternative to Protein A-agarose of GE. Need to conbtact Bill Fisher VP of R@D. 7-28-2006 gave seminar at Baxter Bioscience, LA re MAbsorbents A2P and ii use for plasma isolation. Roman Sackowicz is looking for an affinity method to purify nucleases.  He might try a PIKSI kit, as well as a column screening kit as well as Blue 2. closed lost due to issues with F1P binding Fc region I assayed all the trial samples by Coomassie Plus assay, and ran a gel and blot with 12 ug total protein loading per well. I scanned the gel to get approximate Fab purity for each sample. I dont have a record of the load and pool volumes from the experiments  if you can send me those values I can calculate approximate Fab loading and recoveries. The calculations would be approximate, but Im confident they would be at least as accurate as anything I would get from Protein-G or ELISA numbers.
Overall, there wasnt any improvement in Fab purity in any of the tests. This coli harvest was more of a lysate, and its so filthy with lipids, membrane fragments and small molecules Im not too surprised at the result. This is an alkaline Fab, with a pI of 8.2. At some point when I can find a slow day or two I would like to try capture on cation exchange at pH 7 or 7.5, just to flush away all the lipid, nucleic acid and other garbage. Ive recently used a CIEX step like this, with a steep salt gradient elution, on a coli lysate for an unrelated project, and all but about 20% of the coli proteins went in the F-T at pH 7. The pool was also quite clear and colorless. This might make a much better quality feed for polishing on FabSorbent, and maybe Protein-G as well. closed lost due to pluronic in cell culture media Cory
My client responds that unfortunately they are not in a position to move forward at this time.  We appreciate your followup, but this project did not make it into this years budget.
Scott working on CDA and MTA for transfer of Fibrinogen Adsorbent to IIC for evaluation the smaller scale was decided to be sufficient to provide enough material for first studies.  In matters of purchasing new resin it is very likely that we wont need resin in 2010 and 2011. said GMP run is now delayed until September at the earliest My current purification protocol uses 2-steps: Blue (yours) and Q-Toyopearl (as a polishing step).
One of our consultant pushing us forward, saying that 2-step's purification is not good enough. Normally companies use 3-4 and higher step's purification.
On another hand, the level of impurities in our final product indeed is somewhat close to maximum allowed. And this is dangerous.
Ideally, I need to decrease this contamination level by extra order.
That's why I have started looking for cheap and robust 3rd step.
HIC is one of that.
I have a list of your HIC resins. That's why I emailed you.
I would like to see more info: Binding capacity, recovery, conditions etc. 20L of A2P HF for MAB process if we can work around F68 issue
- outcome was less than half the performance of GE Protein A product 2 liters for process development purposes initial MAb project process largely dictated by CMO (unknown who) with use of Protein A and hydroxyapatite downstream as polishing.  Had wanted to avoid process patent issues and this apparently does so.  Opportunity still open to work on processes for future MAbs platform. Process transfer from CoGenesys Pricing enquiry for client report. Decided to perform work in-house. In my opinion, we failed to differentiate the quality of work to be performed which the customer viewed as routine & that which could be performed by a lower grade technician. This is a waning shot, & we now need to reinforce or relationship at the customer, introduce new conatcts (Richard & myself) in an account where there was an over reliance on one individual at ProMetic. This is the value inc. performance verification chromatography & assays.
The value without this option is 13,943.75. This is for Experiment 1 & 2a.
If this is not successful, the value for Experiment 1 & 2b will be 11,542.64. Alain has recommended that we contact Mark and discuss our custom program as there might be an interesting project No further activity... This amount comes from a price/L initially provided to the customer. Since then, we have been advised that Mimetic Blue SAHL was outperformed by a competitor adsorbent (?) in terms of dynamic binding capacity. funds re-assigned for other projects. longer term possibility depending on outcome of current phase 3 clinical trials, etc. etc.  maintain longer term contact. Interest in custom development program Lack of a CDA/MTA is preventing Abgenix from sending cell culture supernatant to Cambridge for screening.
Thursday 2-16-2006 Duell + Oberg met with Dr.Tamas Blandl + Dr.Ruoheng Zhang  + Wayne Chang in conference room and Mike Duell described our MAbsorbent product line of A1P + A2P + A3P later this year and they were most interested in A3P due to it's projected insensitivity to pleuronic presence in CHO cell culture supernatants.  Most ii the A3P and wonder how soon they could get some for testing ?
Mike and I thought that the above mentioned confidentiality agreements + material transfer agreeement are maybe complete so we can have more discussions with them?
Oberg will copy them on the A1P & A2P applications + brochures, but we also need to get an A3P sample to them ASAP. closed by VB - no activity. Unfortunately, it has been decided by management that there won't be any funding for a FIX affinity ligand project. 
Due to the difficult business environment cost saving measures are implemented in all different fields and on all different levels right now which makes it hard for 'technology projects' to actually get funding. 
Having said this, we strongly believe that your company is a very valuable partner and our efforts so far have been more of a beginning of a strategic partnership. I think we have come pretty far in 'setting the stage' in terms of legal and business related agreements as well as initial scientific discussions. 
One of the points we made during our last meeting was that we could get up to speed pretty quickly as the general path forward was already laid out pretty well and we 'just had to wait for our product'. 
I think having come to that point will enable us to start pretty quickly when new products and new projects are appearing on our screen in a friendlier business environment. At the moment we dont have a consensus for using the F1P because purification of our Fabs is done thru the His tag and the Surrobody does not have a light chain. 25mL Mimetic Blue 1 P6XL has client project where protease is an issue and needs to be removed. This value comes from a discussion with Tony Newcombe at the IBC conference in Prague during which he suggested that we would need to provide 10-15 liters of A2P to pack a BPG 300-450 column to demonstrate packing performance. I have split the costs. One of the possibilities I mentioned was the recent establishment of a US Sales and Marketing effort for Quotient Biodiagnostics that could compliment your existing coverage in the US for example. 7-27-2006 ii A1P and A2P MAbsorbents during presentation to her Downstream Processing Group that does CMO work for a variety of Pharm Firms.  Asked if we have an IgM affinity media? A1P and A2P 25mL each on special offer.  did not want to order, wants samples.  VB decided to offer 10ml of each as sample, because A2PHF now available. could not obtain funding for this project. Forecast 25% down on 2005 figure of 166,339 due to ongoing in2it technical issues into Q1 (Forecast 06 =124,754).
The above figure has been adjusted for the 10L order of Sepharose APB (124,754- 16,287 = 108,467).
Then adjusted for the April order of 40L of Provalis APB (108,467-24,660 = 83,807).
Then adjusted for the June order of 40L of Provalis APB (83,807-49,320 = 34,487). The amount is based on minimum requirement of 12 Liters. Domantis currently have a SO for 12-24 Liters/annum. However, they do not clean with Caustic. I have assumed that the Protein L Mimetic will be equal in price to MAbsorbent. It will more than likely be proportionally more expensive (i.e. Protein A cf. Protein L). The close date is based on 9 months of ligand/adsorbent development. Beta-site evaluation In view of the problems with Biogel, Mitra have agreed to commence investigations into the use of 200 micron Purabead. Initially they asked for details of a comprehensive development & validation programme comprising several batches of product. A quote was issued in March comprising 3 x 1 litre batches @ 12,300/batch and 3 x 4 litre batches @ 42,630/batch. Whilst these prices are reasonable given the amount of work involved, Mitra clearly had a problem with the price. Instead they requested a quote for a single 1 litre batch with minimal QC testing (7845). This batch was made and shipped to Mitra who conducted performance tests themselves, the results of which were presented at the meeting in Lund a couple of weeks ago. There will clearly be a need for more 1 litre batches and another was requested at the time of the last meeting (quotation to be prepared once synthetic method for next batch finalized). So far this year we have supplied a 6 litre batch of MAA powder (made with Biogel) and a 1 litre batch of MAA slurry made with 200 micron Purabead.
We are still experiencing major problems with Biogel (on-going since the beginning of 2004) and do not have a useable batch in stock. Once we do have a useable batch we anticipate Mitra will immediately place an order for a 10 litre batch of MAA powder (worth around 72,000 - see above). Unfortunately we have absolutely no way of knowing when or if Biorad are able to provide a batch of Biogel which meets the required specifications, so exactly when Mitra will place their next order is unknown at present. Scale-up X10. Scale up X10.
Plasmid DNA Production 
Plasmid DNA contract manufacturing
cGMP for clinical trials
FIT Biotech offers aseptic manufacturing of plasmid DNA using a characterized Cell Bank System. The company obtained a manufacturing license from the Finnish National Agency of Medicines at the end of year 2000. This attests to the high level of quality of our current GMP manufacturing area.
Aseptic manufacturing conditions are ensured by up-to-date design and monitoring of the clean room and the HVAC system, effective cleaning and maintenance program of the facility and the equipment, and by an environmental monitoring program. The processes and methods used are robust, well documented and validated. 
 Batch scale 10 - 100 mg 
 Aseptic preparation and manufacturing
- Fermentation process in Class 10 000
- Purification and filling in Class 100
- QA/QC analyses of identity, homogeneity and impurity
- Additional analyses upon request  
 Full documentation package for regulatory purposes is available upon request. 
Complete Master Batch Records are provided to the customer as a part of the contract manufacturing service. 
Production for non-clinical use
FIT Biotech also offers GLP grade plasmid DNA manufacturing services.
 Plasmid production according to GLP 
 From small scale (10 - 100 mg) up to 1000 mg a batch 
 QA/QC analyses for identity, homogeneity and impurity 
 Additional analyses and full documentation package for regulatory purposes upon request estimate 10 L of one or the other or both for scale up work. Use 75-100 1mL Protein A coulmns/yr for antibody characterisation. From: AMW (Ashley Wigley) [mailto:AMW@novozymes.com]
Sent: 13 September 2006 11:46
Subject: Novozymes Delta Anticipated matrix requirments 2006/2007
Steve 
Diane Morris asked me to contact you with our anticipated  chromatography matrix requirements for the remainder of 2006 and for 2007:
2006
Q3 2006 60L PBA (62,720, approx 20 weeks lead time to manufacture ligand and matrix) 
2007
  DBA 
*	Q1 2007 order synthesis of  DBA ligand (equivalent of 200L matrix)
47,400 - manufacture complete approx 15 weeks after order and then stored at Prometic (invoice Q2 2007) with annual DBA ligand storage and requalification charge of  7,200 per annum
*	Q2 2007  manufacture 60L DBA matrix (59,510) using 30% of the
ligand manufactured above, and deliver to CAPP Conference lead.  Dietmar Lang will relay PBL brochure and capabilities to internal colleagues and provide leads if custom programs are their chosen vehicle for future purifications.
Patchy interest.  Have ordered small volumes of media for process development. Paris Conference '07 lead.  Interest in custom program.  Henri Charbre is discussing internally to check level of interest.
Never returned calls or emails.  Not interested? First meeting held following initial contact at Informa Paris April '07.  High degree of interest, need to pursue with CDA and follow up meeting. Micromet AG is a FAB developer and has expressed a strong interest in using a synthetic ligand for its capture. GE Blue gave higher binding capacities - PBL's media only gave 2 mg ml-1 binding capacity @ 200 cm hr-1. Contact:  Boris Schwartsburd AM Pharma have just announced positive results from their latest trial  use of alkaline phosphatase to treat acute kidney injury.  The PR says they are now going to focus on the recombinant enzyme which was the original intention and exactly what we were told last week when we met with AM Pharma in Holland.  The expectations are that AM Pharma will conduct another round of financing before the summer and then, subject to completing their next financing, contract purification development of the recombinant enzyme to PBL! We have been asked to provide a proposal over the next few weeks based upon a downstream purification process incorporating PBLs Mimetic Blue AP adsorbent (NB this is our existing commercial product not the new adsorbent we were developing as part of the original Pharmaaware/AM Pharma project). Process development will be on a fee for service basis (not work for equity like before) and we will transfer the DSP we develop to AM Pharmas selected CMO who will implement the process for manufacture of GMP product for the next stage of clinical trials.  
AM Pharmas (VC backers!) stated intent is to sell the company with the AP product to big pharma on the back of solid clinical data. Having a ProMetic product embedded in their process would put us in a good position when the company is eventually sold.
We have not mentioned AM Pharma to our shareholders for some time.  Perhaps now would be a good time to remind everyone of ProMetics involvement with AM Pharma (eg. note to shareholders or inclusion in next Management update) to tee-up a NR later in the year.
Steve Most recent tests of lead candidate offer no advantage over Mimetic Blue SA HL. Cell line issues. Being driven by Dev. A potential competitor to AM Pharma emailed sales about pricing for 25 and 100ml F1P Our project aims at new platform technology for the efficient separation of antibody with low production cost. Till now, we have developed some processes for the blood-plasma derived antibody separation, such as porcine plasma, goose plasma and chicken plasma. Currently, we are trying for the purification of monoclonal antibody form the mammalian cell broth. Quote sent for  PuraBead 6HF and PuraBead Q 6HF Vincent is a champion of PBLs synthetic ligand adsorbent for the purification of IgG. He used MAbsorbent A2P for the purification of SAR hyperimmune IgG in 2003 and reported that the material worked excellent and he obtained a recovery of 80% with high level of purification.
Livzon are focused on development of monoclonal antibodies for the Chinese market and currently have 3 products in development. The first one is an anti-TNF antibody for which IND has already been submitted; the second product is anti-CD22 antibody and lab scale process development is being worked on this product. At this point the company is evaluating different Protein A adsorbents before final selection for the scale-up by end of Q3 this year. Vincent is keen to include synthetic ligand adsorbents in the evaluation exercise and is open to all available options. 
Dev described the status of MAbsorbent A2P and issue related to the presence of Pluronic F68 in the cell culture medium. The two strategies that we have in-place (capture of the target protein on cation exchanger or removal of Pluronic F68 by the use of reverse phase resin before the MAbsorbent A2P purification step) were described and he is very keen to explore both of these approaches. 
The next steps 
Send the following  documents, presentations on the cation + A2P steps and application note on removal of Pluronic F68)   to Livzon.
Teleconference  technical discussions to clarify the options and provide technical support. 
Send required adsorbents to commence the evaluation for the anti-CD22 monoclonal antibody. 
Ideal to have Dev on site to guide the end user and ensure success (mid-July) General interest in services and products They will to remove the centrifuge stage and use chromotography plus they spend over 5 M will sigma on amberlite so we should look at an alternative device Steve will drop an email to edith and alin to request a meeting in the next couple of weeks custom development project visit to discuss further interest in blue and albupure could be a good possibility to get into Basel.  Steve to visit ASAP possibility to tie in resin order for 2013 attempting to secure supply for 2013.  Email request for update Annual media purchase for Diagnostic kit Preparation of RSF material for Matrix 115
Customer has decided not to proceed with this based on the additional cost (not expected). They believe they have all the relevant information to include in their MVP Feasibility study to develop affinity resin for FAb molecule Francis Meacle left to join Centocor.  Need to find out who to contact and pick up this project. Abbott is working with Plasmid DNA obtained from Aldevron.  They use a ProMega kit followed by the Sterogene kit for endotoxin removal.  Pending a CDA and MTA Lerner is going to try both Perfluorosorb and the endotoxin removal sorbent to polosh the DNA.
3/13/06 Claude Lerner asked not to be contacted again. Rick Mehigh will consider use of MAbsorbent for internal use towards the end of the year.  He asked about the species variation in MAbsorbent binding efficiencies.  Sigma has introduced an antibody based abundant protein depletion sample preparation device that has obviated the need for MAbsorbent. Lerner has agreed to be a Beta Site for the ERSorbent.  In this context he has agreed to share info with ProMetic, not to publish results, and not to try to analyze or duplicate the sorbent.  His application is to remove endotoxin from plasmid DNA.  He is also looking at Perfluorosorb for the same application.
On 3/13/06 Claude Lerner asked not to be contacted by ProMetic again. Interest in purification of trypsin.  Celliance's parent (Serologicals) is being acquired by Millipore.  Everything is on hold until the transaction is closed.  Celliance's parent company, Serologicals, has been taken over by Millipore. Sample of A2P has been sent.  Follow-up pleuronic issue.  Customer waiting for A3P. Fusion protein platform for vaccines. - possibly initial screening program only.  
This is an either/or proposition with standard Mimetics from a Quickscreen
Customer will pursue Mimetic Orange until it proves inadequate. Evaluation for protease recovery and purification.  Renewed interest along with APBoronate. Pfizer is currently progressing 12 antibodies at the Chesterfield Labs.  A2P HF is of interest.  A3P is also of interest.  Custom opportunity involves antibody purification.  Once the Custom project is underway, there will be a better opportunity to close an order of MAbsorbent A2P HF of MAbsorbent A3P. Eventual scale of production will be in 5,000 liter fermenters.
Earlier work at 500 liter scale.
Needs Update Ron Bassuner continues to delay commitment to any business, saying his focus continues to change. Sales of blue to Sigma for their proteomic application have disappeared due to the introduction of an antibody based abundant protein depletion device. 100 liters for Phase III production
Not a focus product for 2007 5 liters for scale up work to Phase III process Graham Tullock will be reconsidering Grand changes in the insulin processes.  We need a difinitive opinion of the freedom to operate issue vis a vis Novo for insulin binding ligands. Set visit for sometime after 4/20. Possible medium to large scale process for plasmid production. Expresesed interest at presentation on 3/31/06. Exploring use of APBoronate for PEG proteins. 25ml Mimetic Blue 1 P6XL Attempted to sell 2 for 1 offer. 2 for 1 offer. supplied contract template for inclusion in grant application.  this opportunity is almost entirely dependent on grant money. Need to separate differentially glycosylated proteins from non glycosylated ones. Use with Blue SA for recovery of albumin and IgG from goat plasma.
Requires follow-up. Leslie Carvalho has asked for ordering information for Blue SA and MAbsorbent A2P to be used with goat plasma.
Requires follow-up William Wessel is evaluating APBoronate for a glycosylated protein.  He has asked for technical support.
Wessel engineered around the problem, so he doesn't need the Boronate. Vaxinnate is interested in a platform ligand for their flagellin-fusion protein vaccine line of products in development.
We may be able to get a quickscreen if the Orange proves inadequate. Interest in a statement as to the probability of success with separating a highly PEGylated phenylase from free PEG. Custom & Puraplate Brochures.
Send Brochures. The project is now at Phase 3 and they are performing (or plan to perform) CHO culture at the 20,000 litre scale for this project. The first capture step is Lysine Sepharose which has a very low capacity for plasminogen (but gives a very good purification). Diosynth contacted ProMetic because this lysine step is a major problem for them. The capacity is so low that they are using (or will have to use  it was not clear if they are now at full scale or if that is the next step) a 600 litre column cycled 9 times to process one 20,000 litre batch. They are aware we have developed a Mimetic ligand for plasminogen (developed for PPPS) which provides a much higher capacity (17g/litre vs 2g/litre) and they are VERY interested in trying out our plasminogen resin (which like lysine gives very good purification of plasma derived plasminogen).
If our plasminogen resin works for recombinant plasminogen then we are looking at a requirement for tens of litres in Q3/08 and enough resin to pack a 400 litre column by the end of 2008. So this could be a requirement for around 500 litres in 2008. Given our resin is unique (patented) and if it works, the advantage it provides to Diosynth will be huge, then this will mean we can charge a premium price for this resin. On the basis we should be able to charge >2,000/litre then we are looking at a potential 1m worth of orders in the second half of 2008. This will go a long way to filling Bruces hole (in the accounts should Millipore not proceed)!
I have agreed with Philip Ropp that the next step will be the provision of a draft CDA and MTA, completion of which will enable us to provide Diosynth with a sample of the plasminogen resin and conditions for use. If they obtain good results then the next step will be the negotiation of a licence and supply agreement.
Steve Willett doesn't want to make advanced payment.  ProMedior funding insufficient to permit scale-up of process for second indication until at least the 3rd quarter of 2009. Asked for quote for 5 X 1 ml columns as well as 500ml and 1 Liter. Prion removal from cell culture media Looking to try APBoronate as a polishing step to remove glycosylated proteins from pichia culture. We are putting together a proposal for a company with a therapeutic application for their DNA.  They need a large quantity of purified material so if we do their project we will definitely try out the resin.  We wont know for a few months. Matt Dickson will order 100 ml for testing. John Herberg interested in MAbsorbent A3P ligand in solution.  They have asked for paperwork to be fulfilled by ProMetic. Asked for quote for 6 X 5 liters of 3125 for new project.
Jason Bustard updated close date to 4th Q 09.
Bustard revised forcast to 80 L Fabsorbent is a possible improvement over any Blue for Merrimack's fusion proteins.  Looks like Merrimack will stay with some Blue adsorbent. Would evaluate immediately Thanks for explaining Prometics mimetic ligands to me last week.  For now, I will keep this information on file for when we start to do protein purification, which might have to wait until 2010. Gentlemen
As many of you know, we have been working with Abraxis on a project involving the removal of prion infectivity from albumin solutions. Abraxis uses the albumin solutions (at 20% or 25% concentration) to produce Abraxane, their product based on albumin nanoparticles as drug carriers.
We are close to the end of the current proposal, which encompassed a screening of our current resins against spiked albumin solutions, a determination of the capacity of the selected resin in the presence of high concentrations of albumin, and the determination of the impact of the resin in the quality of albumin (the last activity is scheduled to start in about a week).
Abraxis requested that we put together a new proposal, which will deal with the use of the selected resin at full scale, under process conditions. They are interested in being supplied with packed disposable columns capable of handling a batch of 45-50 liters of albumin. We have proposed the use of a 1:100 ratio column:challenge, but Abraxis is yet to formally accept that ratio. If they do, we would be using 500-mL columns.
It has been mentioned to me that we might have a partner that has experience with packing prion-reducing resins into disposable columns. Talking to them might be a good idea.
We need to discuss internally that proposal, in preparation for a call with Abraxis to ask more specific questions that we might have. Shall we have a call?
Patrick
Patrick Gurgel, PhD
Technical Manager  PRDT          
ProMetic Life Sciences
Tel: 919.515-5720
Fax: 919.515-3465 Edward Eshetola evaluating says RFP should be delivered mid-July spoke with Simon at BPI regarding 
- getting prometic story in Tecan journal
- co-marketing agreement for prometic and tecan
- put mimetic puraplate in Tecan for LRIG show in December Diane Chinchilla This will probably go to a CMO, either BI or Lonza RobGronke working with blues for monoclonalantibodies Second generation process for Beta interferon/ albumin fusion. Diana Chinchilla working on 2nd generation process. Rob Gronke working with blues for antibodies. Rob Gronke working on Blue for monoclonal antibodies Screening Mimetics for flagellin fusion protein binder. Qinghai Zhou looking for Phase III production Validation of Packing of Disposable Columns for Removal of Prions from Albumin Solutions Using PrioClear B
In relation to the work programme set forth herein, the following fees will be applied:
Determination of Packing Procedure (4.1):				85,527   
Determination of Packed Column Quality Procedures 
and Evaluation of Columns at Full-Scale (4.2 and 4.4):		145,616
Determination of HETP and Asymmetry of 5-mL Columns (4.3):	4,120    	 
Determination of Packed Column Shelf-Life (4.5):
Option 1  complete study						611,854
Option 2  with reduced time points					532,731
Option 3  with reduced time points and reduced prion testing:	487,514
Fees to be invoiced on initiation of each section. Payment terms 30 days net.
Sept 2013:  Still open, however, this will be decided by Pierre in Montreal PLI.
Jan 2014:  Andy will f/u with Steve B. about this. This is the cost of 3 X 20 liters produced in the formal validation program for P F Purabead.  scott Willett has asked for a breakdown of itemized costs of the amount (256,560 GBP) in the quotation. Dependent upon Federal funding for client of Athena ESe Quickscreen interest 2010:  wants copy of poster, also spoke with SB about Custom Development for enzyme said things are moving fast now and requested quote for 100L of 3125, need to ascertain time line for purchase interested in looking at PuraBead HF as future base matrix for Protein A products Objective: Evaluation of ProMetic albumin-binding ligands conjugated through various chemistries to selected and multiple recombinant target Proteins for their ability to bind albumins from different species and retain biological activity of the Protein while extending target Protein half-life without in vivo toxicity. might need additional 100-150L or more of Blue for clinical trials this year but is a guess at this point Dead.  They gave the work to Bioreliance. Possible custom adsorbant synthesis project 
10um beads as purification slurry format
Q - do they have a budget for this or are they wanting us to funding Met with Steve Profit and Steve Burton at BPI Conference in October 2012 (Rhode Island, US), gave business card. 
PBL will follow up by sending email blast with new EtoxiClear Poster link. 1 x4250-00005
5mL EtoxiClear Column				
-43248005 Cancelled by DTRA Steve and I met with Ronald @ GBX Boston '13.  Ronald is an Innovation and virology expert responsible for evaluation innovative technologies and transfer of these projects globally to all mfg site for SA.  He was extremly interested in etoxiclear due to product being off the shelf readiy available  and does not involve large validation and in comparison to current technology etoxiclear product ptential reduction of current purification operational costs Met Scott at GBX Boston '13.  He informed us that project is currently in P2 and should be completed sometime in 2014.  We should hear about P3 requirments and volumes at the completion of P2 next year
1/17/14  MB:  this opportunity is a duplicate on the Promedior Purabead opportunity.  Further update from meeting scheduled for Thurs 1/24/14 with Scott Willet Irwin Chen of Amgen, South San Francisco is working with Albumin fusion proteins and has ordered Mimetic Blue SA HL.  Chen recommends that the ProMetic / Novozymes seminar for albumin fusion proteins and AlbuPure should be coordinated through Ken Walkers group in Thousand Oaks.  Chen also has a possible interest in Etoxiclear. BioMarin:  Nick Zecherle has evaluated p-ABA for an undisclosed protein, but has not provided an indication as to the outcome of that evaluation.  Yanhong Zhang and six other DSP scientists have been given a general products and capabilities presentation.  BioMarin has purchased an Etoxiclear column. ZJ has interest in custom resin development, we need to have 2 technical seminars in the fall '13, Sept./Oc.t, time frame at Syracuse and Hopkington MA Two Steve's are leading this project and should close by 15 June From 2014 Budget file IEX Samples Nov 2013:  email rec'd asking for info on insulin adsorbent.  Steven Long is the Mfg Sup of new prod dev at Sigma.  Sigma sells all types of insulin for R&D use (recombinant, human, bovine etc).  If this is one of their insulin's used as a large-scale cell culture supplement, this could grow into a lucrative Opp.  Application needs to be qualified ~ it is for contaminant removal, could be large volume, Dr. Long has not told me the expression system nor the contaminant.  Dec 2013:  Shrinal to send a sample since we don't have p/n or pricing for the small pack sizes yet. Dec 2013:  New molecule purified form Inclusion bodies, bench scale work just started, goal is for 20-40L Columns, 30-60 cycles, and scaling up between June-Dec 2014.  Aggressive timeline, this is the only column in the process and will be followed by an endo step (Mustang E, Sartorius STIC, ChromaSorb, and Q all being evaluated).  
GE pABA has  >8wk lead time, seems to be a resin GE is not interested in supplying at scale, and the GE price is $7k/L. Too expensive.
May 2014:  Site sold to KBI. Enzyme purification:
Starting up a cGMP lab, need to purif sweet potato AP, Bovine & Porcine gamm-glytamyl transpeptidase, numerous heart enzymes.  Partial purif required, interested in pABA or any other resins we can recommend.  Jan 2014:  have Scott Greifzu in touch w/ Dev for advice. 25mL each of A1P and A2P, 2 for 1 offer she said that Amgen lab already has A1P and A2P in their test supplies, but she has no immediate plans to test it due to major  pluronic sensitivity has tried Prosep boronate.  results good.  sending sample of 10ml for evaluation, would move to 250ml scale next year, and production in 2007 if works out. This is for trypsin purification from Chlorogen's tobacco.  Ron Basuner stated that his focus has changed away from trypsin. emailed about availability of endotoxin adsorbent learned from Q2 2010 newsletter Charles Schmelzer will consult with Greg Blank to see if they want to go through phase I of a ligand development program. New information needs to go to Joe Zhou re caprylate.
Randy Hecht wants samples. Chicago Process Dev Meeting 5-2006 and ii potential use of MAbsorbents A3P for new MAb isolations, he works with Dr. Sam Guhan 100 ml of each 6-20-2006 Zecherle + new Assoc Director of Process Devel., Dr. Kris Antonsen seemed interested in Prometic trying a more extensive screen for them & I told them that this could run approx $300K for 3 months.Have Victor B. send a more detailed quote on what this will entail and time frame in view of us already having items in place from the earlier gross trial at no cost. Nick promised to put together what their requirements would be for a contract resin as a 1st step in the process.
New 6-20-06 Info : The more traditional approach they initially decided on entailed Blue-Sepharose, then copper IMAC, followed by HIC as the final step. Told me this since we already have a Confidentiality Agreement with them.
Months earlier ( 4-2006 ), Prometic performed initial limited screen for Arylsulfatase B affinity media after many months of delay in terms of legal  problems related to MTA approval. This meant that BioMarin had to go with more traditional chromatography  approaches due to a new August 2006 timeline for  obtaining clinical test enzyme amounts from clarified CHO cell cuture supernanant. Customer wants to purify Hemeglobin 1 ac.
Customer had made pilot runs of samples of Hemeglobin 1 ac using the Millipore APBoronate glass beaded material.  The Hb 1 ac is used as a control by their client in a diagnostic application.  The client approved these samples, which locked Cone Bioproducts into using the Millipore material for production.  Tom Bird said he would have preferred to use the ProMetic material because of price, but claimed he had no choice but to stay with the materials approved by their client. Chris Meyer is looking for the earliest possible delivery date.
Lonza is no longer planning to purchase additional Blue SA HL. Working with Shashi Kaithamana for enzyme/s or adeno/AAV.  refer meeting notes from 06/20/06 BR002 Ballantyne wants to be able to extend Aldevron's subsidiary Genovac's service offering to purification of antibodies from hybridoma.  Sample will be evaluated by Genovac. Last ordered 100mL in '09.  Asking for a quote for 100, 250, or 500mL. Customer wants to explore a custom ligand development program.  This is probably avian flu vaccine, although he wouldn't say without CDA.  Would welcome a presentation in mid March.  Presentation has been made.  Immediate problem with current viral vaccine has been solved.  Braendli will assess all the affinity technologies from a corporate-wide standpoint next year. Kedrion will need 1-2 L of B resin and then upto 20 L of B resin in 2013.
PLUS some form of development work perfromed in cambs.   details will come out in the next few weeks closed by VB , no activity. Discussions started in 2010, however, by Feb 2011 we were told they didn't secure funding."Sclerostin" had IP issues, so, chemokine CCL21 & CCL19 which are expressed from E.coli (low titer) is what Amgen wanted to screen.  
It's now late 2013, and Grant wants to do a QuickScreen, this time the project is for the Micromet product lines (BiTE antibodies which have a unique moeity ~ bispecific T-cell engaging ab's) which are very low titer and expressed from CHO.  New Opp:  https://eu1.salesforce.com/006D000000S57l7 Tim Breece has an interest in A2P with Amberchrome guard column. Development of a negative polishing step for the removal of o-linked glycoproteins from non-glycosylated counterparts from a range of proteins - a "generic matrix".
Yeast o-link glycosylated proteins through chains of mannose on either Serine Threonine.
Currently working with a molecular biology solution, Concanavalin A
, which depending on the matrix may only bind higher chain length glycoproteins i.e. > 1 or 2 Mannose carbohydrate units
All above assumes:		(i) Technical success at each stage			
		(ii) Successful negotiation of R&D Agreement under these terms			
		(iii) A Project start date of 010406 for analytical screening of IFN alpha 2b from HEK 293 cell cultures. Interested in DNA removal. Very relevant due to Gram (-) bacteria. Glutathione Sepharose 4B replacement from GE.
Concerns with scaling; redox reactions; packing issues; lack of regulatory support packsge & concerns over future supply creat an opportunity. 2 products in Phase 1.
Currently working with 200 L, eventually X5. Have enough product to last end 05 (40L). This is our window.
Interested in a 2 phase plan to replace GE product -
1) Glutathione 4B copy (short term)
2) New ligand discovery (longer term) additional 8L for Nabi project & other, communicated by Chris Bryant to Steve Burton additional for Nabi project & internal (re info from Chris Bryant via Steve Burton) feasibility study, FVIII/vWF ligand on membranes. additional for Nabi project (re info from Chris Bryant via Steve Burton). dependent on outcome of initial evaluations. additional 250L for Nabi project communicated by Chris Bryant to Steve Burton, dependent on outcome of evaluations for Kedreon project, communicated by Chris Bryant to Steve Burton Eden Biodesign are part of Actavis and are looking to develop a cost effective MAb purification platform. As such they are keen to explore non-protein A purification and want to evaluate MAbsorbents and FAbsorbents. Potential sales to Reliance in India. Very price sensitive market Last ordered 100mL in '09.  
Asked for a quote in 2013 for 100, 250, or 500mL.
April 2014:  quote request for 25, 100, 500, and 1L. Jan 2014:  Per Valery, by the end of the year, might need 100L of Mimetic Blue to be used at their CMO, Vista Biologics.  He'd like budgetary pricing for 1L, less than 20L, and up to 100L. Abbvie MA, call with Kelvin Lau, Kelvin currently working on ligand density on pABA results in Aug. (~750K) Also interest in Etoxiclear for buffer manufacture requested pricing on 5ml for R&D and 10L column for pilot plant.  Smaller 3L column may be feasible for pilot.
Potential 2013 Etoxiclear 50K Potential long term business 1MM+ MicroMet BITE Antibody project:
This originally started in summer 2010, however Amgen TO R&D was unable to secure funding.  Grant Shimamoto's group is trying, yet again, to secure funding for this, and hoped to start in July 2013.   Grant Shimamoto and Steve Smith have been given a QuickScreen Fabsorbent proposal as well as a reprise of the Steve Burton Capture and Polishing presentation. Shimamoto allegedly has funds from another cancelled program.  
Aug 2013:  PBL proposal for custom ligand was rejected by Amgen as far too expensive.
Jan 2014:  called / emailed Steve Smith to let him know I have his Fabsorbent sample.  No response.
Here's that original Opp (which was closed out):
https://eu1.salesforce.com/0062000000ElY5E From: Nemat Keyhani [mailto:keyhani@ufl.edu] 
Sent: 08 May 2014 15:05
To: Sales-PBL
Subject: mimetic blue agarose
Dear Sirs, I am interested in the Mimetic blue agarose. Do you have a US distributor that can provide me with prices and availability?
Thanks,
Nemat
Nemat O. Keyhani
University of Florida
Dept. of Microbiology and Cell Science Jeff Kurdyla is evaluating per Kent meeting closed lost due to lack of info for several months. Dr. Burton and John Collins met at GBX Boston '13 and discussed potential ligand project for lentivurus purification.  Mike B will contact and send ligand screening and custom services brochure Abbott, North Chicago, IL: Wan-Ching Lai has used MAbsorbent A2P HF and Fabsorbent to purify goat polyclonal antibodies and to separate same from fragments created by enzymatic digestion. Lai is working with Abbott Point-of-Care in Ottawa, Canada to use these fragments in a diagnostic system that includes alkaline phosphatase.  Fred Jacobs of Abbott POC has also purchased Mabsorbent A2P HF and Mimetic Blue AP for this application, but a thorough evaluation has not been completed. I made contact with Neil yesterday, Avaxia is developing (Phase 1) polyclonal to be orally administered for treating crones disease , bowel disease.  They inoculate pregnant cows with antigens and produce antibodies from milk.   Process is to remove casein and defat and ideally go ion exchange in SMB.
There is another project as well for affinity resins potentially for antibody purification. Monthly revenue for on going development program Supply of A & B ligands for animal study. OXB have a vector system for delivering anti-cancer treatment and are looking to develop a purification platform to isolate the vector. A ligand development program targeting VSV-G protein is a possibility. HSA for diagnostic kits Refer to Case 00001310:  https://eu1.salesforce.com/500D000000hTBNj Quote to sent later Send out promo on etoxiclear and contact asap. Replaced by several 40L orders Following design-in work in US, process to be transferred to Slovenia CMO (name not known) This Opp started in  Oct 2009 when Dr. Charles Miller (Talecris) met Mike Duell at an IBC Conference.  Since Grifols is considered a competitor to Prometic's PPPS process...this opportunity for AATsorbent must be handled very carefully.  A small sample was given to Dr. Miller under CDA/ MTA.  
July 2013:  Dr. Myles Lindsay tried to place an order for 25mL ~ per Dev, we've put this on hold until PBT says it's OK, and, we'll need an updated MTA. This summer we were discussing a collaboration between ProMetic  Biosciences and ProFibrix relating to the purification of our recombinant fibrinogen using a novel ligand /resin developed ProMetic (Fibrinogen absorbent PC3890).
We had some  discussion about the MTA and by the time these were almost completed, our resin scouting program was finished and we could not include the ProMetic resin in the evaluation at that time.
We recently have started a NEW recombinant  fibrinogen project and in the frame work of that are evaluating new/additional  purification steps.
Because we are still interested in evaluating the ProMetic material , we thought this might be a time to try and start the collaboration  that we discussed during summer.
I have attached  the last version of the draft MTA that you sent me early June and have added a few comments for clarification and one change to clause 4d to bring it in line with clause 4b. 
In 4b we agree that ProFibrix (recipient) will disclose all info to ProMetic  that is gathered in this project using the ProMetic  Research Know how but not the info that is established using the ProFibrix Research know how.
The change in cause 4d simply establishes that ProMetic does have title to the disclosed info (using ProMetic Research Know how ) and not to the non-disclosed info ( using ProFibrix Research Know how) 
Also Attached is  the ProMetic  CDA  with a few small changes .
Please let me know if you agree to  the changes in both documents.
If yes, we can prepare execution copies and start the collaboration .
Looking forward to your response
Kind regards.
Jaap 
Dr. Jaap Koopman
CEO Assumes a revised start date of 30/06/06 - following an unsatisfactory outcome of A3P evaluation to be reviewed at end of May. We are currently constructing a development plan which is likely to include the screening of your mimetic resins for large scale use.  When completed we would be ordering them in due course. New contract mfg business for QSV. Use Protein A and G in multi liter quantities.  Wanted sample. 10 ml will do.  Try to sell 25 ml.  Source of ABs both hybridoma and animal sera. Mike Duell thinks that Mimetic Green maybe an alternative to heparin affinity resin that she asked about. Sept 2013:  Shrinal sent IEX PuraBead resin samples. Dr. Luis Vargas at Abbott Diagnostics (works with Dr. Wan-Ching Lai), is currently screening SP-cation exchange resins.  The protein of interest is captured from CHO-harvest via CEX, they need aggregate removal via this CEX step as well.  This   is an early stage R&D project, cost of the resin is a major factor since this is for diagnostics.  The R&D work will be done in Chicago, then, will transfer to Abbot Diagnostics mfg in the U.K.  He said he will tell us how the resin performed if we provide a sample.  He's more interested in the SP, however, would like to look at the CM as well for aggregate removal.
Jan 2014:  He was non-responsive to calls & emails.  Can only assume he didn't screen and lost interest. This was some kind of platform which dwindled down to only 1 molecule.  Stopped by Allergan at Step 2 of Adsorbent Dev. Project. investigating PuraPlate as OEM for Bio-Rad resins for analytical method development Possible ligand design program for a revised glucagon process. Sasa  was very interested in our abilities to develop a new ligand New, novel molecule harvested from inclusion bodies with a single column (pABA) purification step.  Evaluating endo clearance via:  Mustang E, Sartorius STIC, ChromaSorb, and traditional Q resin.  Jesse is interested in EtoxiClear & Q  
This is a fast-track project, scale-up by June 2014.
May 2014:  Site sold to KBI. Bldg AP8B  Page purifies antibodies and antigens from cell culture and animal sources. Aug 2013:  ImmunTrix contacted PBL RE:  aseptically packed Extracorporeal extraction columns, targeting hyper-immune response.  Will be a mixture of resins which remove cytokines.  
Gen 1:  This will be aseptically packed columns (various vendors) 200mL 5cm x 20cm.
Gen 2: will be a more targeted approach with a PBL resin specific for the cytokine
Jan 2014:  Opp died, they can't afford the service.. Large producer of plasmid DNA.  Asked for 50 and 100 liter ballpark quotes. 50 liters at 1060 GBP (1000 GBP old cascade price, plus 6% price increase since then).
Quotation supplied, but put back to Qualification stage due to uncertainty.
Closed lost due to order for 5L won for small scale packing study. Looking for alternative supplier to CSL 5 year supply agreement for Mimetic Blue for Albiglutide manufacture.  Supply agreement document proposal sent to GSK and  Laveda McDowell March 15 2013 and awaiting review and response from GSK. Per GSK next order in sometime  2016. quote sent to Kenneth Duong, need  confirm delivery dates with Jimmy Tran April Hi Mark, 
I visited your booth at the Geneva exhibition last week. We discussed about the possibilities to adopt Perfluorsorb for purification of DNA. I would like to receive your protocol what you could recommend for the method, ion exchange + Perfluorosorb.
Could you also give us a quotation for a packed 50 ml column, and 200 ml and 1000 ml volumes of the resin. 
Thank you in advance Quotation request for an additional 30L to complete clinical trials. Supply of free Mimetic Blue Ligand for assay development. This figure is a verbal forecast from the buyer and represents an increase of 10% over 05. DNA Process: Cobra uses a process developed by Cobra scientists over a period of 10 years. The process is available to our customers on a royalty free basis.
Features and benefits: 
Enables high productivity (250-500mg/L) 
Ensures high quality through optimisation of harvest point and extraction parameters 
Uses high resolution orthogonal chromatographic approach to finish product in your formulation buffer. 
Meets regulatory requirements worldwide:
- Low endotoxin
- Low RNA
- Low host protein
- Low chromosomal DNA 
Scaleable to commercial scale 
Background: DNA products although not infectious are still regarded as novel and controversial products. They therefore receive a high level of regulatory scrutiny, even at the pivotal pre-clinical and early clinical phases. It is therefore essential that sponsors of clinical trials using plasmid DNA active ingredients use processes which are scaleable robust and capable of meeting the strict level of analytical stringency demanded by the regulatory authorities.
Technical background: Plasmid DNA is a large molecule which is physically fragile and susceptible to chemical and enzymatic breakdown. Within the producer cell the plasmid DNA is surrounded by a milieu of molecules with similar physicochemical properties. Over a 10 year period Cobra scientis have developed a proprietary process which maintains the integrity of the plasmid product through extraction and a series of high resolution chromatographic steps. The main features of this process are:
Optimised fed batch fermentation to increase biomass without formation of corrupted plasmid contaminants 
Optimisation of the harvest window to maximise reduction in formation of open circular DNA 
Optimisation of extraction parameters using Cobras patented extraction procedure 
Optimisation of extraction using Cobras proprietary extraction vessel design and technology 
High resolution chromatography 
The bulk and formulated products are then analysed by a battery of powerful analytical techniques which Cobra scientists have developed or invented over the past 10 years
Product related impurities by PAGE and Free Flow Capillary Electrophoresis 
RNA by proprietary hplc techniques or PAGE 
Host protein by ELISA or Silver Stained SDS PAGE 
Chromosomal DNA by Q-PCR 
Endotoxin by LAL 
Identity by PAGE, Restriction Digests and DNA sequencing 
Strength by UV spectrophotometry 
Cell based potency assay Mimetic Blue for albumin fusion protein licensed from HGSI aim to get sample purchased for initial evaluation. Mimetic ligands, MAbsorbent, Boronate. Handled through Tarun Desai Pfizer has used MAbsorbent A2P with considerable success.  They are using a CM capture followed by A2P.  The combination is still not as selective as Protein A.  They are still binding fragments and "half antibodies".
Martin has invited ProMetic to make a full corporate presentation.  The desired time frame is the fourth week of October to the third week of November.
Pfizer has a collaboration with an unnamed Australian academic that is partially funded by the Australian government.  Martin asked if ProMetic would be interested in manufacturing the sorbent that would be the product of that collaboration.  
Martin suggested that we put into place a CDA to facilitate a more open and productive exchange.
12/1/06  Burton and Duell made A2P HF presentation.  Customer will buy 100 ml for evaluation. offer screening kit foc as well. -----Original Message-----
From: robert.6.woodward@gsk.com [mailto:robert.6.woodward@gsk.com] 
Sent: Friday, July 22, 2005 7:24 AM
To: Sales
Subject: IgG agarose
A colleague of mine acquired some IgG agarose 6Xl from you last year Product code 0630-0250 645 for 250ml.  Could you please let me know if you still sell this product and give me some idea of availability. 
Many thanks, 
Robert Woodward
GlaxoSmithKline
Gene Expression Protein Biochemistry
Gunnels Wood Rd
Stevenage
SG1 2NY
Tel. 01438 768222 Halozyme will contract Avid to one more campaign with the current process that utilizes 3 x 9 liter columns of APBoronate per campaign.  Rajeev Chillikuru expects to give the P.O. to Avid sometime in September with Avid ordering the material for delivery by the end of November. lead from application note advertisement in Bioprocess Intl.
possible use for removal of diols from chemical synthesis process Bioprocess Intl Yearbook 2005 boronate app note Das Prayaga wants a comprehensive list of everything necessary to purify 20 grams af murine monoclonal antibody from 20 liters of hollow fiber produced cell culture supernatant.  Final product must be very low in endotoxin.  He needs a list of column, MAbsorbent, possibly a cation exchanger, buffers, protocol,....everything.
2 for 1 offer. Interest in Blue SA and Blue AP.  Ordered 25 ml. Blue AP. This is used for screening for new Insulin analogues. S Ghose reports to Duncan Low.  She has had an issue with A2P binding albumin as well as their MAbs. Cangene is waiting for A2P Hi Flow. Mimetic Blue for albumin fusion protein licensed from HGSI - next phase of scale up work.
5 liter scale. Interested in the equivalent to Matrex Gel Green A.  Will quote Blue 2 A6XL.  Purifying cofilin from bacterial broth.  Cofilin is an actin binding protein. This group ios doing protease removal from vaccine preps.
Order placed 10/26 blue for interferon purification? 1600 litres Fusion protein platform for vaccines. - 100ml A2P Reference from Natraj Ram.  Presentation to Mark Gustafson et al made 12/24/06.  Pfizer team meeting approved project 9/20/06.  Will begin contract negotiations 9/22/06. Dear Mark/Steve, 
In the immediate future, however we have an urgent need to wash 20L (2 x 10L) of DBA matrix batch FA0527 and to have it back ready for use at our plant by the end of February 2006 at the latest (earlier if possible).  
Later in the year there will also be a requirement to wash 160L of DBA matrix batch FA0527 for return to Delta at the beginning of July 2006.
Could you as a matter of urgency forward a cost for these washes and confirm whether or not you are able to accommodate our very short timescales. 
Apologies for the short notice. 
Kind regards 
Diane Morris 
Purchasing Manager 
Delta Biotechnology Limited 
Castle Court, 59 Castle Boulevard 
Nottingham, NG7 1FD 
Direct Tel:  0115 9551250 
Fax: 0115 9551278 pricing based on 660 USD per liter, for volume purchases, from IEX revenue model. for Nabi project This lead originated from our seminar.
Sandoz are performing a comparison of Protein A alternatives in January. They are aware of Pluroronic F68 issues. will be supplied free of charge with 10 liter phenyl agarose order 120 Liters for Nabi project Assumes that go-ahead is given to Tech Transfer and Manufacture of existing Adsorbent Material.
1.46EUR/. Tony Hong called asking prices on A1P and A2P, 25ml of each, if in stock and how to order. ordered through Fisher Scientific. ordered through VWR continued work with Blue SA Mimetic Blue 1, Blue 2, Green 1, 25ml of each replacement for backup quantity, 75 liters 25 ml Mimetic Blue AP A6XL Plasmid DNA Endotoxin removal kit 25 ml Perf S should order 25 ml of A1P and A2P 1 liter Mimetic Blue 1 P6XL 500 ml Perf S 10 ml each of MAbsorbent A1P and A2P for testing. 25ml Mimetic Blue SA P6XL Small scale His-tag protein purification - want to evaluate as a polishing step
Includes p-ABA screening kit.. Halozyme project - ref notes in Halozyme conf call March 30 2006 Mimetic Blue SA HL 25ml 25ml each of A1P and A2P 25ml each of A1P and A2P for testing downstream of Protein A, order received at 1 x 25ml A2P 1 liter Mimetic Green 1 Dr. Ranganathan is evaluating A2P but eluting low purity product.  Recommendations have been made to improve purity.  He is looking for a platform for purifying antibodies from ascites that he uses to create immunoaffinity columns for the antigens. VB offered 2 for 1 because using rabbit antibodies, not sure which A1P or A2P will be best. evaluation of MAbsorbent for analytical application in Phynexus tip format.  phynexus agreed to fill up to 12 x 160uL tips free of charge, and VB agreed to supply some resin free of charge. New interest for antibody fragment application discussed at meeting on the 3rd May, 2206 quote for grant proposal.  Grant has been approved.  Quantity reduced from 5 liter to 2 liter. using PIKSI. working with red 3.  wants to order more for further use.
Ordered 25ml red 3, 1 x 5ml column pack free of charge. A1P A2P 2 for 1 offer for evaluation order 100ml of each type on the special deal 25ml Blue AP guessing 25ml to start with? Mimetic Blue SA HL - 25ml. (509,780 * 1.43) (source : Draft Adsorbent Development Agreement). 25ml DEAE PuraBead HF 1 liter of Mimetic Red 3 additional order of 25ml each of A1P and A2P - order will be faxed tomorrow (7/27/06) 1 x PIKSI kits 25mL each of Blue SA & Blue SAHL 25mL of Blue 2 -----Original Message-----
From: Dalen, A.W.J. van (Audrey) [mailto:audrey.vandalen@organon.com] 
Sent: Thursday, August 17, 2006 4:42 AM
To: Sales
Subject: POA 2088 ProMetic
Dear Sir or Madam, 
Please inform us on price and delivery time of the following: 
- 0800-00100 Mimetric Green 1 A6XL.  a 1 kg. 
Thank you in advance for your early reply. 
Best regards, 
Audrey 
Audrey van Dalen 
NV Organon 
Central Back Office 
R & D/Operations 
RK 1204, P.O. Box 20, 5340 BH Oss 
The Netherlands 
mailto: audrey.vandalen@organon.com 
Tel: +31 (0)412 66 9108 
Fax: +31 (0)412 66 3537 
NV Organon is an Akzo Nobel company David Greene purchased for delivery before 12/21/06. Year end purchase.  Duell informed Dan Schreiner of the price increase effictive September 2006. A1P 5 x 1mL screening kit A2P 5 x 1mL screening kit Talzmann will process the order via FAX as discussed. Expect order by 1/17/07 Toan Vong has asked for a quotation for 24 liters of APBoronate.
Order placed by Darcy Rule 3/5/07 Product ordered through V A Medical Center. Toan Vong wants to add this 14 L to the previous 24 L order. Natraj Ram has submitted a budgetary figure of $150 for Phase II of the PEG-MAbsorbent project.  He is hopful that this funding will allow physical demonstration of the economic and technical feasibility of an aqueous two phase system using PEG-ligand conjugates prepared by ProMetic for Pfizer. Natraj Ram has submitted a proposal to fund a custom ligand development program for transferrin fusion products.  This would be part of a technology platform to be used in manufacturing the technology Pfizer has acquired from BioRexis. Daniels is processing a 2 liter order with an eye toward comparing lot to lot consistency and performance.  His target protein is still unidentified. Chris Daniels has ordering information for 2 X 1 liter containers.  He has asked if the 2 liters can be obtained from different lots so that they may check lot to lot variability. Maria Cutillo is the purchasing coordinator for Merck's Clinical Manufacturing and Bioprocess Technology department.  She was referred by Chris Daniels.  She is asking for a quotation for 80 liters and possibly more.  She will verify the exact amount during the week of May 28. Sanofi Pasteur has a project that requires contaminant removal of a protein.  They have been quoted the full range of Mimetics.  However, they do not have technicians available to evaluate the full range of ProMetic products.  They are considering a Quick Screen program to contract ProMetic to perform the evaluation on commercial products as well as any candidates that may be in our libraries with possible activity.  Earnst Braendli is the main contact. Beta Site for MAbsorbent A3P and PBL1010
Provided Cell culture supernatant for PBL testing Beta Site evaluation of PBL1010
Looked at A3P and PBL1010 Shashi Kaithamana will order 15 liters of Blue SAHL in parallel with a 120 liter order from Avecia.  He wants the 15 liters and the 120 liters to be from the same lot. Bernardine Abiad called to inquire about price and availability of 5 liters of APBoronate David Jackson has asked for budgetary numbers for 10 liters of Mimetic to compare to QuickScreen Program and Custom Ligand Design Program. Breana Christ taking over Toan Vong's responsibility to negotiate this order. Celeste Cutillo indicates a possible need for the 40 Liters in the March / April time frame. Brianna Christ will consider pushing up the order in advance of a price increase. This 20 liters is not intended for the scale-up.  This will be used in the current campaign, which is soon to be completed. Briana Christ indicates this 30liters will fulfill Avid's reqyirements for 2008. This may be the new CMO for Halozyme. Michelle Cordoba has indicated that Abbott would like to take advantage of our offer to place the scale-up order at 2007 prices.  She will confirm the precise volume of pABA that they would like to order and the expected delivery date by 4/25/2008. Qinghai Zhao is prodeeding with Mimetic Red 3 for the capture step in the Beta interferon / albumin fusion protein project. Qinghai Zhao thinks he will need 50 liters for the first GMP runs for Toxicology and Phase I. Kimberly Barrett has asked for quotation with necessary lead times.  Randy Johnson wants to discuss shipping and payment terms. Bustard substituting for Celeste Cutillo, who is out on maternity leave. Request for quotation from Briana Christ. Braendli wants the same type of screening program for a new protein. Order came in with incorrect price and product description. Inquiry came in fromKristin Valente as referred from Jason Bustard CMO for Merck New project headed by Patrick McHugh.  Order will be placed by Kristin Valente Richard Ding ordering for Chris Meyer. MAbsorbent A2P HF	25mL	3903-00025	$575 Jason Bustard is interested in utilizing year end budget authority.  He is willing to take split shipments. 	You also mentioned that Avid was talking about adding 3 x 100L runs that use APB and that if the client decides to proceed with this you would need to order approx. 35L for delivery August-October timeframe, could you provide me an update here? No decision has been made, we are hoping to hear back from the client in the next couple of weeks their plan to move forward with additional runs.
1.	Is your feeling that the client will likely move forward with the 3 x 100L runs?
I think they will, it is just a matter of making our schedule fit with their  thats what they are ironing out currently. Ordered through Fisher. Recently opened account Former Schering Plough working with Vasgene protein. sent pricing for 20L on 2/3, Stuart indicated that they would need 10L but might purchase 20L if they could get a price break- would require 2 separate shipments for the 20L
As I indicated in our last meeting, Brian Pierce, a Manufacturing Engineer who has been supporting our hemoglobin efforts, has done a tremendous job in improving our purification efficiencies and thus extending our resin usage. As a result of this, I do not forsee a purchase of 20 liters by the year's end.
 The purchase could take place in 2010. PIKSI (R) M Test Kit ordered online via Shop Cory: 
We'll probably first look at it as a full size murine mAb capture resin. 
- David web sale for 200ml of M.Blue SA HL Hexyl Agarose 6XL 25ml 	0425-00025	1	 111.00 
Subtotal	 111.00
Shipping & Handling	 36.46
Grand Total	 147.46 Mimetic Blue(R) SA P6XL 25ml 
Mimetic Blue(R) SA HL P6XL 25ml
Purchased for their CMO, PacificGMP, for an albumin fusion protein process they are contracted to work on Repeat business from Consolidated Technologies.  Purification of Hemoglobin 1 Ac. MAbsorbent(R) A2P HF 100ml 	3903-00100	2	 2,140.00 PIKSI (R) M Test Kit 	1000-00001 	1	 330.00 sent email to sales asking about 1ml columns for possible manufacturing opportunity Decyl Agarose 6XL 25ml Could you please give me a price quote on some of your products, and
also expected delivery times?
I would like to know about the Fabsorbant F1PHF, 25 ml  3904-00025.
Also about the Fabsorbant FIP HF Puraplate, and the pre-packed 1 ml columns. will be used to remove human albumin before using A2P to remove IgG from human myeloma plasma. Will place order via website. Will order 25 ml of Hexyl Agarose through website. Project Proposal
Development of an Antibody B Capture Device for Reduction of Isoagglutinin Antibodies from Single-Source Donor Plasma
Project 153: Phase II 1 x 0320-00025 p-Aminobenzamidine Agarose 6XL	$256 Request for quotation from Briana Christ, 15L APB to ship by end of 2009. 60L to occur in May/June received a call from Aleksa, asked for pricing info for 25ml and column kit, also gave him info to Atoll website for pre-packed columns sent pricing for 100ml to 1L for A2P 1 3125-00500  Mimetic Blue  SA HL P6XL 500 ml   $2595.00 quotation for 6 count of 0.5L PrioClear pre-packed columns to be used for Abraxane campaign in June This is a replacement column (40L with a 5% price increase) for that purchased in 2010 - to be used for clinical trial material only. 1              1003-00001 Mimetic Screening Kit 10x1ml             $925.00 USD sent pricing for SAHL, said they would need to order 10L second half of 2011 purchased 25ml and PuraPlate This proposal summarizes a program of work to be undertaken by ProMetic BioSciences Ltd (PBL) at their research laboratories in Cambridge regarding a  program of work to evaluate a computational approach to develop a mimetic of the anti A isoagglutinins. This document is provided in part response to a request made by CSL Behring for a proposal following discussions instigated on 6th October 2010 and includes a technical description of the work to be performed by PBL, the deliverables resulting from this program of work, associated time lines and costs. sent informal plan of work detailing estimated costs for full development of adsorbent Met with Steve Profit and Steve Burton at BPI Conference in October 2012 (Rhode Island, US), gave business card. 
PBL will follow up by sending email blast with new EtoxiClear Poster link.
Kelvin confirmed he will order multiple Etoxiclear columns for testing in Sept Second phase of the ligand density study has been approved and P.O. number assigned, but P.O. has not been received from AbbVie. Hi Claire,
I hope you are well, please find attached the costing for the Synthesis of Mono-Chloro 115 Ligand as requested.
Please let me know if you require any further information.
Shrinal 
Mon 18/03/2013 13:06
Hi Claire,
I just wanted to check in with you as I hadnt heard back from you since you were quoted for the Synthesis of Mono-Chloro Ligand you requested. I was just wondering whether you wanted to go ahead with your order or whether you needed any further information?
26/03/2013 In Dec 2013, we told AVID that the 2014 1L pack size price $5920/L and the 5L pack size price  is $5395/L = $26,975.  
In April 2014 we raised the 5L pack size to $5637/L = $28,185.  
In SFDC it now says the 5L pack size is $5865/L = $29,325.
Since it's only been 1 month, I don't want to deviate from the quote of $28,185. Bio-Rad traditionally needs 5-10L APB resin/year. 
2008:  bought 10L @ $3810/L
2009:  bought 0,  PBL quoted 10L at $4639/L and 20L at $4229/L 
discount only if received prior to 12/31/09.
Nov 2010:  bought 10L @ $4779/L  
Sept 2011:  bought 20L at $5066/L
July 2012:  bought 15L at $5420/L
2013:  bought 0.  Raw materials have increased PBL's price.  List price is $5637/L.  Cory quoted bulk discount of 30L at $5138/L in March 2013.  Then, in July 2013, Shrinal gave Stuart the option of either full list price for 10L, or, $5138/L for 20L.  Sept 2013, after many requests, Stuart sent us a PO at $5138/L but split the delivery to 10L in Jan 2014 and 10L in May 2014 (which would negate the bulk discount).  
Pricing for 2014 is $5920/L or 20L bulk discount of $5395/L if received as one shipment in Jan 2014. (25% Discount) 11th dispatch Analysis of adsorbent preservative for ligand leachates by HPLC with digest spike Analysis of 2 protein samples for ligand leachates by HPLC For Filling RoboColumns in conjunction with PBL PO# 7520. and 14 buffer sample for leachates by Icms- 
Quote Ref: 1012201201SIJ Quote Ref: 14061301SIJ RoboColumn 5mmId x 10mm
V = 200uL - Mimetic Blue SA HL P6HF
96 well RoboColumn Array Plate
Cover seals, Top & Bottom Mimetic Blue SA HL P6HF Run existing LCMS method onsamples containing ligand and IVIG
Incubate ligand samples on stability for 1 week (40C)
Optimise MS method for ligand leachates
Transfer method to CRO and optimise for uPLC/MS system Evaluation gave low binding and purity when compared to SP Sepharose FF, will follow up by sampling SP Purabead HF 2 x 40 micron sinter plate; 1 x 20 micron sinter plate
4L Jacketed reactor with lid; 1 x agitator; This quote is for Avid's in-house projects (not the Halozyme molecule).  Typically these project PO's come from Brianna Christ in Purchasing for these orders.  Nov 2013:  negotiating with Marla Sugimura in Purchasing ~ trying to lock in a standing order for 2014 in exchange for a deeper discount.  Richard Bradley is the Production Planning/ Inventory control person ~ ship resin to his attn.
2013 1L pack size price $5637/L 5L pack size price is $5138/L 
2014 1L pack size price $5920/L, 5L pack size price is $5395/L 3880-10000	Plasminogen Adsorbent	FA1122	10 Litre
3880-05000	Plasminogen Adsorbent	FA1122	5 Litre
3453-10000	SP Purabead HF	FA1123	10 Litre
3453-03000	SP Purabead HF	FA1123	3 Litre
3890-10000	Fibrinogen Adsorbent	FA1127	10 Litre
3451-10000	DEAE Purabead HF	FA1125	10 Litre
3451-10000	DEAE Purabead HF	FA1198	10 Litre
3451-10000	DEAE Purabead HF	FA1198	10 Litre
3906-10000	MAbsorbent A2P HF LL	FA1126	10 Litre
3906-10000	MAbsorbent A2P HF LL	FA1129	10 Litre 1 x 5mL Etoxiclear Column 4250-00005
Application: in the PD lab ~ they produce material for animal studies and like to keep the endo level low.  Have tried other resins in the past with no luck. Etoxiclear columns to evaluate as platform technology SARS Vaccine:  recombinant protein expressed in pichia that has varying amounts of glycosylation and hyperglycosylation.  Need to purify so that only the main species with a minimal amount of glycosylation away from the hyperglycosylated protein 
Developing the purification method for a vaccine product to go into Phase I production so if it works well, the CMO will need to order in bulk.  3 x 10L fermentor runs due by Aug 2014, then will transfer to CMO. Mimetic Blue AP:  Currently has 25mL, needs 500mL - 1L now.
(Existing Mimetic Blue SA customer) additional 50 litres resin A requested by CSL Resin for AM-Pharma project
Note:  this opp is for additional Ph II material, there is a larger Opp for Ph III material (larger volume) ~ https://eu1.salesforce.com/006D000000TiDUt 3/6/14:  I had emailed Avid/ Peregrine a price of $28,185...this is apparently wrong in SFDC and should have been $29,325.  Andy Davies guidance is if I already emailed $28,150, we should honor that amount for this quote. 200 ml of Resin A and Resin B for further development work. Allergan used the CMO, BI-Fremont, to produce a CHO-expressed protein.  Unfortunately, the final drug product which is at [44mg/mL], arrived with endo contamination around 5EU/mL.  This will be a tricky evaluation since the load solution has been frozen/ thawed and I warned him about endo micelle formation.  He has a 5mL 10cm PPC column which was given to him last year.  I'll follow up in a week to see if it worked.  I've asked Dev/ Buzz for guidance on packing, info on ligand leaching, and, guidance on getting the endo below 1EU/mL for this concentrated drug product. 3/6/14:  I had emailed Avid/ Peregrine a price of $28,185...this is apparently wrong in SFDC and should have been $29,325.  Andy Davies guidance is if I already emailed $28,185, we should honor that amount for this quote. Bruce Baldwin 2 x 200 column
1 x 250 column
with refresh kits Bio-Rad traditionally needs 5-10L APB resin/year. 
2008:  bought 10L @ $3810/L
2009:  bought 0,  PBL quoted 10L at $4639/L and 20L at $4229/L 
discount only if received prior to 12/31/09.
Nov 2010:  bought 10L @ $4779/L  
Sept 2011:  bought 20L at $5066/L
July 2012:  bought 15L at $5420/L
2013:  bought 0.  Raw materials have increased PBL's price.  List price is $5637/L.  Cory quoted bulk discount of 30L at $5138/L in March 2013.  Then, in July 2013, Shrinal gave Stuart the option of either full list price for 10L, or, $5138/L for 20L.  Sept 2013, after many requests, Stuart sent us a PO at $5138/L but split the delivery to 10L in Jan 2014 and 10L in May 2014 (which would negate the bulk discount).  
Pricing for 2014 is $5920/L or 20L bulk discount of $5395/L if received as one shipment in Jan 2014.
Adding 2014 opportunity so revenue forecast in December. Egyptian customer requiring ~1m units/ HSA per annum. Competing with Octapharma, price is the differential Fall 2012:  DARPin project - talks for a custom sorbent started.  Johnney Wu is the Allergan lead.  No progress made due to the Allergan legal team having no time to review the Adsorbent Dev. Project Proposal.
June 2014: New Allergan legal team, read the PBL proposal, but, still want to use their "Materials & Services Agreement"...which is missing important details that are defined in PBL's "Adsorbent Dev Project" document. 
Path Forward:  Update the project proposal with 2014 pricing.  Then, persuade Johnney Wu to simultaneously request project funding and advocate to his legal team that the PBL "Ads. Dev Project" document should be used.  If Allergan still will not use the PBL document, we'll have to do the tedious revision to Allergan's "Materials & Services Agreement" if we want to win this $1.7M project. Currently using Biotest in Germany. Looking for an alternative. Would like to ship plasma from Laval  for fractionation of Factor VIII, Factor IX, IVIG and Albumin. Final fill/ finish in Iran. Jeremy is contact for collaboration work for PE 96 well plates for use in the launch of their new equipment.  Dr. Burton spoke with hin=m in detail at GBX Boston '13.  MB send email contact info and follow up
1/17/14  Project on hold due to significant inventory of old style plates in UK which will not fit the brackets of the PE handling system configuration. Confer with Ben on how long it will take to exhaust current Puraplate inventory in IOM . Cell culture supplement (HSA) for Israel Cell Therapy company Annual usage (2L in 05) expected to double as new K' prime is brought on-line in 06. Ligand Discovery - (47,083*3)*1.43 (source: Novartis figures) BI have signed and embarked on a feasibility study for capture of HCP from CHO cell supernatant.  Should this show promise, then BI would sign up for an extended custom program, which is the nature of this opportunity. Tarun has indicated that Shushun has evaluated the product and will scale up in Q1 of next year to scale of 10L Phenyl Agarose Potential leads:
Syntaxin is an Oxford based company that has developed technology to create recombinant proteins using the membrane translocation domain and the light chain (endopeptidase) of botulinum toxin. They produce, purify and supply these proteins for applications such as pain therapies. This work is being done in collaboration with Allergan. Should we approach this company to discuss the potential for a platform adsorbent for endopeptidase capture, depending on the outcome of the Allergan Phase II discussions?
Dr Keith Foster  Chief Technology Officer
http://www.syntaxin.com/default.aspx Ladies and gentlemen,
I am using one and the same package Mimetic Red3 A6XL since 2002. On the package is written:
Mimetic  Red 3 A6XL   500 ml
Code:    0013-0500
Batch:   FA0455
Preservative:     Ethanol/0.1M NaCl (24:76)
Is it correct that your product Mimetic Red(R) 3 A6XL is still the same? new development project fsh 
Optimising process from 6 steps down 
option for both alpha and beta Bioresearch Online Contact List -
"Application Of in silico Techniques To The Development Of Novel Ligands For Affinity Chromatography" Technical Poster - sent via Bioresearch Online E-NEWSLETTER (23-01-13)
PBL Discount Code = BR002 From: Michael.Schmitt@cslbehring.com [mailto:Michael.Schmitt@cslbehring.com] 
Sent: 28 February 2013 14:42
To: Sales
Subject: AlbuPure quote request
Hello,
We would like to purchase 25 ml AlbuPure affinity resin (Cat. # 3151-00025). Could you please quote a price for this product.
Kind Regards
Michael Schmitt
From: Shrinal Inamdar 
Sent: 28 February 2013 15:21
To: Michael.Schmitt@cslbehring.com
Subject: RE: AlbuPure quote request
Hi Michael,
Thank you for your interest in our product. The price for the product you have requested is 215 for 25ml (3151-00025) and only 619 for 100ml (3151-00100).
Also I have provided you with the link below for any additional information you may need regarding the product.
http://www.prometicbiosciences.com/applications/protein-purification/fusion-proteins/albupure
Please let me know if you would like to go ahead with ordering this item.
Hope to hear from you soon,
Shrinal 
Von: Shrinal Inamdar [mailto:SInamdar@PrometicBioSciences.com] 
Gesendet: Montag, 4. Mrz 2013 10:02
An: Schmitt, Michael DE/MBR
Betreff: RE: AlbuPure quote request
Hi Michael,
I just wanted to check in with you as I hadnt heard back from you since you were quoted for the AlbuPure you requested. I was just wondering whether you wanted to go ahead with your order?
Hope to hear from you soon,
Shrinal 
From: Michael.Schmitt@cslbehring.com [mailto:Michael.Schmitt@cslbehring.com] 
Sent: 04 March 2013 10:46
To: Shrinal Inamdar
Subject: AW: AlbuPure quote request
Hi Shrinal,
Thank you for your quote. We are still interested in your product and will place an order for 25 ml AlbuPure within the next days.
Regards
Michael
CSL Behring PO#4500619241 Hi Laurence,
No problem, could you state our address as:
ProMetic BioSciences Ltd
The Freeport
Ballasalla
Isle of Man
IM9 2AP
Thank you,
Shrinal 
From: Croute, Laurence [mailto:laurence.croute@novartis.com] 
Sent: 12 April 2013 09:32
To: Shrinal Inamdar
Subject: RE: Fabsorbent Column Kit Quote 
Thanks for your reply,
Could you please indicate me your address because between the quote and your website, the address is different. 
Thanks a lot in advance.
Best regards,
Laurence Croute
Best regards, Mit freundlichen Grssen, Meilleures salutations, 
Laurence Croute
Novartis Pharma AG
CHBS, WKL-122.4.27
CH-4057 Basel
SWITZERLAND
Phone    +41 61 6969903
Fax         +41 61 3248001 
Email : laurence.croute@novartis.com
From: Shrinal Inamdar [mailto:SInamdar@PrometicBioSciences.com] 
Sent: Freitag, 12. April 2013 10:19
To: Croute, Laurence
Subject: FW: Fabsorbent Column Kit Quote 
Hi Laurence,
Please find attached the original quote that was sent last month. Please note that this quote expires on the 19th of April, let me know if you would like a new quote with an extended expiry date.
I hope this helps,
Shrinal 
Hi Laurence,
Thank you for your interest in our product Fabsorbent F1P HF Column Kit 5 x 1mL (4904-00001). Please find attached the corresponding quote as requested. If you are interested in placing an order, please send a PO to sales@prometicbiosciences.com or directly to myself.
If you need any further information please do not hesitate to ask.
Thank you,
Shrinal 19/03/13
Hi Laurence,
I just wanted to check in with you as I hadnt heard back from you since you were quoted for the 5 x 1mL (4904-00001) you requested. I was just wondering whether you wanted to go ahead with your order or whether you needed any further information?
Hope to hear from you soon,
Shrinal 26/03/13 3002-00100 1 x Purabead 6 (RM03501) 100mL 
3004-00100 1 x Purabead 6XL 100mL 
3009-00100 1 x Purabead 6HF 100mL 
3012-00100 1 x PC3012 100mL 
- Free evaluation samples 1mL load Octyl PuraBead- research sample, non hazardous. 
research batch of resin Octyl PuraBead HF
research batch of CM PuraBead HF Tech Transfer and Set Up KappaXL Adsorbent
Validation Batch 1 KappaXL Adsorbent 00010 leachables analysis 20.12.2013
1 EA 2,548.00 2,548.00
00020 Stability versus REG buffer 20.12.2013
1 EA 8,082.00 8,082.00
PO sent by mistake - replaced by analysis 1 and analysis 2 (of matrix 115 samples) Send sample of Benzamadine for trypsin purification/removal Defence Science & Technology (DSTL) ordered through distributor Advance payment by TT
Shipping Charges describe DHL Charges from ProMetic to Cadila Facility. Clarifying 2014 pricing... 00010 15 EA 50000005002200 06-Aug-14 101.00 per EA 1,515.00
MIMETIC BLUE STD 100UM, 1ML VIAL
00020 15 EA 50000005002198 06-Aug-14 333.00 per EA 4,995.00
MIMETIC BLUE1-HEMOGLOBIN CONJU, 2MG/VIAL
00030 15 EA 50000005002199 06-Aug-14 1,697.00 per EA 25,455.00
RABBIT ANTI-MIMET BLUE ANTIB, 250UL/VIAL Hi Shrinal
Firstly, sorry for the late reply. Unfortunately your email got swamped/lost in my inbox following a holiday break. 
Secondly, thank you very much for providing the sample of EtoxiClear for evaluation.
So, we evaluated the EtoxiClear and unfortunately it performed the same (~50% removal) as the other endotoxin removal devices i.e. charged membrane filters, that we have evaluated. It seems this gelatin has presented peculiar endotoxin removal problems.
Thanks again.
Regards
Toby BITE antibody purification development. FABsorbent does not meet specificity requirements therefore process development or ligand program required. Distributor discount have pluronic in cell culture media Activity 1 for Project II defined by Gantt chart Looking for cost effective plasma fractionation options. Currently importing from Korea, ideally would like to establish own facility using PPPS processes but only has $5m.
Alternative option would be to act as final finish/ fill for Laval products to India Customer in Israel is using Fibronectin as wound healing agent. Needs GMP grade Fibronectin, currently only one source from US and very unreliable. Setting up MAb purification facility in Iceland and very interested in Evolve columns. Also wanted brochure on all Prometic resins although typically using Pro A for MAb purification met at Boston conference interested in Evolve columns and MAb resins setting up single use facility, interested in Evolve and refresh kits, also glycoprotein purification with APB. Interest in Evolve column range and Prometic resins Met at Bioprocessing Summit, interested in Evolve column range Met at Boston Summit, interest in Evolve 70 and 200 columns Keep in touch with Xiaofeng and meet ASAP 
Ion Exchange 
Mabs 
all  products shoould be pushed 8. Lost or Abandoned 9. On_Hold 1. Qualify 2. Exploring 3. Budget Price 4. Quote Stage 5. Negotiations 10. Delivered 7. PO Received   500   1000 	 650000  900000   2820 2  13000   764 @w 1800000   3300   287 J  330   519  128400 T  340 f  26250 3  1075 ~  382   405 X  600   650   270    254   644  }  32000   1500 z  1146 * 105770 p 70000   464  120000   7600   2000 n!  8558   34038 Q@15322.64 GzT@14248.66 @ 200000 
  2736 0  12500   4059 ~  1150 E  325 @B 1000000    190 `O 348000 UA  16725 /  1327 *  810   34487     0 &  9879 @ 72000 0  560   2052 :  15000 i   105    150 n   110 *  11000 $  62500 "  8870    240   530 ^  350    226 H  54600 T`  24660   500000 
   10    1    250 =7 210749   1955    156 Y  1113 |  380 l  33900  237000    161 p=
@2642.02   5000 $ 75000   8082   41500 fffff@28425.6    200   3800    256 a  25000 P  50000   514    189 E 280000 8J  19000    222 Z  23280 C  17280   41452 p  38000 } 163205 _  4959   260 ,  300   1702 l  27778  100000   4500 @  40000 W  22500 H 125000 |  37500   700 t  628   742 '  10000   3000 5  13696    54784 q 750000 0 256560 @  1600 L  7500   705 h 420000 ` 1500000 | 121212  300000  400000 7  823   38810 :  570   450   750 (\@574.57  250000   760 N_ 483150 ]  24000    800  240000 F  326 v  59510 X 350391 q   113  66972   5552 H  18624  398250 u 95500 d  25740   54000   960 )6  13865   762 O  335   680    225 W 88000    195  N  20000  124550 `  60000 _  42335   35000 XM  19800  298500 _ 941850 (
  2600 ?  575   285 }& 140925 O  20460 6P  20534  103145   710 Ur 94805    203    179 d   100 (~7A1563262.61 0 318000      @1030.5   63150  110000   53000 K  5195 <  55100   910 $  4900 ;  315   3100 A  1345 N  590   4000 +  555  397500 0 190000  2000000 Q 217500 b  25300 )  10750   48550  426500 
E 1066250 \ 220400  8760450  495000  247500 k 355294    220 &C 82726 6  13855   3818 q=
_@110981.99   5533   3263   5600 p  6000   485   1174 \  23800   533 y  31000 f  358 ~ 425600   534   643   45282   537 7  14100    180 fff:A1741701.9 j  6250   659   469 @  7744 J  19156  66000 -  5677   336000  325600 m 128109 z  378 q  625   1567 * 254250    157 ~   126   2250 ?  16287   654 b  25228 $ 68900 Z  346 }  1661   468 	  2488 t  1140 G  327    234    158 Q  337 	  2544 	  265 :*  10810  728985   49320 59  14645 Z   90   2989 I	  2377 g  1383 5  4149   393 =  573 `# 271200 f  48230   45576   52906 I 150000   63400   6878 HF 214600 O   8271 aB  16993  107000 Yo  28505 @  16569 x 96504   681  98254 q 94475 : 80600 
pu@80935.34 0 1323200 ( 75920   57000  1185980 P: 146000 P  4176 	L 4983240  1347730   43000    41760 =  41789   391 4  1076 0 262960   7592    236    136 <  316   772 ?  319 (  41000   453     _A399300.25 |   124 n  1390   1550 "  2850 ^  1886   525   532    245 QT@15529.69   1704   4590   452 &  550 	  2523   1428   434 d  612 Z 106330   47790 O 86000 n  37998 \  604  K  19200  118200   1200 6  46390 cK  19299    544 	  2500    230 7 70199 ;  15330   1768   400 o   111   445 o 815000   4383   451 [)  10587 S  339 ( 76000 0  304    768  248000 0  816   279   282   1700   3525   281  69322    169 |y  31100 #
  2595 ,  11466   46800 %  1573   1818   509 q=
z@430.29 Qh@196.71   433 ]  349 hB  17000 Z  23168   2014   4100   3036 QL@14489.69   473 T 72788   925 "  8935 P  2896 	  2487 '  5671 h  360   3462   1171 @  16550 4!  8500 Y
  2649 5=  15669   5882  133250 Q  849 H  328   698 h 102760   645   62384 k  63595 J 84670 s\ 89203   42881 _  40543  436936  302000   5592    252    207      4w@371.25 -  301 G	  2375   1204   6633    215 Y? 81753 -  49453   1996   661 e  357   1785   3246   3859  246442 h  26650   1685 }  637 I  329 +  1067   418 (\O@63.52 QW  22353   662 X  3416   7451 Q!A582356.16 (\qA434972.39 G@24346.92   412 	  2548 Q  1361   1274 #  547    5   1682 QA425924.78   926 Xa  24920 3 406293      E@2001.25  164357   271 |  45180   1010 33333@55137.6   402 OA431090.23 '  10200 <  15500   7375   1272   2231 
  2760   950 1  817 )2 406057 (A418040.79 v@7286.8 \A@49678.78 ?  16335 _  24550 L  332 k  619 B  322   1300 	  1289 	  2434   5895   51380 - 77070 JH 280650 ffffA339687.1  1039492 ` 252000  k 224000  373253 7  311   927 E  837   1030   58800 5  53813   58813   6285 3333`@32131.05  123064   34000  310000 Z-  11610 \@18803.2 @21492.2 sI  18803  240585 u  885 2  56370 d 380772 \h 354396 =G 345917 @4609.8   38910   3540 i  7785 f  2150 =  1341 nA  16750 B  16911 KA310290.9 &  73766    5376 Px  30800 (  10380   1215 r  370 x  30868  187075 (  10465 N  5710   735 Gz%@23703.57 '  10152   990   6335 = 376125 N 544500 ,4 275500   2015 (  39208   765 
  2800 pq  29040   385 c  355 d1 78180   1990   3070 l  56940 M  6221 (  10405   1430 
  2700   2950   42224   1180   38896 03  13104 T  33620 (  1320 V  1110 l  1900 0H  18480 ,L  19500 >@1231.65    164    172 GzJ@841.31  195613   6549   5505  1677964 4  820   675    175 Q 86400 8  14520 
  2565 (  10400 x 110200   3353   5322   3208  201986 0u  30000 . 405200 L  588 D>  15940   430   497 w  54903   6370 p=
=[A183143.63 =
pd@167.17 )\8@551.12 3333m@28086.8  138494   993    188   462   2021 H  1352      `]@117.5    165 QR@74.38 
  2704      @3685.5 0  2096      |z@423.75   1986   37564 '  10125   5260 6G  18230 -  2861 >  36414   48000 mV  22125 =
d@3378.47 Q@1528.63 !  8660 )  10630 O  1615 s|  31859 fffff}@465.9 (\ @1472.09 #  9095 wB  17015   5565   275   1035 7  14275      @1339.5   535   3555   2005   420   480 ,  4140 L  1100 w  375   1040 R  850     @4@9832.5 Y  345   1750     p@21113.75   794   7407   970 G@2141.99 B  6210 33333@4535.2   1045    185 |  31965 !  8675 	  2320   1674    210   1755   1465 i  1385 >  16000  102870  102900   58500 }  6525 $  3364 X  1880   1715   49365   1185   3304   520 z  890 /  12228 XS  21336 Q@4249.32   5865      @12320.25 y;  15225 q=
v@33716.87 N  3150   495 B  16920      @3312.5 ($L@33377.13 8  1080   540   682   665    244 &  9965    170   4120   2050    235 3  13250 [  1115 2  1330 f  870   44275 (#  9000 U  2133 x   120 4  13498   3235   3575 P  6480 *  6442   1665 Q@5259.02   4525   3565 V^  24150 cA 82275 Q@2808.51   780   486 Gz@4087.04 {G!4@6196.13 b  1890 h  8040 J  1610   3492 `	  2400   2220   3601   5340 l   108   1930 x  1400 7d  25655 z@19491.12   55065 )  10525 ffff6@35253.2   1781  175000   54288 fffffV@39603.2     x@12017.5 3O  20275   465  102175 c]OJA316051.7777 8gDi2 A311308.6028 +B 344619 d  38500 K 216050  170200 tm  28020   472 c]WQA316501.7777 H 247880 @KL 5000000   49910  1626140 
 707465 w  30698 X  22533 *E  17706 !  8663 2 78350 S]  23891  n  28160 Og  26447 @  16536 	  2441 H  18608     @32320.25 X  22665      @19264.5   47358     l@82358.75 \@51103.78 :@91051.1 \V	A209994.87 n 203886 +V 87595 X  49752 _  24572 )  10726 p  28809 s  29675 .  11781 )  10710 %  9639 &  9973   1964 R  1874 &  9884   2063 S  1875 '  10204 +   8235    6176 l  27784   62360 R 192850 s   115 P  20710  970200 /@127728.3 &  5670   42780 TG  18260     0    155    245      P@67.25      =@29.5 a  25000    200      ;@27.75 / 99375   47500   500000 g  54375   6325      @2687.5 ^  24275 A 213250 " 533125 x 110200    `XYA6570337.5 k 420750 5 210375 nA301999.9    220 &C 82726 6  13855   3818    250 @  40000 q=
_@110981.99   5533   2820   3263   1000   5600 p  6000 3  1075   764   485   1174 \  23800   533 y  31000 f  358    179    189 0  560 ~ 425600   405 ~  382   534   643 F  326   45282   537 7  14100    180 fff:A1741701.9 j  6250   514   659   4500 @ 200000   469 @  7744 J  19156  66000 -  5677   336000  325600 m 128109 z  378 q  625   1567 * 254250    222    157 ~   126   2250 q   113 ?  16287   654 b  25228 $ 68900    203 Z  346    190 }  1661   468 	  2488 t  1140 G  327 ;  315    234    158 Q  337 	  2544 	  265 :*  10810  728985   49320 59  14645 Z   90   2989 I	  2377 |  380 g  1383 5  4149   393 =  573 `# 271200 T`  24660 f  48230   45576   52906  110000 I 150000   63400   6878 HF 214600 p  38000 O   8271 aB  16993  107000 Yo  28505 @  16569 x 96504   681  98254 q 94475 : 80600  120000 
pu@80935.34 0 1323200 ( 75920   57000  1185980 P: 146000 L  7500 P  4176 	L 4983240  1347730   43000    41760 =  41789 ?  575   391 4  1076 0 262960   7592 ~  1150    236    136 <  316   772 ?  319 (  41000   453     _A399300.25 |   124   287 n  1390   1550   1702 "  2850 ^  1886   525   532 QT@15529.69   1704   4590   452 &  550 	  2523   1428   434 d  612 Z 106330   47790 O 86000 n  37998 \  604  K  19200 X  600  118200   1200 6  46390   3000   500 cK  19299    544 	  2500    230    800 7 70199   4000   700 ;  15330   1768 ,  300   400 o   111   270   445 :  15000 o 815000   4383   451 [)  10587 S  339 ( 76000    256 0  304   742    768 `  60000  248000 0  816   279   282 @  1600   1700   1500   3525   281  69322    169    161 |y  31100 #
  2595 ,  11466   46800 %  1573   1818   509 q=
z@430.29 Qh@196.71   433 ]  349 hB  17000 Z  23168   2014   4100   3036 QL@14489.69   473 T  340 T 72788   925 "  8935 P  2896 	  2487 '  5671 h  360   3462   1171 @  16550   5000 4!  8500 Y
  2649 5=  15669   5882  133250 }& 140925 Q  849 H  328   698 h 102760   645   62384 k  63595 J 84670 s\ 89203   42881 _  40543  436936  302000   5592    252    207      4w@371.25 -  301 G	  2375   1204   6633    215 Y? 81753 -  49453   1996   661 e  357   1785   3246   3859  246442 h  26650   1685 }  637 I  329 +  1067   418 (\O@63.52 QW  22353   662 X  3416   7451 Q!A582356.16 
   10 (\qA434972.39 G@24346.92   412 	  2548 Q  1361   1274 #  547 8J  19000    5   1682 QA425924.78   926 Xa  24920 3 406293      E@2001.25   762  164357   271    195 |  45180   1010   680 33333@55137.6   402 OA431090.23 '  10200 <  15500   7375   1272   2231 
  2760   950 1  817 )2 406057 (A418040.79 v@7286.8 \A@49678.78 ?  16335 _  24550 L  332 k  619 B  322   1300 	  1289 	  2434   5895   51380 - 77070 JH 280650 E 280000 ffffA339687.1  1039492 ` 252000  k 224000  373253 7  311   927   2000 E  837   1030   58800 5  53813   58813   6285 3333`@32131.05  123064   54000   34000  310000 Z-  11610 \@18803.2 @21492.2 sI  18803  240585 u  885 2  56370 d 380772 \h 354396 =G 345917 @4609.8   38910   3540 i  7785 f  2150 =  1341 nA  16750 B  16911 KA310290.9 &  73766    5376 Px  30800  247500 (  10380   1215 r  370 x  30868  187075  495000 (  10465 N  5710 :  570   735 Gz%@23703.57 '  10152   990   6335 \ 220400 = 376125 N  590 N 544500 ,4 275500   2015 (  39208   910   765 
  2800 pq  29040   385 c  355 d1 78180   1990   3070 l  56940 M  6221 (  10405   1430 ^  350 
  2700   2950   42224   1180   38896 03  13104 T  33620 (  1320 V  1110 l  1900 0H  18480 &  9750    225 GzJ@841.31      @3274.5      @537.5 $  4900 
E 1066250       C@38.25 )   41      @@33.75      h`@131.25  73440 8  14520   520 }   125 D>  15940   430   497 w  54903   6370 p=
=[A183143.63 =
pd@167.17 )\8@551.12 3333m@28086.8  138494   993    188   462   2021 H  1352      `]@117.5    165 QR@74.38 
  2704      @3685.5 0  2096      |z@423.75   1986   37564 '  10125   5260 6G  18230 -  2861 >  36414   48000 mV  22125 =
d@3378.47 Q@1528.63 !  8660 O  1615 s|  31859 fffff}@465.9 (\ @1472.09 #  9095 wB  17015   5565   275   1035 +  555 7  14275      @1339.5   535   3555   2005   420   480 ,  4140 L  1100 w  375   1040 R  850     @4@9832.5 Y  345    175   1750   450   675     p@21113.75   794   7407   970   650 G@2141.99 B  6210 33333@4535.2   1045    185 O  335 |  31965 !  8675 	  2320   1674    210   1755   960   1465 i  1385 >  16000  102870  102900   58500 }  6525 $  3364   710 X  1880   1715   49365   1185   3304 z  890 /  12228 XS  21336 Q@4249.32   5865      @12320.25 y;  15225 q=
v@33716.87 N  3150    240   495 B  16920   1475      @3312.5 ($L@33377.13 8  1080   682   665    244 &  9965    170   4120   2050    235 3  13250 [  1115 2  1330 f  870   44275 (#  9000 U  2133 4  13498   3235   3575 P  6480 4  820 *  6442   1665 Q@5259.02   4525   3565 V^  24150 cA 82275 Q@2808.51   780   486 Gz@4087.04 b  1890 h  8040 x   120 J  1610   3492 `	  2400   2220   3601   5340 l   108 F  1350   1930   540 x  1400 7d  25655 z@19491.12 /  3375     X*@41298.75 ffff6@35253.2   1781  175000   54288 fffffV@39603.2     x@12017.5   42500     p@17233.75      ]@116.25      Xa@138.75  102175 c]OJA316051.7777 8gDi2 A311308.6028 +B 344619 p  28875     A162037.5  170200 tm  28020   472 c]WQA316501.7777 H 247880   49910 K 1382219    Z"A601345.25      Z@107.5 w  30698 X  22533 *E  17706 !  8663 2 78350 S]  23891  n  28160 Og  26447 @  16536 	  2441 H  18608     @32320.25 X  22665  N  20000      @19264.5   47358     l@82358.75 \@51103.78 :@91051.1 \V	A209994.87 n 203886 +V 87595 X  49752 _  24572 )  10726 p  28809 s  29675 .  11781 )  10710 %  9639 &  9973   1964 R  1874 &  9884   2063 S  1875 '  10204 +   8235    6176 l  27784   62360 R 192850 s   115 P  20710  970200 /@127728.3 &  5670   42780 5  13695       ?     Q?   2   {Gz??(      F         ?      ?      @-   
      d   {Gz?          L&@333333???P   <                              '     @     x   {Gz?K        Q?9                |  Z     .      ?L           @+   8  n   3      $            )\(?@         @@?   ffffff6@=   Q=f@Hze@Qf@        Q]f@4    ,  ~@@@\  @+  @+@	@/@  >@~@^@@@~@M  V  x  l  @u  >@@@  >N@^@    @  @@~@@  @  )  ~@@_  @~@@U      ~@{@5  @^@^@>@  @    ~@  ~@@   @^@      ~ @  >(@    7@Y@e@  @@@    q    @j  ~  	@H@/  :    >@>@  k@v@~l@  [  t  N  @W@@  g  m  Q  +@    {    @@  	@=  ~3@U@9@~7@>@@  ^@  @  =  @?  @<  @^@@  @  @>@  @^@@>@:  5  @@  .  @@      8      ^@  &      ;@j@<@~m@  >s@:@>L@`@@  q    G  @-  r  @>@~@  >@  X  G@&@D@p  m  @  @~k@  ^n@g@y@>w@>t@@~@b  ~@O  ~t@      @3    @@@^7@V    @@^@r@M  +  @2    @~@@=  @  @  w  ~  @c    ^@A        @>@  @    @  ~@~@>@@O  @@I  >@@@@^@@@@@@>@^@@@>@@  @@@@@  @@@k  ~@@^@        j  &  %  ~
@.  C  J  @W  G  
@_  @i  f                @  ~@~@^@z  @^@~@>@>@^@^ @@@@@>@>@~  >@~@^@^@~@^@@@>@    >	@~	@~@        ~"@    )@$@)@  6  *@.@^5@.@>.@^2@1@R@  ^Q@W  ~P@^X@R@U@S@`@~[@^d@g@f@^e@h@@  T    U  [  b  }  h              ~@  p                                  {@}@}@@@^@@@@@@@@@~@@^@>@@^@@@    ^@  @@                C      E  @^@^@~@>@>@@@@@~@@@^@  @J  @>@@@~@@  >@?  ~@@@@@F  c  @@;  r    n  }    r@>G@;  `  ^I@  =@Y  u  >6@        ~J@<  >  a  V  P  R  A  I  X  Z  ^  `  ]  d  f  h  K@l  n  o  s  t      ^L@r  2@2@3@3@~4@5@6@~6@6@~7@9@9@:@~K@><@^<@<@=@^?@A@B@@@@@@@~A@A@  ^B@>E@~C@E@^F@G@H@I@I@^J@K@h  L@H@q  y@C  >@      T  @x  w  |  ~        u    k@    c@^g@o@          h@g@v@c@^m@>o@p@d@e@f@e@b@>c@    i@>g@m@n@`@  q@t@@@r@>q@s@@~@t@@    ?  ~`@  G  h  @/  >@@1  @X  D  @  M  ^@g  @>@@>@^@@@^@~@@@@@B  ^@@~@~@@^@~@@@@?  J    ~@@@  p  P  T      @    (  =@>K@r    v  m            3@^5@~5@>7@^8@7@4@8@>9@;@>=@?@>?@?@A@D@F@^K@~I@I@i    }  ~a@                                  ~b@  ^`@e@b@d@d@p@f@  >h@~h@j@k@m@~n@o@q@>p@~s@u@y@r@  u@>u@^u@  u@~u@>x@^w@x@w@y@x@x@y@        F       *  >@7    +  Q  2  S  8  >  J  j  @@~@^@@@>@^@@@^@>@@@~@^@^@@@@@@@@@@@>@@@@^@F  >@~@>@  V  W  X    @      l  i  ^@~@  >@@_  @C    f  >@@d  \  m  @@N  @~@@^@      *  @@~@^@>@@  =  \  {    @~@)@  !  H@  k  @Q    New Business Existing Business Prices MTA MTA for screening Visit customer CDA Support Mimetic Green results New contact person quote awaiting outcome of scale up at 5L Send Quote Would only evaluate free sample Follow-up on ordering information sent Negotiating CDA & MTA Project on hold due to funding Generate proposal Supporting Info Provide tech info confirm he got email 2-16-2006 9AM Apt. with Duell Presentation followup Follow-up with references awaiting order from Pam Cifra evaluation unsuccessful, too much non-specific binding set up meeting to present on F1P indicated they would purchase sample for evaluation awaiting online order information sent, no follow up from client awaiting purchase online quote sent Iwai to place order for 25-100ml Await online order CDA and MTA Follow up on proposal send quote when ready Qualify ordering schedule with Nicola Digney Close Conference call to discuss proposal for collaboration visit with dev to UCB On-hold as too expensive at this stage of the project Technical support to follow up on poor results obtained during evaluation supply draft contract set up follow up meeting MTA/CDA pricing FIX project on hold, awaiting monthly updates from Tim Herrmann sent prospecting info, follow up in 1 week Present Nabi packing study results scheduled call with Tim Morley Follow-up on technical information sent provide contract draft Obtain formal forecast for 06 and negotiate new agreement CDA/MTA approval Call for update on Q4 trial On-hold until 2007/2008 Steve to send BioRad letter Call for update on CDA Follow up mail Technical support to follow up on evaluation Call for update on A2P screening initial test of purchased samples prices to tarun Awaiting 1mL column issue to be resolved Send revised quote Call beginning of July '07 Call to confirm interest Receive CDA back from them Secure NDA A3P Waiting for funding Supply Data Make Contact when A3P available Dev to follow up on technical information provided to Proxcys (13/05) Follow-up on proposal every 2 weeks Follow-up evaluation of lead candidate. Follow up on evaluation sample provided FOC CDA & MTA signed check that CDA & MTA signed, we can then send a sample On-hold pending outcome of AM Pharma check to see if still alive still going to place order online? check on pending order to be contacted to discuss program steve b to contact directly contact georg meet first week of October send quote follow up quotes Budget proposal Replaced by 20 litre order Follow-up 1/06 evaluating purchased samples Send Protocol Send Brochure Send Sample of Endotoxin Removal Adsorbent Application Note Follow-up Sample meeting Follow evaluation Evaluation of A2P  HF Win PD evaluation Application List Send Application List Visit Follow up quotation Send Info / follow-up Follow-up with small purchase and evaluation Quotation Next Client Campaign Requote Competitive comparison Data and Pricing Provide Pricing bidding for contract, touch base in 2 months time Follow-up pricing information Return forms from Pfizer purchasing Visit week of 5/4 call to check in on purchase Meet with Merck to discuss leaching Follow-up evaluation sample indicated that he put 1L of MB into 2010 budget Follow-up success with elution strategies Follow-up evaluation Investigate feasibility Sell evaluation sample not yet ready for protein production, asked me to follow up early 2010 Contact Atoll send literature check to see if CDA in place speak with Simon on Nov. 3rd await order follow beta test Follow scale-up Follow Scale-up Follow Beta test establish beta test Quote custom bid for work and set up CDA Monitor Phase III wait on feedback from quote Detail Validation Costs Account Visit price sent follow up on pricing sent follow up on proposal and CDA delivered call to discuss proposal MIKE to follow up ASAP Email Blast Await Reply face to face first week of June A3P as commercial product send quote and info set follow up meeting to get update on schedule to evaluate both A2P and F1P (already purchased) Follow-up Info to JZ get him to test resins set up meeting to present on A2P check on status of A2P evaluation and timeline for F1P Lab tests at Teva Send Sample Follow-up with CDA drive project Quote PuraPlates Introduce  A2P HF Negotiate contractual elements: can Novozymes do PD work to save . Call for update on evaluation Send Process Design kit Pricing strategy Dec 2013: have Fabsorbent sample to give to Steve, he hasn't agreed to meet. is this still alive? meet in Dec 12 follow up on informal plan sent no feedback for over 3 months assume project stalled Forecast data from Tom Chen Submit formal proposal - Rich Pricing and Availability send info on Etoxiclear no reply from prospect order from online Shop Confirm Forecast in Jan 2015 Call quotation Get MTA back from Grifols check if sample was sent Evaluate current A3P follow up to see if development plan is complete, will then purchase resin to evaluate Follow-up info Sample call await online order Resin samples sent.  f/u for feedback. Ship 25mL sample of SP PuraBead HF. Sept 2013:  Contact Dr. Chan - is project dead now? evaluation successful however validation will take 1+ years supply Bio-Rad with two plates filled with Bio-Rad resins Send Info and follow-up meet with sasa and team Send quote send info Wait to see their reaction to pricing for 100 column batch Oct 2013 Send email Mike to qualify value and timing of opportunity send draft supply agreement Demo/ Visit firm up forecast for 2016 Obtain formal forecast for 06 Continue dialogue Provide info as per meeting General Presentation Prices and info revise quote Sample A2P HF Monitor Progress confirm pricing delivery costs? pricing info Send quotation Call to follow up mail New Info re Caprylate Product Availability Seminar in October define next scale volume High Level Discussion at Pfizer Sign MTA currently with Henrietta Huisinga Quote Maintain dialogue waiting confirmation of volumes, June confirm later in 2006 order thru VWR send protocols of use Improve Purity Feasibilty study receive order Assist Order Process Follow-up 2L evaluation Complete CDA Supply Quote, Confirm Shipping Date AW to place order confirm order sign agreement Follow-up Price Info Secure Advanced Payment Have decided to go with Standard Octyl for now Follow up on evaluation Follow-up on evaluation Qualify future requirements Meeting in Cambridge to develop new opportunities (23/05) send quote when requested Competitor evaluation follow-up on quotation For scale down studies in 180L column For John Liddell's routine screening work - no specific application delivery quote customer visit to learn about application product ordered online, follow up about application on behalf of the CMO- PacificGMP Quotation delivered will purchase once transferred process is able to be optimized Dev to follow-up on evaluation Follow-up on evaluation at NOVARTIS send pricing and then official quotation customer to purchase online arrange meeting to discuss products and application Qualify ordering schedule sent quote follow up from website pricing info sent awaiting order from Alan ship order, arrange visit to follow up awaiting order order closed via website purchase send email email indicated would order after T-day break, possibly 5 liters sent pricing info, await PO client will purchase sample Assist in purchasing follow up on evaluation awaiting PO from Symmetrix so we can send pro-forma Support evaluation at ViruSure Ordered deferred until end of 2011 Richard Dodd generate proposal for 25ml sample wait for quote request follow up from inquiry follow up on proposal sent Obtain P.O. Follow up quote Johnney to use his 5mL PPC given to him last year as a sample. PO receipt IOM testing prior to sending samples PO Shipping formal quotation Dev to follow up on samples provided to Atoll (in May) and evaluation at GSK Follow-up on discussion at conference Decided not to progress due to cost and re-validation constraints follow up quote Rev. the Allergan document to include everything from our Ads. Dev. Proposal Demo Call to update on product development CDA/MTA prposal Review MTA Arrange visit with Steve Present new project plans PBL Experimental SB to sign MTA Respond to Conference Enquiry Enquire re decision which Blue Meeting requested with Sarah Howell - no response Re-qualify interest Follow up on information requested for media 'overview' follow up with Tarun, not sure when order would be placed cold call Dr. Keith Foster what is their application?  could they use anything else? meet with Martin EtoxiClear Email Blast SI - 17/10 Follow up Provide program details send lit No requirement for 2015 Other Employee Referral External Referral Seminar - Internal Trade Show Referral (External) E-mail Advertisement Referral (Internal) Exhibition Conference Website (ProMetic) Research Word of mouth Web Partner Direct Mail ZoomInfo               Omitted Pipeline BestCase Closed Forecast Omitted Pipeline Best Case Closed Commit 701200000000Q5QAAU 701200000006OVjAAM 701200000000iUnAAI 701200000000iUxAAI 7012000000065Q3AAI 70120000000387LAAQ 701200000003qGkAAI 70120000000gfAgAAI 701D0000000pHn7IAE 701200000000QunAAE 701200000006nTQAAY 701200000000iUsAAI 701200000000iUiAAI 701D0000000pHnCIAU 701200000000a3UAAQ 701200000000iUtAAI 701200000005ST7AAM 701200000006QXMAA2 701200000005IOFAA2 70120000000gibkAAA 701D0000000pIDWIA2 701D0000000CNbYIAW 701200000000iV2AAI 701200000000QuYAAU 701D0000000r3R1IAI 701D0000000rn1fIAA 701D0000000r8kfIAA 701D0000001BX2sIAG 701D0000000rMLpIAM 701D0000001KkOIIA0 701200000000QdNAAU 701200000000l57AAA 701200000006ClYAAU 7012000000032E1AAI 701D0000000cB98IAE 701200000006ZCbAAM 701D0000000pXAHIA2 701D0000000pdXvIAI 701D0000000qB5dIAE 701D0000001BJ0LIAW 701D0000001B2bMIAS 701D0000001KzV2IAK 701D0000001QxQuIAK 701D0000000cMA2IAM 701D0000000c2obIAA                                                  USD GBP EUR     ?      ?      ?      ?333333?                  1 @       `     A
      P  (   @ 0    8     `   	  r 	@      q   
H@
    r$ P`   ( X  ,  `   0 h     4  p   8  x     $ 8       8  @      8  `      4  (       4      <      @    "D      $H       &L @  (P `      ! T         T  	 *X        q \   	 ,`          d  ! 	
 .h  "        l  #    0p $@     t  %` 
  x &   2|   '      (    4  )    6   *     8  +!    :  ,A    6   -a    6   .     <  /(  > 0        10         28    @  3@!      B  4A   D  5Ha      6P 
 F  7X      $ 8  8`  H   9h       4   :`      ;p!       4   <`A$    =xa    8  >     8  ?     @!   T AH  rJ BH "   C!#  qL 	DA$  L  Ea%  N` F       G&( P  H      8  I'     J	    8  K!	(   R  LA	       8  Ma	)    aTT N	    V  O	*    Xp  P	         Q&(   R	    Z  S
+, \  T "
,   c^ UB
     Vb
-  q   W
0 `  X 
.       Y 
/  1b Z(
0     [0    d   \!      T  ]8B1 	   ^@b     _H      f  `,4  ha2  1jbP3   1lcP    1ndX"4  2peXB5  2rfa      tT g`6   w hh7  ax 
ip      {   jx8  !|k9,   L  l":    L mB;    L nb<    \ o=    p>   \ q?8   \  r@  \ 	s    q  t"A   L`  uBB   L` v@`C   wD      xX;     $ yE  (zE    ({E   (|p"F ! , }BG   $  ~bE   r(X ! 0H " 4        8        8        < #       <  C     @(cI " sD 0J   D8K   H@L   DHM   LpN   LP#O #   pB         Xc        `  #  P h      T p      4  x   $  X P   4  #      8  C      X b,$ \    %  ` `Q % &d            &   h (&   l &( '  #&('  A&( (  c,    p <     t R ( x E  )  | (  )    S * 	 T * 	  U$+ ) CV   	 cW     X + T 6  ,    ,  6  -  6 -   $  . H  D,@. e  dY   ! L (6  /  0Z / 8[  0  [ 0  \  1  @$]   a L HD^ 1 b Hd_ 2 a  P`   X[ 2 !  `    T hA3 T  p6 3 ! x$ 4  xD] 4  d 4     \  - 5   D5    D      6    ,D6   ($W 7   Aa 7  ab 8   c 8   d  9   d 9    H :   , :  $e ;   Df ;   dR<  g<   h  =   i =  0j >  iL   $P    DP     ek >   [L?  l    $ m   ( !    , 0 n   d@   0 o ? d0 Ep   4 eS      q0 @ 8 (  @   A0r  A = m A A  8   B  E @%s    I HEt B  L Pek C  P u C 
U Hv D I Hw D Y Z E ] X E a $[ F e  PE& F =  (ex  G 	 y G i `z H  l h[H 9  ({    p (!    t 0$       4   D   I   xd       | p& I  h x   J    |$             [    " P%         E T        `          $J   a}$ K    ~K $ t< L &  X     t   X     t %  X     t E  X     t 	e  X     t 
  X     t   X     t   X     t   X     t ! X     t %! X     t E! X     t ye! <L  (u ! <L  (u! <L  (uy! <L  (u ! <L  (u" <L  (uI%" <L  (uD" <L  (u	f" <L  (u" <L  (u"   M  *!" M (,)",  N  #\N 	 1&#   O  	   D#  O    !9f#  P 	   "!" M (,#!" M (,$!" M (,%!" M (,&!" M (,'!" M (,(!" M (,)!" M (,*!" M (,+!" M (,,!" P ),-!" P ),.!" P ),/A#[  Q 	 0A#[  Q 	 1I#m      2	#3 Q   3# R  B4Q$ R  C5Y&$ S  C6aF$ <L  (u7if$ S  8$`T . 9q$ T ]\ :$6  U 0 ;y$[    <%      =!% U   0  >@%    2 ?`%d V 4 @% V 6 A% W 8  B	% W X  C	%    :  D&    #<E&&      FF&      Gd&,  X     H&] X T  I& Y  JQ& Y > K&, !Z  L! ' T       M&' X     t NF' X     t Of' <L  (uP'  Z  (Q'  [ @ R' [   S',  \ B	 T \ D U( <L  (uV&(  ] !   WE(t ] FXf(   q\\ Y( <L  (uZ   ^ !H [A(  2 \A( ^ BJ)])(  _  ^	) X     t _I )  _  QL`I@)  ` 0   aa) `  ` b) a  ` c)l a  d) "b  ea) b  f) #c  g!)    
   h)! c 	Ni*k d 	P j&* d  $AkaA* $e 	 Cl"[ e 	  mg*3 Q 	 ( n* f )R-@o!* f  0Ap	"R  g ) 4q)*    	 8r1*   	 < s+A g  t#+   
 @u#+   
 Dv!)    
 H w!" P *,MxA+   T5  y9         z!f+R    
 P {A+k   	V |+E  h	 T }I+  h 	  ~Q+  i	 X A#[  Q	 \A#[  Q	 `A#[  Q	 Y, i	XY, i	XY, i	X#,  j	  aG, j
Zeig,   ]a!,   	^ !,[   	^ !,[   	^ !,[   	^] !,[   	^a !,   
^i !,   
^Q q,   k  laG, j
ZqaG, j
ZMaG, j
ZuaG, j
Zyy, k `I C,       |  a -  l   "R<l bA!-    d  AA-    f 9b- m 
h@-    zj-   zj-      :x -    * L. m lD'.   	  G.3 n n@i  n  p c. o qr] .  o  t 9  p !v.    8  .         . p axQ / <L  (u'/ q zA/    4p  a/     | / <L  (u/  q  	~ )/ r 	/ r 	0    % '0 T s   aF0 <L  (uId0 s    Y0,  t   &(t   Q0    0      
  Q0 u  @1 u  Y'1    
  DH1  v 	 	h16 v  1 w  Y1   
 p  1h'  B1    
 d  !2l   @)(2    @1H2  w  if2   
 	92p  S2p  S2p  SA2p  SI3p  SQ(3p  SYH3p  ah3t  Si(2 
 	Sq0  
 	Sy3E   Ri3     * " x    	3|  
m	3| 	
 l	W4     
 l	(4      yH4E   d4  Q
i4    	4  x A4   4  VI5p S$5 x QyE5   Pyg5 " +Sy5 " +S95   R95   Q95    P96   S(6 ( 	$SYG6   $TYg6   #UY6   #WY6   #UY6    $TY6   $WY7   $TY'7   $WYG7   $TYg7   $WY7    $T7   $U7   $Wi7  y` 4 7 y0  4!8   0 0 (8  z1 $4")@8H     (4 h8m z11'A8 1 ,4$)8  {11#	8 { @	0 I8  |!a14"9 |" 543 "9  }#  (4  H9   $94 bb9W    <4 29 }%aA4#9W ~a D4!R9   &P 0 9H     H4!* :   '0 L4!(: ~(@ P4 :B:  ) U4#	h:*Y4 
:   +  \4 :   , 03 :   - a4 *:] .a4 ;6  / d4 );   &  h4 F;   0 l4 
i; 1q4 
;  -  t43#z;   - x4 z;   2  x4 Z;  3}4 	<   4j4 * <   5P 4 :G< 6  43!`<  2 43#< %43#<   5@}4 "<d  '` |4 "<]d  . 4#=    p T4#B$=d  7` 43# 
@=  8A4"!*i=   -  43#"2= - 43##*  9  43#$*= -  4#%
= ):q 4'&=@5` 4#':	>   2  3#(B)>]   .  4#)B>  ; 4&*a>\   < 4#+J> =q 1%,>l   >  4#-2>& ?q4#.R>]   .p 4#/?   @4*0Z)?   -q 4"1B@?  AqL 3&2B`? * Bq4%3a) C 0"4b?@ &A 4"5?3  0"6*?   D4&7) +E 0"8? Fq 4+9@  & 4":!@   G 43);jI@ H4"<Bd@  &a 4"=@  I 4&>B$=d a 4"?R@  J  5"@@ ,7! 4"AF; K5"B@` L! 5"Cr	A  5q 5"Dz)A M! 53&EzIA N! 5&FiA& 5!GA  5"H> O 5!IA3   5%JA - $5"KA  P (53&LB  Qq 4&M)B R0)N:BB S-5!O:bB T3"P
B   5!QB  U 05!RB  V!1!SB- W! 45!T	C  V!55!U)C  X 85!VIC	Y <5'W`C41 @5!XCZ 1)YC[qE5 ZC	1 H5![RC \! L5%\RD  ]! L5%])D-  W  53!^CD3D 0!_J`D^LP5$`D _ T5)aD ` T5)bDa X5 crD- Wq 0!d	E 1 ,5!e)E[ 0!fJE  Vq ,5!gjE	bq ,5!h1
 c 2%iE- W \0!j
E- W \5 kEda5+lE
 e d5%m
F/ f h5%n)Fg \0!o"JFhq D5 p*jF i l5 q2F 0 Lp5$rF 1 t5 s:F V x5 t2F	 b |5 u GM j 5 vB*G- Wq 1 wHGkL5(xhGl 5(yG       03 z
G 8 53#{Gh 53#|Gm  1 }Hm  1 ~2*H  n 53$FH o 53 JjH  1   X0+HD  p 5%RH\ <53#:Hq 53":H3r53&ZIW  53":"I2s 53!2DI t 53#2dI u 53#Iv53!Iw 53!Ix53!Id  y 53#
 J3  53"" J3  53!*@J z5$jJ {5$J  | 53 RJ } 53 RJ!. ~ 53 BJ" 53$:K   53 $K#53!:BK$4 53#cK| 53!:K%5 53"K&53!:K !53!zK' 63!L(6 63!R%L) 63!REL*  63 zgL+ 63 L,
 63 :L  63#Lm 63#ZL{   63#M-%63#
 M.8  (63$FM/=13#cM0,63"bM1 063#M2 56&
M   863#jM3 =13'N4  % <6#`    @6##N5 D63#ZL6 H63#"AN   L6"`N*    P63#rN7  # T63"zN8 Y6&N9 Y6&N:$ ]6&
O; a6&:"O<e63!JO= i6&hO>  l6'O? q6&O  Y6&rO@ # t63"ZOA x63"
Pi |63"!PB 6&APC 63&gPD   63"PE   63"PF 2&PG 6&JPHM  03"J QI 6&*QJ 6&J@QK	 63&eQL63#QM  63"QN  63"hO>  6&QO   63"QP   6&RQ  2"*RK 63":BRR 63!aRS 63%RT  03!RKM   p03!RU/  6%R  803! SM  js0%J SV s6%JSW63!jSW 63!S  63!SX03!Su 63!"SM  j63%OM  j6%"TM  j63%*T  63!J@TY. 63%jTZ 63%bT[  
63!T\.03!TKM   p03!BT   63 BUW  63 'U   63 JUU/ 6$aU]  6$U  63 U 63 U   63 Uq   63 
V^  63$'V  63 EV_  63 eV_  B13#Vh   s  73 V`  63 Va 7$V F13 Wb  33"Z*W8  "
73#
KWc 73#`W_  $7#Wd   @13#We   @13#Wf  7' Wg 73'ch  H73!XM  j  73'%X    $73#SFXY   (73##kXi  ,73'+X     173#sXs  # 073#X      473#	X      473#
3Y      03#!Yj   873#;BY  <73#;bYk  @73"Yl   873#Y6 / D73"Y3 33&;YZ I73&CZm  &03"C+Zm  &03"KKZn  03"SkZz  (23"Z    23"SZo   L73"sZ    P73!Z    T73![[3 23&([p  03%SA[q Y73&c[r:  X7&cT[  
^73![s a7% c[P  e7%!k[t  h73%"c[u `73!#C\v  l73%$+%\w  p73!%@\x u73%&3f\y   23!'s\z  x73%({\{  |73%)\| 73%*\} *73%+]=  73&,!]~ 73$-[P ,73'.SA[  73$/SA[  P23$0H]  73%1h]4 .N23$2]  73$3]P  73%4] 73%5K]~  03$6{ ^~  73$7c+^   73$8C^073'9j^  73 :[^ 273';^3 73$<^ F23$=^~  73$>_W ;  73$?s+_~  73$@K_    73 Ase_z473#B_  73'C_3   403$D_<  73'E{_    &673"F	`   403$G `$  73'HK`   73#I[g`873'J[`E  X23$K`R   73"L[`   23"M`   7"NaR<(7#O&a :73&P@a *7"Qca 73&R;a  7`Sa  	( 7 Ta 
 7"Uaz    8"Vb  73"W+b 	83 XGb 8cYab  	 13$Z[,iX8%[[,iX8&\[,iX8&][,iX2&^[,iX8%_[,iX2%`[b 	 8&ab  	  8&bb  	 $8&cb 
 (83fdb  ,83'e;c;  083&f;'c  483&gKc  73&hkc  883"iSc  <83&jc;  @83"kc$  D83"l;c  H83&md3  	 13$nC d  083&oC@d   L83&pid$! P83"qd " T83&rd # X83&sd $ \83&td % `83"ue  883"v e & 883"wIe;  d83&xie  d83&ye  ' d83&zca  ( h83&{e ) l83&|e * p83#}e + t83&~f , t83",f - t83"Lf . t83"df$ / x83&f 0 |83&f 0 |83&3f 1 83&f 0 83"f 2 |83"e3 2& gF = 4 7&#c  83&e 5 8%&g. 6 83&Lg 7 83'cg 8<8'g9<8'g : 8![c ; 83!g_  < 83%gF  4 83%h = 83%$h > 83%Hh ? 23%3fh @ 83%Sh3   8!h A 83%e B 83%kh # 83%kh C 8%#Le ; 83!	i  D 83!$i E 83%Ji F 83%C`i  G 83%i H 23%i3   83%i I 83!#i  J 23! j % 83#%j  D 83%C@j K 83%Saj L 83%+j + 83%j E 83!Cj     83$j M 83$3k + 8 $k  D 83 Ck N 83$hkO 83$k P 8$CkQ 83$[k R 83$k3 	  93'l$ S 83 +l + 93 SAl T 93$Sgl U 93 [l R 93 j V 93$l W 83$l  93$l$ X 93 [m 	 93 !m Y 83$[Gm Z 83$[gm[  93';m \ $93#m ] $93'm \ $93'm # $93'n # $93'!n 7 $93'CLn  ^ (93#Kln3  ,83'n 	 ,93#Sn _ 83'kn ` 093'n a 493';o  83'(ob 89$Go c 73$;bo$d 83cko + <9c[o e	 7$[o e	 @9'[o^  f
 D9f[p^  f
 H9e(p  g L9'(p  h P9'[Gp e	 T3$[o e	 T9'[o^  f
 X9f[gp i
 \9e[p
 j
 3e[pk `93'p l d93'+p  h93gcp	 l9#kqm p93gs,q + 3b{Lq!  n t93'Clq ^ x93'q o |93#kq  p 93'#f+  q	 93%#f+  r	 93&#f+  r	 93&#f+  r	 93%#f+  r	 93%#f+  q	 93$#f+  q	 23$#f+  s	 13$[q+ 9c[q ; 93'[rt 9b['re	 2%[Lr u	 93&[gr  v	 93&#f+  w
 d33d[r  x	 9&b> 	 9%b> y	 9%[r z	 93$r? {	 93%r ? |	 9$s? }	 9$#s? }	 9$Cs? {	 93% cs? {	 93%s? {	 93%s? {	 93%s~	 9ats 	 9at	 9ab  	 8&(t> 	 9'Ht> 	 9'	ht	 93%
t	? 	 93%t? }	 93$t? }	 93$t
;)>93a\u  	 93%\,u  	 93%\Lu  	 93%D`u  	@23$u	 9ab> 	 9%u  x	  :3'\uA 	 93$u 	 :3$v  	 :3$\'v  
 :d\Gv  
 :dav$ 	<:dv  	 :3 v 	 :3`v 
  33f<v.   :c\w  
  :d \'w  
 $:d!@w   	 (:3 "D`w 
B.:3e#w 	 @93c$wR   	 0:3#%\w 	 4:3#&w 
 8:3b'<x. 	 <:3%(<"x. 	 93%)Lx 
 @:3b*dx. 
 D:3b+<x 
 
 H:3b,x - 
 L:3a-x  
 P:3b.\x!B 
 T:d/\y"C 
 X:d0\'y  
  :d1,Gy# 
 \:3b2cy$4 
Db:3e31  
 d:3b4\ylp > h:b5y% 
 8:3b6y 
 l:3f7y& 
 p:3b8z'D 
DN33e9,z( 
 p:3b:Gzq  
 t:3e;az) 
 x:3f<z*jE 
 |:`=<x 
 
 `:3a>lz+  :a?z, 
 :3a@z-4 
 :3eA{.v$  :aB'{/  :`CG{0 
 :3aD`{A   :aED{1v  :eFD{2v  :eG{3F 
F:3eH{4  
 :3!I|  
 `:3eJ#|5G 
 :3gKL|6nH 
 :3`La|7 
 :3fM|b 
 :3gN|lt > :`O|8v  3`Plq9 
 :3dQ|    :#R}:  
 :3 S,}) 
 3dT|E};; 
 :3cUl}Rt   VD}<HVW\}  
 :gX}=  !L 	Y}      K. Z~>  H[,~?  L
 \L~  s:$]l~@I t L23$^$~A  
NnG_~Bv  U`<~)"  P
Ga~;c QbR|   l	c | 	 lSdD{t  
 :3#e|g5 " *:cfdKC  lGgm,  hD )Ri3  	j\3  	 
 k3 	 lyl 	 RmLl 	 Rnyl 	 Ro$yl 	 Rp,yl 	 Rqyl 	 Qr4-% 	 Rs<yl 	 QtDyl 	 Sua2E 	 RvLF 	 RwDfG 
 *"SxHJ   $*TyI? 
 :3'zLJv   lG{Kv  	 |$[  	
 l	}#I? 
 :3'~\G  
  ;g<bL; 
  ;3cTp  TC\p   CdM  at\ 	      QV" lN$  t- D     \  lL3   X" hO  Z^ 	dP \" dE   "^F   `. Q  b6 H  d. l-   f*A       < $b      h
M  j;3$LR  , |       D|Q  LL S	  L<+     j  M       8  |j      l  Tn;3&<&   p     r  E(  t X    t13'- X     t M X     t m X     t  X     t  X     t  X     t  X     t  X     t - X     t M X     t m X     t  X     t  X     t  X     t  X     t  X     t . X     t N X     t n X     t  <L  vv$ <L  (u, <L  (u4 <L  (u< <L  (u# <L  (uDN <L  (ui <L  (u    U *73&LM j 73&T               -3  x.93'TL _  ;'cV  083&3    $ \;  83&d)  83"l 7 83&3  	 ( t. + ,;3"JW  0;"|n : 23"X  23"Y  4;3& * 4;3&LfZ;  23"\ R 8;"[;  <;3",\
  @;3",@8   D;3&n]  H;%^  83%_  8%l`  L;%|!  n P;%3   83%!3   83%N 7 T;3%lc 7 T;3%a  X;3%b  \;3%, ^ `;3!\c  d;3%\d  d;3%\#e  d;3%N3   h;3%n3   h;3%f  l;3%3   p;3%$g;  t;3 h  x;3$
3    |;3$.i   83$Cj  ;3$ck  ;3$l  ;3$k  ;3'3  93$m   ;3'3   $93'l.`  ;3'lN`  ;3'cn  493'o  2#^  093' " ;3'p	 ;3&q  73$(r  ;3'N \ 83'|ls  |93'|t  |93'u  ;3'  7 l93'v  l	 w	 ;3e#x 	 ;3&Hy  23' nz   93'{  ;3'|  ;3'_  ;3'E}  ;3'~ 	 ;3&# 	 33&H  	 33"g  	 ;3&	m 	 ;3&
 	 93& 	 ;3& b	 ;3&  {	 ;3&5# 	 ;3&uF 	 ;3&mn  	 ;3&m  	 ;3&=+ 	 ;3& 	 ;3" 	 ;3f	 ;3&U! 	 ;3fA     	 23&b 	 ;3f 	 93eG 	  E 	 ;3b=  	 ;3%3 	 ;3e/G  	 ;3%=G  	 93% =g  	 93%! 		  <3a"   	   #=  
	  <3%$=F  	 <3%%%   	 <3%&( 	 <3d']L 	 <3%(l6   /	 93%)_  <	 <3g*] 	 <3%+ 	 <3%, 	 <3%- 	 13d.#{ 	 <3'/}Lq!   n	 93%0C  	 93%1a+ 	 93e2 	 <3e3 	  <3$4-   A5 	 <3e65 	 93%7.   	 13$8EL  	  <3 9=o9 	 23$:  		 $<3$;	 (<3$< 	 ,<3d= 	 93$>m 	 :3$?E/ 	 0<3$@K 	 4<3$AMoW  	 8<3$BU   	 < C]W  	 8<3$De  	 < E x	 @<3gF  	 73 GE,   	 D<3$HK 	 8<3$Imo  	 H<3'J  	 L<3$K 	 (:3dLu  
   FM   	 P<3$N}  	 T<3$O] !	 X<3&P], "	 X<3&Q]L #	 X<3&RUo  	 \<3$S  	 `<3$T   	 @ CU $	 13$V x	 13'W   d<3'X},  %	 13$YC  &	 h<3#Zo  	 h<3'[ '	 l<3'\% (	 p<3']U 	 t<3'^  )	 @93'_   	 x<3'`# 	 x<3'a]D  *	 |<3'bmn 	 <3'c] +	 <3'd 	 @<3'e 	 @93'f%W  	 <3'g 	 <3gh  ,	 <3'i/ 	 <3gjA -	 T93'kg  	 0:3cl  .	 <3'm!  n	 <3'n} /
 <3fo   
	 4:3'p 0	 <3#q! 1
 <3frH 2
 <3fsa 3
 <3ft 4 x33eu?  5
 <3ev 6
 <3ew! 7
 <3fx- 2 8 Vy"; 9
 x:3fza| :
 :3f{N ;
 <3f|o 
  F} 6
 <3f~$ <
 <3f] 
 <3f=G =
 <3f x 
zn   >
 <3fE n ?
 <3f5M 
 l:3bo)  
   @
 L:3eU A
 X93f= B
 X93fU C
 d:3f D
 L33e E
 L33e#& F
 <3fC) 
 <3fo G
 <3em H
 <3e I
 L:3eE J
 L:3e 
 t33e  
 d D/b 
 <3eA  
 <3eo K
 <3eE L
 <3e M
 <3d  
 <3e) 
 <3e N
 <3e0E O
 :3aOh    
  ]g P
 <3d Q
 t33e!  n
 <3e  %
 <3d =
 <3e]K R
 <3e]  $
 <3d$ S
  =3`}B T
 :3epE O
 =3e U
 :3dz, 
 =3a  "
 =3d] 
 `:3a5 V
 d33d} W
 `:3eM, X
 =3eMM Y
 =3da; Z
 =3d  
   @} [
 =3d \
 =3d% ]
  =3d ^
  =3d, _
 $=3d-P( 
 (=3`'.  
 ,  jb 
 0=3d3 L 
  =3d `
  =3`5b 
 d33d 
 =3d; a
 =3d]#Z  
 4=3gA b
 8=3di c
 <3dMd
 $=3d=1 e VE  f
 33$m  
 33$m9  
 <=3$M0 g
 @=3gO  h
 D=3$d  S
 33$  
 H=3$UW   
 $:3 E  O
 :3$]  
 H=3$ebi  
 L=3'm0b 
 P=3g@`  
 T=3'cb  
 X=3'   "
 4=3'=bL; 
 \=3c1n  `V     u i
 d=3gM j
 h=g]'  
 h=gBb 
 X=3gl 
 l=3c=)  083fyl k p-RN l #"R};  
 \ G]  ! L]  ! `M]'  ! J]G  ! tM]g  ! L]  ! J? m" xM4I? ! |M4I? ! M45G !
 M4z-4 !
 M4W]' n" ME@ o" M4cE p" C4VO q" C4V r" pMV[   s ,* t -RI? 
  ;3'01  VP u Up v UM u VM1  U     1  UP w
 =3g(Q x
 H3gHQ x
 H3ghR y
 :gR y
 =gR y
 =gcb   M4 S z	 9'F {@~-"~5 " *=cjT | -Qyl 	 Q0;  V^G  !
 JW^lU }
 =3c*   
 =3'	^V ~
 =3g
$ 
 3gW 
 H3g^'C 
 =g  -3    PR||npR|  |nR| |n	n[}	
m	[} 	
m	  g"
M4R| l0{| 

m	^l "
 C4SIX  -Qi Y  -Pk +~F  V^'
 d3d^' 
 ='^'
 <f^' 	 9' ^' 	 9'!^' 	 1'"^'
 =f#^'
  3f$^'	
 L3e%^'

 t3e&^'
 x3e'^'
 p3d(^'
 3d)^'  
 H3'*^' "
 lC+^' " `M,^' " L-^' " J.^' " M/^' " M0^' " J1^' " M2^' " M3^' " M4^' " M5^' " M6^' " C7^' " M8^' " M9^' " M:^' $! M;^' " M<^' " M=^'  "  N>^' " N?^'  " N@^' " NA^'! " NB^'M   NC^'" " ND^'# " NE^'" "  NF^'$ " $NG^'% " (NH^'% " ,NI^'& " 0NJ^'' " 4NK~( "
 8NWL~( 
 3dM~( 
 =gN>"). 
 <>3cOVO F
 <>3gPp* " MQ+ 
 @>3gR   "
 =3'S~,% 
 =3cT     =3'U- 
 =gV^. 
 D>3gWF /# "
 M4WXQ0;  H.R